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1.1. Cancer  
 
With more than 100 different subtypes and accounting to 13% of all deaths around 
the globe (Ferlay et al., 2015), cancer is one of the most complicated and highly 
mortal diseases worldwide (Figure 1). Research in the vast field of cancer is 
comprehensive and in general aims to unravel mechanisms characterizing the 
different malignancies in such a way that it may help in prevention, identification, 
and treatment. 
 As per the latest world cancer statistics of 2012 (Ferlay J, 2013), there was 14.1 
million new cancer cases, including 7.4 million men and 6.7 million women, around 
the world. The corresponding number is projected to be 24 million new cases in the 
coming 20 years (Ferlay et al., 2015). The most common cancer types for both sexes 
around the world are breast, prostate, lung, colorectal and stomach, and in case of 
Norway, common cancer types for both sexes, are prostate, breast, colorectal, lung, 
and melanoma of the skin. Among males, most frequently diagnosed and high 
mortality cancer is lung cancer. Prostate and colorectal cancer had higher incidence 
rates, while liver and stomach cancer had higher mortality rates followed by lung 
cancer in males. Among females, the most common cancer and leading cause of 
cancer death, is breast cancer. In females after breast cancer, colorectal and lung 
cancer had higher incidence rates while higher mortality was observed in lung cancer 






Figure 1. Age specific mortality rates from both sexes around the world. Created 
from http://gco.iarc.fr/today (Ferlay J, 2018).  
   
 While the underlying and evolving genetic disturbances for cancer may seem 
somewhat global, mostly varying between cancer types, the environmental factor 
influencing cancer development vary substantially between regions of the world. For 
example, in India the most prevalent cancer is cancers in the lip and oral cavity. This 
cancer ranks number one among men and third among women in terms of the 
incidence rates. This high incidence rates most likely accords to smoking and eating 
products related to tobacco as well as alcohol consumption (Byakodi et al., 2012). 
Lung cancer is the leading cause of cancer incidence and mortality for both genders 
combined. The highest incidence rates of lung cancer among males are found in 
Eastern Europe and the United States. For men, the most common occurring cancer is 
prostate cancer while in females it is breast cancer. Breast cancer is prevalent in 
highest rates in Western Europe and the United States and the lowest rates are found 
to be in Africa and Asia. Regarding melanoma, this is highly prevalent in Norway 
and Scandinavian countries as well as Australia, very likely due do fair skin and high 






 Irregular growth of cells is generally known as neoplasm or tumor (which simply 
means mass). Tumors can broadly be divided into the two sub-groups benign and 
malignant. While benign tumor in general can be considered as a mass of cells that is 
localized (non-invasive) and malignant tumors (cancer), has a more invasive growth 
pattern and often the potential to spread (metastasize) in the body (Cooper, 1992). 
Cancers can be further classified based on the primary site of cancer and type of 
tissue in which the cancer (histological type) arises. The International Classification 
of Diseases for Oncology, Third Edition (ICD-O-3) classifies hundreds of different 
types of cancer into six major categories based on the histological type. They are 
carcinoma, sarcoma, myeloma, leukemia, lymphoma and mixed types. Carcinoma are 
class of cancer that arises in epithelial cells, internal or external lining of the body. 
Carcinoma are of two types – adenocarcinoma which occurs in a gland or an organ, 
and squamous cell carcinoma which arises in squamous epithelium. Sarcomas are 
neoplasms that originate in mesodermal cells (bones, muscles, tendons, cartilage, 
etc.). Myeloma instigates in plasma cells of bone marrow. Leukemias, commonly 
referred as blood cancers are cancer that arise in bone marrow, where blood cell 
production occurs and it is often observed with abnormal production of white blood 
cells. Lymphomas are cancer that arise in the nodes or glands in the lymphatic 
system. Lymphomas that are present in specific organs such as brain, stomach or 
breast are known as extranodal lymphomas. The other two categories of lymphomas 
are Hodgkin lymphoma and non-Hodgkin lymphoma, which are distinguished based 
on the presence of Reed-Sternberg cells. The last type of cancer are mixed as the 
name suggest cancer arises from different categories mentioned above (Fritz et al., 
2000). As these malignant cells arise from different tissue types, the process of 
initiation of cancer (carcinogenesis) and the  further advancement e.g. the spread 
from primary site (metastasis), differ in their molecular details as well (Pecorino, 
2012).  
 In yester years, surgical removal of entire tumor along with lymph node were done 
to treat breast cancer (Halsted, 1894), until spreading of tumor through blood cells 
were reported (Paget, 1889). More recent advancement of technologies have made 




combining surgery with chemotherapy and / or radiation therapy (Fidler, 2003). The 
success rates in treatment lead to further improvement in chemotherapy (Chabner and 
Roberts, 2005) and using drugs along with antibodies to target specific cancer cells 
(Parish, 2003) and chemo protective drugs to reduce the side effects (Summerhayes, 
1995). Another treatment improved over time is hormonal therapy, which uses 
hormones directly or various strategies to control hormones. The latest major 
improvement in cancer treatment related to immune therapy by use of so-called 
checkpoint inhibitors or by reprogramming of immune cells (CAR-T) (Oldham and 
Dillman, 2008). While application of chemotherapy after surgery (adjuvant 
chemotherapy) is commonly used, downstaging of tumors by chemotherapy before 
surgery (neo-adjuvant chemotherapy) has also become a widely applied principle 
over the latest decades. (Notably, the latter strategy provides a good setting for 
research, since the growth or shrinkage of tumors may be directly assessed through 
the treatment (Sudhakar, 2009, DeVita and Chu, 2008, Lonning, 2003).) 
 All these enhancements of treatment came about by understanding tumorigenesis, 
growth of malignant tumor through multistage process of genotypic and phenotypic 
changes, which may occur over a period of time (Ashkenazi et al., 2008). To 
understand this compound and intricate disease, six hallmarks of cancer have been 
proposed as characteristic competencies that facilitate tumor development and 
metastatic propagation. These six hallmarks include “Self-sufficiency in growth 
signals, Insensitivity to anti-growth signals, Evading apoptosis, Limitless replicative 
potential, Sustained angiogenesis and Tissue invasion & metastasis” (Hanahan and 
Weinberg, 2000). As advancements in research moved forward, four more emerging 
hallmarks were later added on: “Deregulating cellular energetics, Genome instability 
& mutation, Avoiding immune destruction and Tumor-promoting inflammations” 
(Figure 2). Cancer treatments started improving and getting better by targeting and 






Figure 2: Hallmarks of cancer along with emerging and enabling characteristics 
proposed by Douglas Hanahan and Robert A. Weinberg. Modified. (Hanahan and 
Weinberg, 2011)  
 
 The work presented in this thesis is based on genetic and genomic analyses of 
samples from patients suffering from malignant melanoma and breast cancer. In the 
following sections, these two cancer forms are described in some more detail. 
 
1.1.1 Melanoma 
   
From previously being a rare kind of cancer, melanoma is now a cancer with high 
incidence all around the world (Ferlay et al., 2015, Erdmann et al., 2013, 




profoundly increased in developed countries and especially in people fairly skinned 
as compared to darker skinned (Tryggvadóttir et al., 2010, Erdmann et al., 2013). 
Increase in prevalence can be attributed to improved prognosis of disease along with 
added exposure to sun for recreation (Azoury and Lange, 2014). In the Nordic 
countries, the incidence were increased along with mortality, but improved treatments 
and prognosis has bettered survival rates among both men and women (Tryggvadóttir 
et al., 2010).  
 Melanoma is cancer arising from melanocytes, which produces melanosomes 
containing melanin in response to UV light from sun, giving skin different shades of 
color (Vijayasaradhi, 1995). Melanoma is likely to take two ways of developing into 
a malignant kind, it may originate from a normal nevus (mole) on the skin or it may 
appear on skin without a previous mole. The majority of melanomas occur de novo in 
sun exposed skin and it occasionally appears in eye and internal body mucosa (nasal, 
gastrointestinal, anorectal, etc.). However, there are also melanomas arising for other 
tissues: There rare cases of melanoma arising from the eye (ocular melanoma; about 
5.2 % of total cases), cases from mucosal sites (mucosal melanoma; 1.3%) and 
around 2.2% cases from unknown sites (Chang et al., 1998). Notably, there are also 
other types of skin cancer defined as non-melanoma skin cancers. These are basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC). Both of these cancers appear 
mostly at sun-exposed regions of skin and are less malignant than melanoma as they 
hardly metastasize (Xiang et al., 2014).  
 Melanoma of the skin can be divided in to subclasses - superficial spreading, 
lentigo and acral lentigo and then nodular – invasive form of melanoma (Clark et al., 
1986). Superficial as name suggests grows along surface of skin. It is found as 
discolored patches or benign nevi along trunk, leg (mainly in women) and back 
(mainly in men) of the body. Lentigo melanoma is similar to superficial melanoma 
that starts as brownish patches and spreads into other parts of the body. It often 
develops in parts of skin that are often sun exposed (arms, face, ears etc.). Lentigo 
melanoma is often found in elderly population. Acral melanoma (acral lentiginous 
melanoma) starts as a black or brown at extremities of the body, like hand, feet, toes 




predominant form in darker skin populations, in Africa and Asia (Bradford et al., 
2009) and it is unrelated to sun exposure. The most aggressive form of melanoma is 
nodular melanoma, which grows deeper into the skin and is often diagnosed as a 
bump on the skin at chest region or back (Clark et al., 1975, Chamberlain et al., 
2003). Some other rare types of melanomas are mucosal lentiginous melanoma that 
occurs in mucosal membranes of internal organs (nasal passage, pharynx, mouth, 
vagina, anal canal and rectum) and it is not associated with sun exposure. 
Desmoplastic melanoma that occurs in thick inner layer of dermis or connective 
tissue surrounding mucosa. 
 
 
Figure 3: Age-standardised (Norwegian standard) incidence rates of melanoma per 




 Risk factors involved with melanoma ranges from sun exposure to genetic 
disposition. The main risk factor of melanoma is exposure to UV-radiation from the 
sun as well as other sources (e.g., artificial tanning bed) and other underlying risk 
factors include history of sunburn, skin color, predisposition of nevi, family history 
and genetic factors.  































































exposure to sunlight, common source for UV radiation (Oliveria et al., 2006). People 
living at equator or higher altitudes are exposed to higher UV radiation and also 
people who use artificial sources of UV such as tanning light or tanning bed, that 
makes them highly susceptible to risk of melanoma (Boniol et al., 2012). People with 
history of sunburn as well as freckles are at increased risk of melanoma as it points to 
increased sun exposure. Fair skinned people are at increased risk of having melanoma 
as they have decreased levels of melanin, that helps in damage protection against UV. 
The risk of melanoma is also heavily dependent sensitivity to UV radiation but for 
people with darker skin such as Asians or Africans or Hispanics, the diagnosis of 
melanoma tends to be in late stage of melanoma and this is an obvious problem 
considering the survival of patients (Cormier et al., 2006).  
 Presence of nevi or multiple nevi are associated with increased risk of melanoma. 
Increased number of nevi, and large sized nevi are often correlated with higher risk of 
melanoma. A large fraction of non-familial melanoma are often diagnosed with 
atypical nevi or dysplastic nevi (Pampena et al., 2017). People with impaired immune 
system such as people who take immunosuppressants (e.g. after an organ transplant) 
or who have disease that immunodeficiency syndrome (e.g. AIDS) have shown 
greater risk of melanoma (Psaty et al., 2010). In history of melanoma disease, family 
history is one of the strong risk factors of melanoma. Risk of melanoma is correlated 
to whether first-degree relatives (parents, siblings, children) has melanoma and risk 
increase with number of first-degree relatives that have melanoma. In some of these 
families, it is observed that there are some common genetic abnormalities (Rastrelli et 
al., 2014). 
 In melanoma, the most common germline genetic abnormalities associated with 
high risk is mutations in the gene cyclin-dependent kinase inhibitor 2A (CDKN2A) 
encoding the p16 protein, and in rarer cases, mutations in cyclin-dependent kinase 4 
(CDK4). p16 is an inhibitor of CDK4-activty, when mutated (inactivating mutations 
in CDKN2A and activating mutations in CDK4), this promotes cell cycle progression 
through increased phosphorylation of pRb (target for CDK4 activity) and subsequent 
release of E2F1. For both genes, mutations act in a dominant manner, resulting in 




genes are only found in about 25% of families with apparent hereditary melanomas 
(Borg et al., 2000, Hussussian et al., 1994, Harland et al., 1997, Kamb et al., 1994). 
So there are most certainly other germline variants strongly associated with risk of 
the disease as well (Azoury and Lange, 2014, Hawryluk and Tsao, 2014, Rastrelli et 
al., 2014).  
 Regardless of underlying causes, the best way to prevent melanoma is, avoiding 
excess exposure to sun or UV rays. Then following “ABCDE”s signs of melanoma, 
which is A for finding asymmetric lesions or nevi, B for Borders of the lesions or 
nevi, which are irregular, or not well defined or being serrated, C for color, mainly 
ranging from black to brown to gray, D for diameter and E for those are evolving in 
any of the “ABCD” (Erdei and Torres, 2010).  
 Melanoma is staged using the TNM classification. TNM classification is based on 
the primary tumor (T), regional lymph node (N), and extent of metastasis (M). The 
classification is made by measuring dimensions of cancer mainly at T stage, tumor 
thickness and number of mitoses (Keohane et al., 2018). Further, melanomas are 
classified based on histology, into subtypes such as nodular, superficial, lentigo 
malignant and acral lentiginous melanoma (all cutaneous). Clark and Breslow micro 
staging is used to describe the spread of melanoma. Based on Breslow depth, T in 
TNM classification can be further classified into T1 - less than 1.0 mm, T2 - 1.01 to 
2.0 mm, T3 – 2.01 to 4.0 mm and T4 - more than 4.0 mm. Survival rates of 
melanoma decreases with increase in Breslow depth (Breslow, 1970). Clark’s level 
describes spread of invasion and helps in prognostic distinction for tumor lesions. 
There are 5 levels of in Clark’s scale, Level 1 – melanoma is confined to outer layer 
of the skin (epidermis) and also called as “melanoma in-situ”, Level 2 – melanoma 
has crossed into outermost layer of the dermis (papillary dermis), Level 3 – 
melanoma has completely invaded papillary dermis and has touched the deeper layer 
dermis (reticular dermis), Level 4 – tumor has invaded the reticular dermis and level 
5 – melanoma has reached into layer of fat under the skin (subcutaneous tissue) 
(Clark et al., 1969, Clark et al., 1975, Clark et al., 1986). Clark’s level has been no 
longer used in current staging systems as it is less prognostic and more subjective. In 




(Cho and Chiang, 2010).   
 Different types of treatment are available for melanoma and it is decided based on 
several factors including melanoma characteristics and patient characteristics.  
Surgery is first and standard treatment. Surgery involves an operation that removes 
tumor and surrounding healthy tissue. Types of melanoma surgeries include wide 
excision (removal of primary melanoma), lymphatic mapping and sentinel mapping 
and lymph node biopsy, lymph node dissection. A second form of treatment available 
for treating melanoma is radiation therapy. It involves high energy radiation mainly 
x-rays or other form of rays to eliminate cancer cells or arrest their growth. Radiation 
therapy is generally carried out with an external radiation machine that sends high 
energy to target regions in the body. This form of therapy is mainly used when cancer 
is functionally inoperable. Radiation therapy may also be given after surgery to 
prevent cancer recurrence (adjuvant radiation therapy). Radiation therapy is also 
given to patients to alleviate symptoms and help in improved life quality, such 
radiation therapy is known as palliative radiation therapy. Chemotherapy, is also 
used. These are in general drugs to stop growth and spread of cancer, usually by 
stopping the cancer cells from growing or dividing. A chemotherapy regimen may 
include a single drug or drugs in combination, a set number of times over a specific 
time period. Some of the established drugs used in chemotherapy of melanoma are 
Dacarbazine (DTIC), Temozolomide (oral version of DTIC), cisplatin and taxanes 
(e.g., paclitaxel (taxol)). Chemotherapy with combination of the drugs tend to have 
more effectiveness along with increase in side effects. Side effects of chemotherapy 
depends on several factors such as dose of the drug used, health status of patients 
treated. Targeted therapy as the name suggests it uses drugs to target specific gene 
and proteins that enable cancer growth. This treatment causes less harm to normal 
cells as they are targeted to cancer cells. Two main types of targeted therapy are 
BRAF inhibitors (dabrafenib, vemurafenib, encorafenib), that blocks activity of 
proteins from mutated BRAF gene and second is MEK inhibitors (trametinib, 
cobimetinib, binimetinib), that blocks MEK1 and MEK2 proteins. Activity of these 
proteins are essential for the cancer cells to grow and survive. Combination of BRAF 




Davis et al., 2019). Immunotherapy is treatment of melanoma using the patient’s 
immune system.  It is also known as biologic therapy as it uses medications that are 
made by body or in a laboratory to boost, target and restore body’s natural immunity 
system to fight against cancer. A main form of immunotherapy is by using immune 
check point inhibitors, here the medication blocks immune check point protein, such 
as T cells that keeps are immune system response in check in turn increase immune 
system capability to killing cancer cells. Two main immune check point inhibitors are 
PD-1 inhibitors and CTLA-4 inhibitors. Some of the known PD-1 inhibitor are 
nivolumab and pembrolizumab, as the name suggest they block PD-1 protein on 
surface of T- cells and free T-cells to kill the cancer cells. A well known CTLA-4 
inhibitor is Ipilimumab, it works by blocking CTLA-4, a protein on surface of T-cells 
and removes the check on T cells. Another immunotherapy is Interleukin-2 (IL-2), 
which boosts growth and activity of T-cells, thus enabling body to kill cancer cells. 
Interferon therapy is another form of immunotherapy that slows down tumor growth 
and arrest division of cancer cells.  
 In Norway, surgical removal of primary melanomas cure about >90% of the cases 
(Robsahm et al., 2018). For metastatic melanoma all modes of cancer therapy is used, 
including radiotherapy, chemotherapy and targeted therapies as well as 
immunotherapy (Erdei and Torres, 2010). Historically, dacarbazine (DTIC) 
chemotherapy remained sole treatment, with response rates of <20%. Improvements 
in therapy includes BRAF inhibitors and MEK inhibitors (Vennepureddy et al., 2016). 
A massive shift and improvement of treatment of advanced melanomas was brought 
about by the introduction of immunotherapy. Immunotherapy as a concept includes 
the use of vaccines and inflammatory cytokines helping in patient’s immune system 
to recognize and eliminate cancer. However, the major breakthrough in terms of 
melanoma treatment over the recent years is related to the use of so-called checkpoint 
inhibitors, blocking negative signaling from cancer cells to T-cells. Successful 
treatment of melanoma based on this principle has in particular been related to use of 
ipilimumab which blocks the CTLA4-surface receptor and nivolumab blocking PD-1 





1.1.2. Breast cancer  
   
The second most common and fifth ranked in mortality amongst cancers both sexes 
combined, breast cancer is a most common cancer in women around the globe (Bray 
et al., 2013, Ferlay et al., 2015, Vennepureddy et al., 2016). Even though global 
incidence is on the rise, there is a slight decline in mortality in recent years, which 
can be accorded to better understanding and treatment of the disease as well as 
screening and early detection (Paap et al., 2014, Hofvind et al., 2013).  
 
 
Figure 4: Age-standardised (Norwegian standard) incidence rates of breast cancer 




 Breast cancer is a heterogeneous disease with large differences in the biology of the 
tumors. While, traditionally, breast cancer can be stratified according to their 
expression of hormone receptors (estrogen- and progesterone receptor) as well as 
overexpression of Her2, they are in later years also often stratified according to 
molecular ‘intrinsic’ subtypes based on mRNA expression patterns (Perou et al., 
2000). While several additional subtypes have been proposed, five major subtypes are 

















































enriched, Basal-like, and Normal breast-like (Perou et al., 2000, Sørlie et al., 2001). 
 
 
Figure 5: Schematic representation of breast cancer subtypes. Blue and brown oval 
group represents subtypes based on ER/PR expression. Orange oval subgroup 
represents Her2 amplification.  
 
These subtypes differ in incidence (Millikan et al., 2008), survival (Cheang et al., 
2009) and also to some extent in response to treatment (Nielsen et al., 2010, Hu et al., 
2006, Ma et al., 2004, van 't Veer et al., 2002). Luminal A and Luminal B subtypes 
are in general ER+ (or PR+). and Luminal A is relatively slow growing cancers. 
HER2 subtype usually has higher expression of the HER2 protein and lack ER (ER-). 
This subtype has been linked to poor prognosis (Prat and Perou, 2011), a feature that 
has been reversed by the successes of anti-Her2 therapy. The basal-like category is 
largely overlapping with “triple negative” breast cancers (negative for ER, PgR and 
Her2 overexpression) and in general has a poor prognosis (Sørlie et al., 2001, Sorlie 
et al., 1999). “Claudin-low” is a more recent subgroup of “triple negative” breast 
cancers, which has lower levels of claudin gene expression. Normal-like breast 
tumors group are poorly categorized and have been grouped with true normal as they 




characteristic lies between luminal-like and basal-like and do not respond well to 
neoadjuvant chemotherapy. They lack in expression of genes like ER, PR, HER2 
(similar to triple negative) as well as CK5 and EGFR (non basal-like). (2012, Bastien 
et al., 2012, Prat et al., 2012, Perou, 2010, Perou et al., 2000, Sorlie et al., 2001, Prat 
and Perou, 2011, Nielsen et al., 2010). This subtyping of cancers has helped in 
improving the prognosis and treatment of the disease and have paved the way for 
development of prognostic expression profiles that may identify patients where 
chemotherapy is necessary versus those it may be omitted (Cardoso et al., 2016). 
 Breast cancer risk factors are diverse and mainly depend on the individual women, 
their age, personal history and family history, obesity, hormonal exposures and life 
style choices like drinking alcohol (Barnard et al., 2015, Dumalaon-Canaria et al., 
2014). Aging is one of the most important breast cancer risk factors. Incidence of 
breast cancer increases with increase in age. Risk of breast cancer increase in women 
those have first degree or second-degree relatives with breast cancer. Factors 
associated with reproduction play a part in breast cancer risk. It is reported that 
women with late menopause as well as early age at menarche, low parity, and late age 
at first birth were associated with increased risk of breast cancer (Nagata et al., 1995). 
Breast cancer risk are increased in individuals with hormonal levels, including 
endogenous and exogenous estrogens as well as hormonal therapy. Lifestyle factors 
such as high dietary intake, sedentary lifestyle, smoking and alcohol consumption are 
associated with increase in risk of breast cancer (Iwasaki and Tsugane, 2011).  
 With respect to known genetic factors involved in breast cancer risk, these 
comprise about 30 genes that contribute only ~30% of familial risk (Collins and 
Politopoulos, 2011). The inherited genetic variants that influence breast cancer are a 
very variable with respect to penetrance. Some genes can harbor high penetrance 
variants. Among these are BRCA1, BRCA2, PALB2, ATM and CHEK2 (Kamińska et 
al., 2015, Collins and Politopoulos, 2011, Michailidou et al., 2015). Additionally, 
variants in other genes only contribute to a low or moderate increase in risk and/or 
only in combination with other germline variants. In addition, amplification of genes 
such as HER2, EGFR, c-Myc, Ras are also documented with increased risk of breast 




 The treatment strategy for breast cancer most commonly includes surgical removal 
of the tumor followed by adjuvant chemotherapy, and/or adjuvant hormonal therapy 
(Rosenberg and Partridge, 2015, Perou, 2010). Surgical treatment can be performed 
with a breast conserving therapy (BCT) or by total mastectomy (Dutta et al., 2017).  
In early stage breast cancer patients, the widely used adjuvant treatment methods are 
endocrine treatment, chemotherapy and anti-HER2 treatment. Endocrine therapy has 
grown to be a preferred treatment option for the Luminal A and possibly for Luminal 
B subtype of breast cancer, and there are now several efforts to use this strategy only 
and to omit the use of chemotherapy from the treatment of hormone sensitive cancers. 
Adjuvant chemotherapy regimens for early and advanced stage breast cancers include 
active classes of cytotoxic agents such as anthracyclines like doxorubicin and 
epirubicin (Hortobagyi, 1997) and / or taxanes like paclitaxel and docetaxel 
(Rowinsky and Donehower, 1995).  The first combination adjuvant therapy regimen 
was CMF (cyclophosphamide (C), methotrexate (M), and 5-fluorouracil(F)) followed 
by CAF (cyclophosphamide (C), doxorubicin (A), and 5-fluorouracil(F)) or CEF 
(cyclophosphamide (C), epirubicin (E), and 5-fluorouracil(F)). A common regimen of 
adjuvant therapy for breast cancer is AC-T (doxorubicin (A), cyclophosphamide and 
paclitaxel (T)) (Citron et al., 2003). In Norway, a common regimen has been “EC90” 
consisting of epirubicin and cyclophosphamide. 
 The most established adjuvant endocrine regimen is tamoxifen. This is a so-called 
selective estrogen-receptor modulators (SERMs), which acts by blocking the estrogen 
receptor for binding of the ligand (estrogen) and thereby blocks estrogen-related 
growth signaling to the cancer cells. Another well-established strategy relates to the 
use of Aromatase inhibitors (AIs). Tamoxifen started out as standard treatment for 
pre- and post-menopausal patients. While many pre-menopausal receive tamoxifen 
with a combination of LH-RH agonist. AIs are mainly used for postmenopausal 
patients and it lowers the concentration of serum estradiol by blocking the enzyme 
(aromatase) that converts androgens to estrogen. GnRH agonists, another SERMs, 
restrains ovarian function and it is used for premenopausal patients as it induces 
menopause like condition (Lumachi et al., 2011). 




overexpressing the HER2 receptor (Peto et al., 2012, Sorlie et al., 2003, Davies et al., 
2011). In HER2 positive tumors, humanized monoclonal antibody, trastuzumab used 
as anti-HER2 treatment (Anampa et al., 2015). Recent studies have also revealed that 
dual treatment (i.e. concomitant use of two different anti-bodies such as trastuzumab 
and pertuzumab) is superior to the use of trastuzumab alone (Swain et al., 2015, Loibl 
and Gianni, 2017).   
 Neoadjuvant therapy (medical treatment in the timespan before surgery) is often 
used in case of patients with larger tumors (so-called locally advanced breast cancers) 
and increasingly used for smaller tumors, in particular of the triple-negative and 
HER2+ types. In this group of tumors, where surgery followed by adjuvant 
chemotherapy proved to be a far-from-optimal treatment strategy leading to a high 
rate of relapses. Some decades ago, the strategy was changed to neoadjuvant 
chemotherapy, in order to reduce the tumor burden before surgery and thereby 
increasing the success rate of curative surgery and reduce the risk of relapse. 
Importantly, for the research in the field of chemoresistance, such treatment has 
proven to be an optimal study setting in as much as one can accurately monitor the 
effect of a given drug by measuring the growth/shrinkage of the tumor during 
treatment. This contrast the adjuvant setting where the effects of a drug can only be 
assessed by assessment of relapses, meaning that effects must be assessed over very 
long timespans. Further, a clinically effective method in the adjuvant and palliative 
setting, is radiotherapy. Radiotherapy is given to residual breast of patients following 
undergoing breast-conserving surgery (BCS). Irradiation after BCS reduces the 
chance of local recurrence, modestly improving survival rates of patients (Joshi et al., 
2007). 
 Immunotherapy has been tested in breast cancer, but the results are so far somewhat 
disappointing (Schmid et al., 2018). The most promising effects of this treatments 
concept has been seen within the subtype of triple negative breast cancers, but also 
here the effects have been limited (Jia et al., 2017, Schmid et al., 2018). However 
there are hopes that, there may still be an important role for immunotherapy in breast 
cancer, pending identification of predictive biomarkers that can predict which of the 




novel immuno-based therapies, other than the ones available today (Emens, 2018). 
    
1.2 Molecular characteristics of cancer 
 
 
Figure 6: Overview of cellular homeostasis and factors affecting them. 
 
Homeostasis refers to the network of complex interactions that help maintain and 
regulate internal condition of the organism under stable conditions (Figure 6). Any 
imbalance in regulation of homeostasis can in turn result in tumor formation and 
other diseases. In tumor formation is a complex process involving different factors, 
that is discussed in subsequent chapter.  
 
1.2.1 Tumor suppressors and oncogenes 
 
Distinct and stochastic forces drive whole mutational processes depending on each 
individual cancer type, stage and interaction with other important processes involved 
in tumorigenesis. In tumors, the uncontrolled growth of cells that hinders vital 




oncogenic pathways (e.g. mutations in ras, src, abl) and/or inactivation of tumor 
suppressing pathways (e.g. mutations in tumor suppressor genes such as TP53, RB1, 
PTEN, etc. (Weinberg, 1994, Lehman et al., 1991).  Understanding specific elements 
of the cellular pathways in which the mutated oncogenes and tumor suppressor genes 
execute their function is important with respect to finding a way to improve 
treatment, reduce toxicity and overall survival of the patient. (Borges et al., 2005). 
 Oncogenes are genes where activating mutations in a proto-oncogene cause 
hyperactivity of the encoded protein, and where this hyperactivity gives the cancer 
cell a growth advantage or malignant phenotype. On the other hand, tumor suppressor 
genes work antagonistically and have functions keeping order in the cells’ 
proliferation and repair. Rather than hyper-activating mutations, cancer related 
mutations in tumor suppressor genes are usually resulting reduced or abolished 
protein function. Regarding tumor suppressors, the first found was the retinoblastoma 
gene RB1, where germline defect are strongly linked to retinoblastoma in kids (Lee et 
al., 1987). Knudson proposed two-hit hypothesis in retinoblastoma, that postulates 
recessive nature of mutations in tumor-initiating gene and inheritance of familial 
cancer (Knudson, 1971). This hypothesis was confirmed the by demonstration of loss 
of heterozygosity at 13q14 in RB1, leading to no functional allele in cells with 
previous heterozygous mutation in the RB1 gene. This laid foundation to concepts 
such as tumor suppressor genes and loss‐of‐heterozygosity (LOH) (Cavenee et al., 
1985). In breast cancer, the RB1 gene has been found inactivated in 30 % of cases 
through either mutations or deletions or allelic loss of the entire gene (loss of 
heterozygosity; LOH) (Burkhart and Sage, 2008).  
 In cancer, the p53 signaling pathway is vital for protection against stress and 
imbalance caused by oncogenic pressure. The tumor suppressor gene TP53, is known 
as the guardian of the genome (Lane, 1992) as it facilitates apoptosis or senescence 
and help in damage control and repair mechanisms making it an important component 
in maintaining genomic stability (Park et al., 2016). Germline mutations in TP53 
causes Li-Fraumeni syndrome and female carriers of this gene mutations carries a 
risk of 5% even before the age of 30 and approximately 50% of all cancers cases 




to DNA damage, the protein products of genes like ATM, CHEK2, MDM2, MYC, 
RAS, CDKN2A are some of the genes that play a major role in arresting growth or 
induce programmed cell death by activating p53 and counter oncogenic 
transformation and proliferation (Palmero et al., 1998, Lowe and Sherr, 2003, Zhang 
et al., 2011, Smith et al., 2010, Zindy et al., 1998). 
 Importantly, recent studies show that the same gene might act as an oncogene and 
as a tumor suppressor depending upon the cancer type and also depending on the 
status of the gene (whether the gene is wild-type or mutated may flip the role from 
oncogene to tumor suppressor and vice versa) (Borges et al., 2005, Zhang et al., 2010, 
Wang et al., 2009, Hutchinson et al., 2004, Lynch et al., 2008) (The Cancer Genome 
Atlas et al., 2012, de Jong et al., 2002). The TP53 gene is generally considered to be 
an extremely important tumor suppressor. However, there are also more recent 
studies providing clear indications that some of the TP53 mutants may be gain-of-
functions mutants (Lozano, 2007). Thus, TP53, seemingly can be both a tumor 
suppressor and in some cases an oncogene. In breast cancer, mutations in TP53 are a 
little less frequent than in many other cancer forms, with approximately 20% of 
breast cancers being affected. Other important tumor suppressor genes, strongly 
related to breast cancer are BRCA1 and BRCA2. Somatic mutations of BRCA1 is 
observed in more than 5% of breast cancer patients, while mutations of BRCA2 are 
less frequent (Nik-Zainal et al., 2016). BRCA1 and BRCA2 are genes involved in 
double stranded break repair act as tumor suppressor genes. Germline mutation in 
these two genes impart more than 75% of lifetime breast cancer risk to female 
carriers (King et al., 2003). Similarly, genes like PTEN and CHK2 mutation cause 
increased risk of breast cancer (Osborne et al., 2004, Lee and Muller, 2010). PTEN 
gene, is an important tumor suppressor gene, mainly known for Cowden syndrome 
(autosomal dominant disorder). Allelic loss of PTEN (Phospatase and Tensin) was 
present in ~20% of melanoma (Yin and Shen, 2008). CHEK2 (Checkpoint kinase 2),  
vital player in DNA damage response and deletions in this gene causes increased risk 
of breast cancer as well as multiple risk associated with susceptibility to multiple 
other genes (2004). PALB2, Fanconi anemia assosciated gene (also called as FANCN) 




 Oncogenes like HER2, MYC, PI3KCA, BRAF, etc., are found frequently 
deregulated in breast cancer. HER2 oncogene activation is found in about 20 % of 
primary breast cancers (Guo et al., 2006). Similarly MYC gene is found to be 
overexpressed in around 15-20% of breast cancers (Steeg and Zhou, 1998). In breast 
cancer PIK3CA mutations are found in 20-30% patients. BRAF mutations especially, 
position V600 (Davies et al., 2002), has been reported in 10 % of all human cancers 
with oncogenic effects (Dhomen and Marais, 2007). 
 
Table 1: Summary of some major somatic mutations and amino acid (AA) changes 
for oncogenes (in red) and tumor suppressor genes reported in COSMIC v89(Forbes 
et al., 2017). 
 
 
Mutation in BRAF is prevalent in malignant melanoma around 30-70% and common 
mutation found is BRAFV600E  which accounts to more than 90% of mutations (Pollock 
et al., 2003). In melanoma, isoforms of the RAS gene are N-RAS and K-RAS, with 
N-RAS being commonly mutated, while K-RAS happens to be a rarely mutated form 
(Jafari et al., 1995, Shukla et al., 1989). AKT has three isoforms AKT1, AKT2 and 
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AKT3, out of which AKT2 and AKT3 are isoforms mainly found dysregulated in 
melanoma (Read et al., 2016, Wangari-Talbot and Chen, 2013, Stahl et al., 2004). 
Mutations in the tumor suppressor gene, CDKN2A, result in increased risk of familial 
melanoma ~20-60% (Goldstein et al., 2006). TERT (Telomerase RT), a reverse 
transcriptase subunit of telomerase complex, is important in regulation of telomere 
length. Somatic mutations in TERT promoters was observed in more than 29% 
melanoma (Vinagre et al., 2013).   
 In addition to mutations (either somatic or germline), epigenetic mechanisms, such 
as methylation and chromatin organisation, are important in modulation of genes that 
play important role in neoplasia. In particular, in cancer, hypermethylation of tumor 
suppressor genes, thereby inactivating them, is a key event. This is described in more 
detail in chapter 2.4. 
 
1.2.2. Genome instability 
 
A modern cancer hallmark, is genomic instability that arise from mutations and 
chromosomal rearrangements and drives tumorigenesis (Hanahan and Weinberg, 
2011). Genomic instability occurs from somatic point mutations, copy number 
alterations and they also show structural variations in chromosomes (chromosomal 
instability) via change in number of chromosomes or structural changes as well as 
microsatellite instability brought about via increase in mutation burden and rate. 
Normal cells differ from tumor cells with acquirement of these genomic alterations 
giving rise to more aggressive tumor subclones resulting in tumor initiation and 
progression. Genomic instabilities provide malignant tumor cells to bypass cell cycle 
checkpoints and other important cell processes, making them a hallmark in better 
understanding of cancer (Nowell, 1976). Abnormal chromosomal structures and 
aberrant chromosome numbers are a main cause of genomic instability during 
mitosis. Another key source of genomic instability is presence of somatic copy 
number variations. A cancer cell can gain or lose a copy of chromosome during 
tumorigenesis and regain copies or again lose copies based on the cellular 




chromosomes causing disruptions in integrity of chromosomes leading to genomic 
instability (Andor et al., 2017).  
 DNA damage repair machinery of cells are vital in tackling genome instability and 
their shortcomings. DNA repair pathways are important to shun tumorigenesis by 
facilitating DNA repair or initiating apoptosis. It is maintained by DNA mismatch 
repair system which corrects mismatches along with correcting insertions and 
deletion on DNA. Mutations in DNA mismatch repair mechanism leads to increased 
mutation burden causing instability in microsatellites affecting the genomic integrity 
(Kunkel, 1995).  
  
1.2.3. Tumor heterogeneity 
 
Heterogeneity, both functional and phenotypical, is very important in context of 
tumor. Notably, there are several layers of heterogeneity that should be recognised: 
first, inter-individual heterogeneity represents the differences seen between tumor in 
different individuals. Secondly, inter-tumor heterogeneity can also represent 
differences across tumors in an individual patient (typically heterogeneity between 
different metastases). Finally, intra-tumor heterogeneity refers to the differences 
between different subclones (or even single cells) within a single tumor.  
 The levels of heterogeneity, is often a reason that make cancers a complicated 
disease to treat, gives rise to inaccurate diagnosis, different clinical responses as wells 
as outcome (Heppner, 1984, Illingworth et al., 2010). Rapid evolution in the field of 
genome-wide studies and high throughput sequencing brought about deeper insights 
into mechanisms involved in tumor heterogeneity. Tumor heterogeneity occurs in 
cellular and molecular levels that can be driven by clonal evolution caused by 
genomic instability as well as altered levels of genetic and epigenetic factors. 
 Heterogeneity can be found in non-heritable manner that arise form phenotypic 
plasticity and cancer stem cell differentiation and heritable manner of heterogeneity 
arises from clonal expansion in Darwinian tumor evolution. In tumors this plasticity 
affects the ability to form different forms tumor cells with influence of 




brought about from changes in genotypes and environmental conditions can give rise 
to heterogeneity in tumor cells (Park et al., 2000). Similarly stem cells in tumors 
possess ability similar to stem cells to replenish tumor cells as well as differentiate in 
to different tumor cells (Dick, 2008). Any changes in this differentiation of stem cells 
give rise to heterogeneity that is no-heritable in manner (Kern and Shibata, 2007). A 
large portion of tumor cell heterogeneity arises from these non-heritable manners of 
mechanisms. The other main way of tumor heterogeneity is clonal evolution, that is 
mostly accumulated from mutations in genes. Tumor progression is generally 
propagated by stochastic process in acquirement of mutational events in response to 
genomic instability and tumor cell proliferation (Parmigiani et al., 2009). Mutational 
events are selected in Darwinian way, that are advantageous to tumor progression and 
make way for clonal expansion. This process is influenced by changes in tumor 
microenvironment and selective pressures in tumor cells, thus providing tumor 
heterogeneity (Parmigiani et al., 2009). Clonal expansion can be linear as mutations 
drive linear succession of tumors and it can also be expansive as mixture of multiple 
co-existing and expanding linear clones. Clonal heterogeneity differ from tumor 
heterogeneity as former is caused by clonal expansion and latter is genetic differences 
in tumor cells (Marusyk and Polyak, 2010). 
 Genomic sequencing study of primary tumor and metastasis pairs has revealed sub 
clonal evolution in breast cancer. Variable degrees of genomic heterogeneity were 
found across breast cancers as well as subclonal heterogeneity across subgroups of 
breast cancer. It was also reported that subclonal mutations were found in only a 
small fraction of tumor cells but were variably distributed allele fractions. Clonal 
expansion occurs by accumulating mutations and happens until it reaches a mass, 
therefore represents a rate limiting step in development of breast cancer (Yates et al., 
2015, Nik-Zainal et al., 2012). 
 
1.2.4. Methylation and epimutations 
 
Epigenetics is a broad field covering a multitude of different molecular mechanisms, 




epigenetic mechanism is DNA methylation. Research has been expanding in the field 
of exploring different characteristics of DNA and methylation (Gayon, 2016). 
Methylation in genomic sites and patterns are known to play key roles in different 
stages of early development. In addition to turning on and off genes that are required 
to be active / inactive at different stages of development, methylation also plays a 
crucial role as a cancer protective mechanism through transcriptional silencing of 
regions harbouring transposons and viral elements (Reik, 2007, Weber and 
Schubeler, 2007, Cedar and Bergman, 2009, Schubeler, 2015).  
 In the eukaryotic cell nucleus, DNA is tightly packaged with the help of histones as 
chromatin, a highly ordered structure. Chromatin is a physiological center for all 
genetic information, encompassing DNA, histone and other protein forming 
nucleoprotein complex (Luger and Richmond, 1998). The chromatin is largely 
divided into 2 distinct classes based on transcriptional status – euchromatin, that is 
decondensed and transcriptionally active, and heterochromatin, that is condensed and 
transcriptionally shut down (Akey and Luger, 2003). Histone tails are target for post-
transcriptional gene regulation mainly via modifications such as methylation, 
acetylation, phosphorylation, ubiquitination, sumolyation to name a few that are 
covalent in nature (Roth et al., 2001, Strahl and Allis, 2000, Paro, 1995, Hsu et al., 
2000, Lachner et al., 2001). These modifications alter the accessibility of the DNA 
for transcription, and as such, can modulate gene expression. DNA methylation is 
stable inherited epigenetic modification that alters chromatin density and modulates 
gene regulation (Holliday and Pugh, 1975). It is a reversible process and it is affected 






Figure 7: General model of DNA methylation and effects on gene transcription.  A) 
Unmethylated CpG islands in gene promoters allow the binding of transcription 
factors (TF) that enables transcription and gene expression. B) Methylation of 
promoter CpG islands inhibit the binding of transcription factor, which in turn 
inhibits transcription and gene expression.  
 
 The process in vertebrates happens with addition of methyl or hydroxymethyl 
group at 5’ end of cytosine by DNA methyltransferases (DNMTs) and it occurs at CG 
(CpG) nucleotide rich promoter regions in a symmetrical fashion. In plants and 
embryonic stem cells non CpG methylation is observed that occurs in context of 
CHH and CHG, where H being A, C or T and it happens in an asymmetrical fashion 
(Robertson, 2005, Lister et al., 2009, Bock et al., 2012). DNA methylation happens in 
a non-uniform manner across region. In genome, CpGs occur methylated in majority 
but a minority of CpGs occur unmethylated at in CpG dense regions known as CpG 
islands, which is rich in GC content and CpGs with an average length of 1000 
nucleotides (Smith and Meissner, 2013, Bird et al., 1985). More than 70 % of curated 
gene promoters, including promoters for housekeeping genes and widely expressed 
genes are associated with CpG islands (Saxonov et al., 2006, Larsen et al., 1992). 
These promoters generally show distinct chromatin organization and transcriptional 




making it an important player in post transcriptional gene regulation (Deaton and 
Bird, 2011). This shows importance of CpG methylation levels as a biomarker to 
study gene regulation to help studying different diseases including tumor. 
 Epimutations, does not involve changes in DNA sequence but rather imply 
epigenetic changes such as changes in methylation status of DNA or other chromatin 
modifications (Holliday, 1987). In disease conditions aberrant chromatin states gives 
rise to aberrant epigenetic patterns which is identified as epimutations. Epimutation in 
general involves epigenetic process that causes repression of active genes without 
suppression of expression, or activation of gene expression (Oey and Whitelaw, 2014, 
Horsthemke, 2006). It reduces levels of gene products by preventing translation and it 
can affect either allele of gene or both.  
 Epimutations in cancer typically appears at somatic cells of non-cancerous tissues 
at the stage of tumorigenesis as well as later stages in tumor evolution sometimes 
even later stages of metastasis (Banno et al., 2012, Greger et al., 1989, Sakai et al., 
1991). Inactivation of promoter activity by CpG hypermethylation was first found in 
human retinoblastoma (RB1) tumor-suppressor gene (Ohtani-Fujita et al., 1993). 
Similar inactivation of tumor suppressor genes such as CDKN2A, MTSI, MDR1 in 
human cancer were found to associated with CpG island hypermethylation (Merlo et 
al., 1995, Herman et al., 1995, Kusaba et al., 1999, Herman et al., 1997). BRCA1 
gene promoter hyper methylation has been reported in breast cancer and ovarian 
cancers supporting in tumorigenesis (Esteller et al., 2000). In colorectal cancers, 
MLH1 hypermethylation is associated with microsatellite instability (Herman et al., 
1998). GSTP1 appears to be silenced in prostate cancer in which the process 
identified is epigenetic silencing via hypermethylation (Millar et al., 2000). Profiling 
of CpG island methylation in different kinds of tumors can help in treatment and 
diagnosis of cancer (Melki et al., 1999, Esteller, 2002, Clark and Melki, 2002).  
 DNA methylation and chromatin remodelling events play a key repressive role at 
gene promoters of tumor related genes (Fahrner et al., 2002). Mechanisms involved 
in DNA methylation are different in malignant cells versus normal cells, as they may 
appear more abnormal in malignant cells. DNA methylation patterns can have 




methylation of genes have vital effects in controlling the behaviour cancer 
development and progression (Jones and Baylin, 2002, Esteller, 2006, El-Osta, 2004). 
Epigenetic modifications usually happens at early onset of carcinogenesis and these 
modifications are reversible in nature thus potentially making them a good target for 
cancer diagnosis and treatment (Herranz and Esteller, 2007). However, so far, the 
successful use drugs targeting epigenetic features in cancer cells has been limited. 
 Although hypermethylation of tumor suppressor genes has been recognised as an 
important gene inactivation event in cancer cells, little has been known about the role 
of normal cell tumor suppressor methylation as a cancer risk factor. Over recent years 
some few studies have addressed this question and the preliminary findings are 
intriguing. In colorectal cancer, mosaic methylation of the MLH1 gene has been 
observed in leukocytes (Gazzoli et al., 2002), indicating that there is a background of 
normal cells with methylation in some of the cancer patients. Also, there are reports 
of specific families with high risk of colorectal cancer, where MLH1 methylation of 
normal cells seem to be inherited (Hitchins et al., 2007). Further, promoter 
methylation of the MGMT gene, it epigenetically silences the DNA repair gene. High 
levels of promoter methylation of the BRCA1 gene was observed in peripheral blood 
cells implicating predisposition of early onset of breast cancer in some patients 
(Iwamoto et al., 2011, Al-Moghrabi et al., 2014). Importantly, recently, our team 
performed a large case-control study identifying normal tissue BRCA1 promoter 
methylation to confer a significantly increased risk of high-grade serous ovarian 
cancer. In this study the risk was also seemingly proportional to the level of 
methylation (Lonning et al., 2018, Lønning and Knappskog, 2018). Notably, BRCA1 
methylation was also detected in cord-blood from newborns, indicating that 
methylation is an event taking place very early, presumably in embryonic life. 
 Taken together, these recent findings have led to the novel hypothesis that a certain 
fraction of cancers are caused by early methylation of normal cells. As such it is 
highly interesting to assess the tumor suppressor methylation landscape in healthy 
individuals, in order to potentially find new genes where methylation varies between 







 The discovery of microRNA (miRNA) two decades ago brought about a shift in 
small RNA molecular biology and changed the understanding of processes that 
involve post transcriptional regulation. miRNAs are single stranded 20-23 nt RNA 
molecules that play a pivotal role in modulation and stability of an array of molecular 
processes in physiological and pathological pathways. These pathways include 
embryonic development, metabolic, as well as pathways involved in tumor 
progression such as apoptosis, differentiation, stress response, homeostasis, 
inflammation, neoplastic progression, cell cycle process. All of these characteristics 
of the small RNA molecule family obviously make them an important class of 
molecules and also provides a new field of research for potential biomarkers and 
therapeutic targets with respect to cancer.  
 The first miRNA was discovered in Caenorhabditis elegans, a nematode model 
organism. The study found downregulation of protein LIN-14 with accordance to 
transcription of lin-4 gene without translation. It was also noted lin-4 encoded two 
transcripts 22 nucleotide and 62 nucleotides that regulated LIN-14 translation by 
binding to the 3’UTR regions with antisense RNA-RNA interactions (Lee et al., 
1993). This first study was published in 1993(Wightman et al., 1993) and a second 
miRNA was discovered years later, in 2000, in the same organism, C. elegans 
(Reinhart et al., 2000, Slack et al., 2000).  In this study, they found the miRNA let-7 
21nt transcript, that works similarly to lin-4. Also another group found let-7 to 
negatively control genes important for larval development (Reinhart et al., 2000, 
Slack et al., 2000). Homologs of let-7 miRNA was then found in different species in 
different phyla, including humans, with functions in developmental stages 
(Pasquinelli et al., 2000). 
 miRNA biogenesis can be split into two pathways, namely the canonical and non-
canonical pathways. In the canonical pathway (Figure 3), miRNAs are transcribed 
from coding or non-coding regions of genome as primary miRNAs (pri-miRNAs) by 
RNA polymerase II. Pri-miRNAs are usually several hundred nucleotides long and 




pri-miRNA are then processed into a long precursor miRNA (pre-miRNA) in the 
nucleus by a large protein complex known as microprocessor. The pre-miRNA 
contains premature forms of miRNA that contains a hairpin structure created with the 
help of Drosha, a type of RNase III enzyme and DGCR8 (DiGeorge syndrome 
Critical Region 8 or also known as Pasha), a type of RNA binding protein in 
Microprocessor (Lee et al., 2003, Han et al., 2004, Denli et al., 2004). Exportin, a  
Ran-dependent nuclear transport receptor protein (Yi et al., 2003), exports pre-
miRNA, with a  distinctive 3’ nucleotide overhang (approximately 2 nt in length) and 
a 5’ phosphate into cytoplasm, where the stem loop structure of pre-miRNA is 
cleaved by Dicer, RNAse type III enzyme.  
 Dicer form a protein complex with double stranded RNA (dsRNA) binding cellular 
protein, transactivation response RNA binding protein (TRBP) that finally process 
pre-miRNAs to mature miRNA (Chendrimada et al., 2005). The two strands are 
separated with respect to base pairing, duplex stability and thermodynamic factors to 
form a guide strand, i.e., miRNA and passenger strand, that eventually degrades. The 
Dicer-TRBP complex facilitates the formation of microribonuclear protein complex 
(miRNP) called RNA-induced silencing complex (RISC) that includes a dsRNA 
binding protein, trinucleotide repeat-containing gene 6A (TNRC6A) and Argonaute 
protein 2 (Ago2), a catalytic protein (Schwarz et al., 2003). The formation of this 
complex is followed by degradation of passenger strand and binding of guide strand 
to 3’UTR of target mRNA. The RISC along with guide RNA inhibits the 
transcription by degradation. The path involves formation cytoplasmic bodies called 
processing bodies (P-bodies) by localizing miRNA-mRNA incorporated Ago2 
proteins into them and results in either degradation or translational repression 
(Castilla-Llorente et al., 2012, Hammond, 2015, Bhaskaran and Mohan, 2014).  
 The non-canonical pathways of biogenesis of miRNAs usually that bypass splicing 
by Drosha or Dicer independent or independent of RISC complex (Ruby et al., 2007, 






Figure 8: Representational figure of canonical miRNA pathway. Adapted.(Yeung et 
al., 2005)  
 
 The processed, mature miRNAs function by binding to their target genes with 
sequence complementarity in regions of mRNA, mostly UTR regions. The miRNA 
sequence from 2nd to 8th nucleotide (called as seed region) (Lewis et al., 2005) binds 
to UTR of mRNA and suppress the expression of the gene product in two different 
ways: either by degradation of the mRNA or by inhibition of the translation. The 
repression of target depends on the complementarity between miRNA seed and target 
mRNA. If the complementarity is partial, the target genes are in general repressed 
from translation, while when complementarity is perfect the target mRNAs is more 
likely to get degraded (Gregory et al., 2005). Notably, translational repression of 
mRNA is reversible while mRNA degradation is not. The level of gene regulation 
conferred by miRNAs is complex: a single target gene can be simultaneously 
translationally repressed by multiple miRNAs with sequence complementarity at 
different regions of mRNA. Similarly, a single miRNA can control multiple targets 
and regulate their expression (Li and Kowdley, 2012). A lot of the miRNA mediated 
gene silencing and mRNA decay takes place at P-bodies in the cytoplasm. P-bodies, 




contain ingredients involved in mRNA decapping, deadynelation, RNA degradation 
(Cougot et al., 2004).  
 The miRNAs play a vital role in reproduction as studies suggest failure in 
expression of miRNA lead to abnormal reproduction as they affect tissue 
morphogenesis, apoptosis (Kloosterman and Plasterk, 2006). It has been studied that 
miRNAs play a key role in regulation of stem cell pluripotency and programming as 
well as differentiation and self-renewal capabilities of embryonic stem cells (Melton 
and Blelloch, 2010, Kanellopoulou et al., 2005, Li and He, 2012). miRNAs are 
known to play a vital role in development of organ systems, such as neuronal cardiac, 
lung and other major organs. It usually involves controlling expression patterns 
(temporal or spatial expression) of tissue specific miRNAs in tissue development and 
differentiation (Hobert, 2006, Zhao et al., 2005, Lu et al., 2007, Ebert and Sharp, 
2012, Poy et al., 2004). Even if miRNA still is understudied compared to genetic 
alterations and regular epigenetic features (DNA methylation), given the total volume 
of evidence emerging, it is natural to assume that miRNAs are more or less 
ubiquitously involved in a multitude of cellular processes, similar to genetics and 
epigenetics methylation.   
 As miRNAs are found to regulate targets that are important in cellular functions 
such as differentiation, apoptosis, cell growth, it directly translates their importance 
into initiation and progression of human cancers (Schickel et al., 2008). A seminal 
study in 2002 showed that frequent deletion of miR-15/16 cluster was associated with 
tumorigenesis in chronic lymphocytic leukemia (CLL) (Calin et al., 2002). It was 
observed that there is a downregulation of miRNAs which was associated with 
increase in levels of mRNA expression. Also it was more prominent in tumor tissues 
than in normal tissues (Lu et al., 2005). Expression profiling of miRNA in human 
tumors has revealed signatures of altered expression levels as compared to normal 
tissues. Such altered signatures has also been associated with prognosis and response 
to treatment (Calin and Croce, 2006, Lu et al., 2005). 
 In general, the concept of oncogenes and tumor suppressors is also applicable to 
miRNAs: Upregulation or downregulation of miRNAs as part of a malignant 




miRNAs (OncomiRs) or tumor suppressor miRNAs (Kota et al., 2009, Trang et al., 
2010, Costinean et al., 2006, Ji et al., 2009, Schickel et al., 2008, Calin et al., 2002).  
 In melanoma, a multitude of miRNAs are found to be differentially expressed and 
this is in general associated with genomic regions with frequent gains and losses in 
the tumors. Several miRNAs control and regulate MITF, an important gene in 
regulation of melanocyte development. E.g. the miR-137 act as a trigger of MITF 
transcription (Bemis et al., 2008), while miR-182 acts as a negative regulator of MITF 
expression (Segura et al., 2009). The miR-17-92 cluster (miR-17, -18a, -19a, -20a, -
19b-1, and -92a-1), was found to be playing oncogenic roles with observed 
upregulation in primary tumor cell lines than in normal melanocyte (Mueller et al., 
2009), while inhibition of expression of miR-221 and miR-222) is often oncogenic 
and it usually involves downregulation of c-KIT receptor and p27Kip (Felicetti et al., 
2008). Further, MET, an oncogene that mediates invasive growth, was negatively 
regulated in melanoma by miRNAs, miR-34b, miR-34c, and miR-199a (Migliore et 
al., 2008). In addition to the mere mechanistic observations, several miRNAs have 
also been linked to clinical features of melanoma. The miRNA mir-15b was 
identified as a potential biomarker for tumorigenesis of melanoma as expression of 
this miRNA was correlated with both poor recurrence-free survival and overall 
survival (Howell et al., 2010, Satzger et al., 2010), while low expression of miR-191 
and high expression of miR-193b were associated with poor survival rates in 
melanoma (Caramuta et al., 2010).  
 All of this points to the miRNAs being an important class of molecules, that should 
be subject to many future investigations focusing on identification of clinically 
applicable biomarkers.  
 In the present work (paper III) miRNA was studied in breast cancer samples. In 
breast cancers, miR-10b, miR-125b, and miR-145 are previously found to be 
downregulated and upregulation of miR-21 and miR-155 was observed (Iorio et al., 
2005). As such, association of clinical parameters with expression of miRNAs has 
proven important in understanding and improving breast cancer clinical outcomes 
(Nassar et al., 2017, Goh et al., 2016). A study found invasiveness of breast cancer as 




group of miRNAs including miR-210, miR-21, miR-106b*, miR-197, miR-let-7i, and 
miR-210 (Volinia et al., 2012). In another study of breast cancer, metastasis and poor 
survival has been found to be related with expression of miR-21 (Yan et al., 2008). In 
specific subtypes of breast cancer, miRNAs let-7b-5p, let-7c-5p, and miR-30a-5p 
where found to be downregulated in luminal A and basal-like subtypes. Also, miR-
130a-3p, miR-92a-1-5p, miR-211-5p, and miR-500a-3p were found to be upregulated 
in those tumor subtypes (Oztemur Islakoglu et al., 2018). While, in breast cancer in 
general, the mir-181 family of miRNAs are  found to be upregulated, the miR-181c in 
particular is activated by the expression of HER2 (Tashkandi et al., 2015), and thus 
closely linked to this HER2 positive cancers. Further, in ERα-positive breast cancer 
cells, mir-140 has been found suppressed by estrogen stimulation. This is most likely 
due to ER response elements in the flanking element of the miR-140 promoter (Güllü, 
2015). Despite the many emerging correlations between different miRs and specific 
subtypes of breast cancer, mechanistic information about if and how the miR 
influence the phenotype of the cancers is to a large extent lacking.  
 Some of the well-known oncomiRs and tumor suppressors in breast cancer are 
listed in Table 1. 
 
Table 2: List of miRNAs that act as tumor suppressors (in blue), and oncomiRs (in 
red) in breast cancer along with their target genes and mode of action in tumor (Di 
Leva et al., 2014, Corcoran et al., 2011) (Sassen et al., 2008, Di Leva et al., 2014, 




Mode of Action 
miR-15/16 Wip1  
Regulation of DNA damage response and 
tumorigenesis 
Let 7 family Il6 positive feedback loop control on epigenetic 
transformed state  











It sustains cancer stem cell growth as well as 
invasiveness.  
Down regulation of EGF-driven cell cycle progression, 
and invasion. 
Sensitization of cells to CD95 mediated apoptosis.  
Inhibition of cell motility and anokis resistance 
miR-125 HuR It reduces cell proliferation, migration and induces 
apoptosis. 
 
miR-205 HER3 Inhibition of clonogenic potential and by removing 
HER3 mediated resistance improves response to 
tyrosine-kinase based inhibitors 






Suppression of the tumor suppressor and apoptosis 
promoter gene p27Kip1. 
Promotion of epithelial to mesenchymal transition 
(EMT)  
In basal- like breast cancers 
Repression of Dicer in ERa negative breast cancers 
causing associated clinical aggressiveness 
miR-21 TPM1, 
PDCD4 
Increases tumor growth.  
 Negative regulation of apoptosis. 
miR-155 WEE1, 
FOXO3A 
Decreases efficiency of DNA repair and mechanisms. 
Negatively affect cell survival and response to 
chemotherapy. 
miR-27a Sp Promotes angiogenesis and proliferation 
miR-96, and 
miR-182 





1.3 Contemporary sequencing methods assessing biological factors in 
cancer  
 
“Sequencing” means techniques used to identify the order of nucleotide bases in a 
strand of DNA. Watson and Crick solved 3-dimensional structure of DNA, with help 
of crystallographic data produced by Franklin and Wilkins (Watson and Crick, 1953, 
Franklin and Gosling, 1953), which lead to new era of finding exact order of how 
nucleotides are arranged in DNA, it’s conformations, replication and translation. The 
first real sequencing of nucleotides came from ribosomal RNA from microbes and 
sequencing transfer RNAs (tRNA) (Holley et al., 1964, Holley et al., 1965). At the 
same time period, long DNA sequencing methods, using detection of radiolabeled 
and partial digested of ribonucleotides was also established (Sanger and Coulson, 
1975). This technology, called a ‘plus-minus’ method, was used to sequence the 
complete genome of bacteriophage phi X174, that became the first genome to be 
sequenced (Sanger et al., 1977a).  
 A major development in the field of sequencing was Sanger’s developed of the 
‘chain-termination’ (dideoxy) technique (Sanger et al., 1977b).  Sanger sequencing 
continued to be improved over the years, with improvements in labeling (Ansorge et 
al., 1986, Smith et al., 1985), and detection using capillary gel electrophoresis 
(Ansorge et al., 1987). These arrays of improvements lead to first set of automated 
Sanger sequencing and commercialization of sequencing (Hunkapiller et al., 1991).  
The first generation of sequencing was capable of sequencing DNA of lengths less 
than 1000 bases (1 Kb) and advances in the fields of recombinant DNA (rDNA) 
technology and polymerase chain reactions (PCR), lead to a range of dideoxy 
sequencers (Smith et al., 1986).  
 The next set of evolutions came from introduction of “sequence-by-synthesis”, 
which used measuring of pyrophosphate production using luciferase activity, which 
emits light proportionate amount of pyrophosphate (Nyren and Lundin, 1985, 
Hyman, 1988). This method became popular as it can be observed real time and no 
modification of deoxy ribonucleotides (dNTPs), used in Sanger-sequencing was 




and was licensed by 454 Life Sciences, which became major company in next-
generation sequencing (NGS) technology. 454 sequencing machines (later acquired 
by Roche) innovated using emulsion PCR, which increased the amount of DNA 
sequenced (Tawfik and Griffiths, 1998, Margulies et al., 2005).  
 Sequencing by oligonucleotide ligation and detection (SOLiD), developed by 
Applied Biosystems (which is now Life Technologies), was another popular choice 
for sequencing (McKernan et al., 2009). The development in sequencing world is still 
ongoing, evolving and innovating, some of them are Ion Torrent (Life Technologies), 
which uses difference in pH caused by release of H+ ions (protons). Single molecule 
sequencing are being developed by companies like Pacific Biosciences, VisiGen 
Biotechnologies and various institutional collaboration with companies to name few 
(Heather and Chain, 2016, Ansorge, 2009, Barba et al., 2014). The Solexa method, 
which was purchased by Illumina, replaced emulsion PCR with complementary oligo 
nucleotides fastened to flow cell using solid phase PCR (Turcatti et al., 2008). The 
Solexa method was first implemented in the Genome Analyzer (GA), which could 
sequence DNA as paired end (PE) reads. These sequencers where followed by GAIIx, 
HiSeq and MiSeq systems, which made sequencing accessible, affordable, faster and 
efficient. This technology has over the recent years rapidly become the market leader 
and most sequencing facilities today applies illumina instruments with Solexa-based 
technology. This type of sequencing is also the basis for the work performed in the 
present thesis: all NGS data presented here is generated by Solexa/illumina 
technology. The specific approaches applied are described in some more detail in the 
sections below.  
 The recent technological explosion of developments in the field coined High 
Throughput Sequencing (HTS) or Next Generation Sequencing (NGS) or Deep 
Sequencing or Massively Parallel Sequencing (MPS), has revolutionized the field of 
genomics, and hereunder the field of cancer genomics.  
 In the following chapters, we will discuss the different sequencing strategies used 






1.3.1. Whole genome and whole exome sequencing 
 
Mendelian disorders for selected genes are often investigated using conventional 
methods such as Sanger sequencing (capillary sequencing). The limitations of 
conventional methods required numerous experiments to uncover complex molecular 
and genetic pathways. The introduction of NGS opened the possibility of carrying out 
complex experiments in a cost effective and comprehensive manner. The high 
throughput MPS have brought about advancement in the field of genomics that opens 
a horizon of opportunities as well as challenges. Application of NGS in different 
forms include sequencing such as ChiP-seq (Chromatin immunoprecipitation on 
DNA microarray chip), RNA-seq, de novo assembly of gene and genomes, etc. Here 
we discuss the application whole genome and whole exome sequencing and in 
sections 3.2 and 3.3 we will discuss bisulfite sequencing and small RNA sequencing, 
respectively. 
 Whole genome sequencing (WGS), is a helpful tool to understand the detailed 
organization of the entire genomic landscape. WGS helps in identifying a plethora of 
genomic alterations including point mutations (SNVs), indels, copy number changes 
(CNVs) and structural rearrangements (SVs) to name a few. It also has a unique 
ability to identify exact breakpoints and the nature of SVs, i.e. whether they are 
inversions, translocations tandem duplications etc. (Tuna and Amos, 2013, Xuan et 
al., 2013). Given that WGS provides such a comprehensive overview of the genomic 
landscape of a sample, this strategy can also be used to detect patterns such as 
mutational signatures tumors, reflecting the mutational processes the cells have been 
subject to during the tumor evolution (Alexandrov et al., 2013). 
 
The main advantages of WGS can be summarized as follows:  
 a)  It can comprehensively sequence the whole genome and identify all types of 
genetic alterations. 
 b) Achievable coverage of the genome (percentage of the genome covered) is 
very high. 




 d) It can detect DNA not annotated to the human reference genome (e.g. viral 
elements) 
 d) Wet-lab procedures (library preparation) is relatively easy, since no selection 
of regions is required.  
 
The main disadvantages of WGS can be summarized as:  
 a) Churns out gigabytes (Gb) of data, making it difficult to analyse (requires 
large computational infrastructure). 
 b) The sensitivity to identify mutations and subclones etc. is less as compared to 
other methods (e.g. whole exome sequencing) since the sequencing depth is 
typically lower (due to costs).  
 c) WGS is still expensive (Brittain et al., 2017). 
 
While WGS covers the entire genome and comprehensively captures vast amounts of 
information per sample, there are some drawbacks, as described above. In many 
cases, including many cases of cancer research, there is a more narrow interest in 
somatic mutations affecting protein coding regions, and/or there is a need for higher 
sequencing depth, at a lower cost than what is feasible by application of WGS. The 
alternative solution to study protein coding regions in genome at a lower cost is 
Whole exome sequencing (WES). WES can capture protein coding regions of the 
genome (exons), and potentially other functional regions of specific interest (miRNA 
genes, and non-exonic untranslated regions (UTR) etc. For the purpose of assessing 
alteration within the protein coding regions of the genome, this approach is very cost 
effective (Meienberg et al., 2015).  
 
The main advantages of WES can be summarized as follows:  
 a) It is cheaper and more cost effective than WGS, when assessing only the 
protein coding regions of the genome. 
 b) Data churned out is in more manageable for smaller computational 
environments. 




depth in regions that get sequenced.  
 
The main disadvantages of WES include 
 a) Only a minute portion (1-2%) of the genome is assessed (Brittain et al., 2017), 
thus many alteration affecting regulatory elements etc are lost. 
 b) Structural rearrangements cannot be assessed. 
 c) CNV calling is less accurate than for WGS 
 d) Wet-lab work and costs related to sample preparation are higher for WES than 
for WGS, since baits must be used to capture the regions of interest.  
 
WGS and WES are effective in identifying somatic mutations and indels (small 
insertions / deletions of 1-10 nt) mainly in coding regions as well as in splicing sites 
in exon-intron junctions. But WGS can detect mutations in intronic sites and in 3’ and 
5’ untranslated regions (UTR), that are important in post transcriptional regulation of 
RNA and translational processes. To detect copy number alteration (CNA), primarily 
DNA chip or array CGH was primarily used before advent of WES/WGS. CNA 
analysis using WES with higher depth, produces results that are lower resolution and 
more prone to bias than WGS. WGS helps in analysing CNA in a more unbiased way 
even at a lower depth. As WGS covers the genome more uniformly than WES, and 
covers potential breakpoints, it is suitable for detection of structural variations. 
Similarly, as WES does not capture mitochondrial genomes WGS is well suited in 
that scenario. WGS also helps in effectively identifying sequences from unknown 
pathogens making it an important method of studying pathogen and host human 
genomic interactions in diseases (Nakagawa and Fujita, 2018, Petersen et al., 2017, 
Stranneheim and Wedell, 2016).  
 WGS and WES differ mainly in the cost of experiment, the amount of time taken 
for experiment and the data generated per experiment. Cost difference between these 
technologies are getting closer as well as the time used to sequence is getting 
insignificant. However, in addition to costs a main issue and challenge is the handling 
and analysis of the data generated. While WES produces manageable amount of data 




aspects.  So moving forward in the field, in the near future, most likely will comprise 
the use of a combination of both WES and WGS in an experimental setting as WES 
can provide relevant information effectively and elaborate study on findings can be 
carried forward using WGS (Nakagawa and Fujita, 2018, Petersen et al., 2017, 
Stranneheim and Wedell, 2016). At the same time, in a slightly longer perspective it 
is likely that WGS will become standard when sequencing costs and IT-cost becomes 
more affordable for most research teams. 
 
1.3.2. DNA methylation detection - Bisulfite sequencing 
 
Genome wide identification techniques to identify epigenetic alterations are being 
developed rapidly. To study DNA methylation at single nucleotide level, the popular 
and reliable way is bisulfite sequencing.  
 In general, there are mainly four categories to profile DNA methylation based on 
preparation 1) MRE-seq – DNA methylation that are sensitive to restriction enzymes, 
2) MeDIP-seq – DNA methylation captured by immunoprecipitation using 
methylcytosine-specific antibodies, 3) MethylCap-seq – DNA methylation captured 
using methyl binding domain of MeCP2 (methyl CpG binding protein 2) and 4) 
Bisulfite-seq – DNA-methylation captured using bisulfite treatment of DNA. The 
bisulfite method has an edge over other methods as it can measure methylation both 
at a large number of CpGs and with a resolution of single nucleotides (Baubec and 
Akalin, 2016, Nagarajan et al., 2013, Wreczycka et al., 2017). Also, bisulfite 
sequencing has the advantage of capturing the majority of (all) CpGs, allowing 
identification of less methylated regions in the genome, including regulatory 
elements.  
 Bisulfite sequencing can be done whole genome wise (WGBS), reduced 
representation (RRBS) and targeted (applying a specific panel of genes / regions). 
Irrespective of the type, the steps involved in bisulfite sequencing are the same: 
Genomic DNA of interest is fragmented into smaller sizes in order to prepare 
sequencing library. The fragmented DNA is then ligated with adapters containing 5’ 




procedure, all unmethylated cytosines are converted to uracils. The bisulfite treated 
DNA is then amplified using PCR and any uracils are replaced by thymines. The 
methylation calling in the sequencing procedure depends on bisulfite conversion, 
library amplification and sequencing depth.  
 WGBS helps in obtaining global coverage of CpG methylation and considered as 
global standard. Since WGBS needs larger quantities of DNA as well as being one of 
the most expensive methods, in real life it is often a less favorable choice of analysis.  
 An alternative is to get methylation information with higher resolution is treating 
the genomic DNA with restriction enzymes thus obtaining only regions in genome 
with higher CpG content (RRBS). This step is a tradeoff for cost effectiveness as it 
only sequences at CpG dense regions, it tends to miss out on low methylated regions, 
enhancers, intergenic regions etc.  
 Targeted bisulfite sequencing is similar to WGBS, but instead of whole genome 
specific regions are selected based on interest. This method helps in sequencing 
targets from genomic regions of interest in more cost effective and reproducible 
manner. This provides an affordable solution to run large number of samples by 
multiplexing and sequencing without compromising on high resolution (Baubec and 
Akalin, 2016, Nagarajan et al., 2013, Wreczycka et al., 2017). A specific targeted 
bisulfite sequencing protocol used in the present work involves is the SeqCap Epi 
protocol, a proprietary protocol to targeted enrichment of bisulfite DNA. The SeqCap 
Epi, a procedure that helps on to focus smaller segments of genome for studying 
methylation analysis at a higher resolution, also has ability to multiplex and sequence 
multiple samples to study methylation data in an inexpensive manner (Wendt et al., 
2018). For details on how this was performed in the present work, see materials and 
methods, Chapter 5. 
 
1.3.3. Small RNA sequencing  
 
 To understand transcriptional regulation, there has been a need to study the small 
RNA transcriptome. This class of RNAs are not transcribed to protein but have their 




nucleotides in size and they span in diverse classes based on size and functions. Some 
of the small RNAs are transfer RNAs (tRNAs), micro RNAs (miRNAs), piwi-
interacting RNAs (piRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs 
(snoRNAs), short interfering RNAs (siRNAs), etc (Mattick and Makunin, 2005, 
Wang et al., 2017). Evolution of high throughput sequencing and next generation 
sequencing platforms has vastly contributed to our novel understanding of the 
complexity of the small RNA transcriptome. In earlier stages, small RNA sequencing, 
was synonymous to miRNA sequencing, but nowadays one can isolate and sequence 
small RNA species including both miRNA and several other species  (Wang et al., 
2017).  
 Before deep sequencing, the general strategies used in profiling expression of 
miRNAs was done with large quantities of total RNA run on Northern blot, that 
required radioactive isotope enabled autoradiography. Sequences of miRNA were 
identified by cloning products and sequencing with Sanger sequencing method. Also, 
to some extent microarrays were used in unraveling expression of miRNA signatures 
in different tissue level expression in a variety of patients (Liu et al., 2004). 
 Developments in sequencing miRNAs, helped in creating database known as 
miRbase that hold information of 218 miRNA sequence loci from 5 species. In the 
latest release, the miRbase has more than 38,000 miRNA entries spanning 271 
species (http://www.mirbase.org) (Griffiths-Jones et al., 2006, Griffiths-Jones et al., 
2008, Kozomara and Griffiths-Jones, 2011, Kozomara and Griffiths-Jones, 2014). 
Bioinformatic tools exploit biogenesis of miRNA mechanisms to predict sequences 
and structures. It would unravel new miRNAs as well as known miRNAs that can 
shed light into different biological processes involved and their involvements. There 
are several databases that holds information on miRNA family annotation (Rfam, 
http://rfam.xfam.org) (Nawrocki et al., 2015), as well as intragenic and structural 
details of miRNAs (miRIAD, http://www.miriad-database.org) (Hinske et al., 2014). 
With respect to predictions based on biological features there are myriad number of 
algorithms that helps in discovery and quantification of miRNAs. miRdeep2 
(Friedländer et al., 2012), a tool that predicts canonical and non-canonical miRNAs 




ViennaRNA package (http://www.tbi.univie.ac.at/RNA), that holds information on 
RNA-RNA interactions as well as their evolutionary conservations (Lorenz et al., 
2011). RNAstructure (https://rna.urmc.rochester.edu/RNAstructureWeb/) imparts 
information secondary structure prediction and stability of it with respect to the 
energy of binding (Bellaousov et al., 2013). These are few examples of tools used and 
there are plenty available that works in a similar lane of objectives that are well suited 
for next generation sequencing (Chen et al., 2018). Once prediction or quantification 
of miRNAs are carried out, a typical next step for researchers is to predict the target 
genes that these miRNA target. For this purpose there are established databases that 
hold target information from de novo predictions as well as experimental validations, 
e.g. miRanda (Betel et al., 2008, Betel et al., 2010), TargetScan (Lewis et al., 2003, 
Lewis et al., 2005), miRDB (Wang and El Naqa, 2008). 
 
1.3.4. General approaches in analysis of deep sequencing data 
 
For the type of work presented in the current thesis, it is essential to describe how 
transformation of an idea or hypothesis to results occur in a bioinformatics setting.  It 
is important to understand knowledge gathering and information processing, with 
help bioinformatics tools and methods, to fully understand and resolve complex 
biological issues. Another important aspect is to integrate data from different sources 
and platforms to fully exploit bioinformatics approaches, that helps in unravelling 
complex biological puzzles. Advancements in NGS technologies and availability of 
cost effective ways to handle bulk amount of data have paved a way for availability 
wide variety of genomic data. It will be recommended to use combinations of 
multiple platforms and different types of NGS methods to yield results with higher 
accuracy and fidelity. I.e. even when applying NGS technologies one must use 
different approaches for different biological questions, e.g. mutational analyses vs. 
expression or methylation analyses.   
 As similar to a wet lab experiments, work with biological questions from a 
bioinformatics perspective, can roughly be split up into three main stages; design, 




proper tackling of a biological problem / research question as wells providing 
solution for processing information in the same objective. Subprocesses within these 
three stages will obviously vary depending of the biological problem / research 
question. In the following, we will describe some general features of the three stages, 
and also some features that are more specific for the work in this thesis; features that 
are of particular use and relevance for the field of cancer research.    
 
Figure 9: Overview of Bioinformatics experiment workflow. (I) Design, (II) 
Experiment, (III) Analysis. 
 The first stage can be described similarly to how any experiment is conceived and 
designed, regardless of whether it is a pure wet lab experiment or a project where the 
main work load will be on the bioinformatics side. This is the preliminary stage 
where an idea is evolved into a research question and consequently to a research 
project. The main steps involve gathering already known information about the 
concept and define the areas which is already known and defined. Once the 
hypothesis is ready after refining through already known information, the next step is 
gathering already available data and design a study to achieve the goal. With 
relevance to the present work, here, we discuss with a study design that involves wet 
lab experiments followed by bioinformatics experiment. As required wet lab 
experiments suitable to our study design are concluded, we then proceed to finalise 
what kind of sequencing (e.g., WGS, Bisulfite Seq, RNA-Seq, etc.) on what platform 




sequencing to be used is, heavily dependent on costs. For the field of cancer research, 
this is also often a question of available material, not only from the tumor, but also 
other tissues, as normal tissue is still required to distinguish somatic mutations from 
germline variants in individual patients. Once one has finished wet lab experiments 
and carried out suitable sequencing, the second stage comes, where the main 
bioinformatics and computational approaches of the work take over.  
 The second stage is dependent on the type of sequencing set up in a desired / 
available platform and the experimental approach. Once sequencing is completed, 
data from the platform used for sequencing is carried to computational platform 
accordingly to available facilities. The sequencing of DNA occurs in two different 
ways, a) single-end, that is the fragment gets sequenced only from one end of DNA, 
b) paired-end where the DNA gets sequenced from both ends. The first step after 
sequencing is to ensure the quality of sequenced FASTQ files, a common output 
format for sequences. These file contains a numerical quality score called PHRED 
(Ewing et al., 1998, Ewing and Green, 1998) that describes probability of incorrect 
sequencing per base. This score gives information regarding quality of sequencing 
between lanes and cycles, GC content, sequence bias, artefacts and other 
contaminations. This step of quality control can be generally done in software on 
board platforms or openware tools like FASTQC. The next step involves filtering the 
sequencing data based on quality score, removal of adapters and other artefacts and 
make the sequenced reads, ready for analysis. The data analysis step in this stage 
involves making sense of reads where they come from. Based on experimental set up 
these reads are aligned to a reference genome of interest with help of tools like BWA 
(Li and Durbin, 2009), Bowtie (Langmead et al., 2009), etc. For the work presented 
in this thesis, we used three different version of human genome references such as 
build b37, GRCh38 and hg19. The choice of genome version was dependent on the 
nature of the work involved and other factors involved, such as how and when the 
library preparation protocols were designed. Aligned reads can then be used to 
identify regions of interest in different kinds of formats and study them both 
quantitative and qualitative. The analysis from here starts to become diverse based on 




statistical methods to resolve biological problems as per design of experiment. This is 
where extensive use of different types of programming languages and software is 
required. For analyses of human cancer genomes, this step usually involves mutation 
calling and / or use of sequencing depth or germline polymorphisms to assess copy 
number changes. We used algorithms such as MuTect (Cibulskis et al., 2013a) and 
STRELKA (Saunders et al., 2012) to call somatic mutations and indels. The 
algorithm results for somatic variants were improved by filtering against variants 
detected in matching blood samples. Copy number variations (CNVs) are identified 
from NGS data using several methods. We used a program called as ASCAT (Figure 
10) (Van Loo et al., 2010), to identify somatic CNVs, that calculates allele specific 
copy number profiles along with calculating tumor ploidy. ASCAT achieves this goal 
by calculating allele counts with help of read depth at SNPs. This allele counts are 
then used to calculate logR (normalized log transform of read depths from 
tumor/normal samples) and BAF (allele frequencies in tumor / normal samples). 
ASCAT algorithm uses BAF and logR along with GC correction to provide 
information regarding copy number estimates along with estimation of purity (Raine 
et al., 2016). Notably, common algorithms for CNV calling has a threshold for how 
low the tumor cell fraction (TCF) can be in a sample before CNV calling is 
hampered. E.g. for ASCAT, this is around 20-25%. Thus, for the present work in 
paper II, this problem led us to create an in house algorithm aiming to improve CNV 
calls and tumor purity estimations in samples with low TCF.  
 As a main step in bisulfite sequencing, mapping requires special programs since a 
crucial step in wet lab protocol changes unmethylated cytosines (C) to thymines (T). 
Programs that maps bisulfite sequencing reads tackles this problem as well as 
calculates methylation by taking in account of all C – T conversion in aligned reads 
and taking into account the Cs and Ts in genome. This step makes it difficult to 
distinguish C > T substitutions caused by the bisulfite treatment and C > T SNPs that 
were present in the genome of the samples in the first place. Solving this problem 
requires dual strand sequencing and special SNP calling programs for bisulfite 
sequencing reads (based on the fact that SNPs are located in single base pairs, while 




nucleotide from one DNA strand to the complementary strand). Methylation calls can 
be carried out using several methods but our choice of method was BSMAP (Xi and 
Li, 2009) and  SNP calling was done BisSNP (Liu et al., 2012).  
 After the data is condensed into variants of different types, these are then usually 
annotated to genes and effect on the gene level (e.g. amino acid change) and also 
usually used for higher level analyses, such as mutational signature analyses, 
subclone analyses, co-occurrence / mutual exclusivity – analyses, pathway analyses / 
gene ontology etc. Annotation of single variants in works in this thesis, were carried 
out mainly using Annovar (Wang et al., 2010), while higher level analyses were 
performed using tools such as DAVID (Huang da et al., 2009), KEGG (Kanehisa and 
Goto, 2000) and GATHER (Chang and Nevins, 2006). In identifying and quantifying 
miRNA, tools effectively exploit mechanisms involved in miRNA-mRNA 
interactions. We used Miranda (John et al., 2004) and mirDeep2 (Friedlander et al., 
2008, Friedländer et al., 2012) algorithms in analysis of small RNA sequencing for 
miRNA analysis. 
 The last and final stage involves refinement of analysed data and linking the data to 
biology; i.e. what does the data tell in terms of the biological questions / hypotheses 
that was the starting point for analyses. As per sequencing type, we can collect and 
gather different types of statistical analysis on data attained from stage II. This stage 
also holds the important part of presenting and publishing the relevant findings. 
Although, sometimes thought of as trivial, making proper and readable presentations 
of complex genetic and genomic data is often very challenging and requires large 
efforts form an informatics side. Once desired statistics is obtained, it can be then 
visualised using different kind of tools and software such as SPSS, R, Matlab. 
Visualisation of data and results is most important as this stage directly 
communicates to the audience. It is easier way to represent our results in an easier 






Figure 10: ASCAT profile containing allele specific copy number (left), tumor with 




2. Aims of the study 
 
In the work presented in this thesis we aimed at applying different approaches to 
massive parallel sequencing and subsequent bioinformatics analyses to gain a better 
understanding of the molecular characteristics of human cancers. The sequencing 
approaches applied were whole exome sequencing (paper I), promoter methylation-
specific sequencing (paper II) and microRNA sequencing (paper III). The biological 
characteristics assessed in the analysed samples were multiple and related to survival, 
response to therapy, tumor heterogeneity as well as cancer risk. 
 More specifically, the aims of each of the sub-projects (papers) included in the 
thesis were as follows:  
Paper I 
We aimed at performing a comprehensive characterization of the genomic evolution 
in advanced melanoma, through whole exome sequencing of metastatic deposits. This 
included several metastases from the same patients, and samples collected pre- and 
post- different types of therapy. Based on these data, we wanted to assess the intra-
patient, inter-metastatic heterogeneity including the potential differences between 
early (“trunk”) and late (“branch”) mutations. Further, based on these data, we aimed 
at building a model for the timing of events (mutations and copy number changes) 
through the tumor evolution in advanced melanomas. 
Paper II 
Our aim was to try and establish a screening method for methylation patterns in 
tumor suppressor genes at base-pair revolution. Avoiding the cost of methylation 
specific whole genome sequencing, we established and applied a predesigned panel 
consisting of the promoter regions of 283 tumor suppressor genes.  A sub-aim here 
was to establish a relatively fast and cost effective method that could be run on larger 




instruments with relatively quick turn-around-time (i.e. MiSeq). We also wanted to 
establish a data analysis work-flow for data generated from the sequencing, in order 
to identify potential differentially methylated regions. The back-drop of this work 
was the identification of BRCA1 promoter normal cell methylation being a risk factor 
for ovarian cancer, thus, the overall aim was to establish a method for identification 
of other potential genes where normal cell methylation could be a cancer risk factor. 
We then aimed to assess the feasibility of our strategy and provide proof of concept 
by pilot analyses on normal tissue (blood) samples from 34 healthy postmenopausal 
women. 
Paper III 
We aimed to identify potential novel miRNAs in breast cancer tissue, and if any such 
were found, to explore whether these microRNA are specifically expressed in breast 
cancer (as opposed to non-cancerous breast tissue). Also, we aimed assessing any 
such microRNA’s biological functions by predicting their mRNA targets as well as 
analyzing correlations between their expression levels and the expression levels of 
mRNA involved in different pathways / cellular functions. Further, we aimed at 
exploring any potential clinical roles of the identified microRNAs, as predictive and / 




3. Materials and methods 
 
3.1. Biobank material and previous work 
In the work presented in this thesis, we have analyzed samples from several biobanks, 
based on studies designed for different purposes. 
 
Paper I 
The analysed samples were from patients included in a single arm study originally 
designed to assess response to dacarbazine therapy in metastatic melanoma (REK no: 
020/00-109.99) (Jonsson et al., 2010, Busch et al., 2010). Tumor samples were 
collected and snap-frozen in the operating theatre and peripheral blood was collected 
as control/normal tissue. From a total of 85 patients, 114 samples from 60 patients 
were available along with matched normal tissue for whole exome sequencing 
analysis. From 23 out of these 60, two or more metastatic lesions were analysed and 
used for assessments of intra patient heterogeneity. The collection of samples and 




We analyzed blood samples from 34 women drawn from a study including a total of 
114 anonymized healthy postmenopausal women (Helle et al., 2002). These women 
were recruited from routine mammographic screening at Haukeland University 
Hospital, Bergen, Norway. At the time of selection, women with diabetes or with 
other endocrine disorders or individuals undergoing hormone replacement therapy 
were omitted. These 34 individuals were at BMI range of 19.4 – 39.6 and age range 
of 56 – 71 years. The collection of samples was performed during the PhD work of 
Svein Inge Helle and the use for the present project was initiated by Stian Knappskog 






We included patients from two different studies of breast cancer. The first set of 
samples were incisional biopsies from a study 223 patients with locally advanced 
breast cancer aimed to study treatment responses to epirubicin and paclitaxel 
monotherapy (REK no: 273/96-82.96). Primary responses to therapy along with a 
follow up of more than 10 years or till death were recorded and available for our 
analysis (Chrisanthar et al., 2008). We first studied miRNA expression from 50 
patients taken from this study and quantified expression of candidate miRNAs using 
qPCR in all 223 patients. The second study we took advantage of, included 46 
anonymized breast cancer patients who were undergoing mastectomy. The study was 
originally designed to determine tissue estrogen levels in tumor tissue, normal breast 
tissue from the tumor bearing quadrant, and from non-tumor bearing quadrants 
(Lonning et al., 2009). The collection of samples was performed during the PhD work 
of Svein Inge Helle and the use for the present project was initiated by Anne Hege 
Straume, during her PhD work in the laboratory.  In paper III we drew samples from 
13 of these patients where RNA was available from both tumor and a non-tumor 





3.2 Methods in brief 
 
The methods used in the projects in this thesis follow a pattern of sequence library 
preparation for high throughput sequencing before the actual sequencing process. The 
data obtained from the sequencing is then analyzed different ways according to the 
aim of the projects. The results from the analysis is then in turn interpreted with 
respect to potential implications for clinical aspects. 
 
Paper I 
We carried out paired-end whole exome sequencing of samples, followed by quality 
control of sequencing data. Analysis ready sequencing reads were aligned using 
BWA algorithm (Li and Durbin, 2009) to the human genome reference build b37. 
The cleaned data was then called for somatic mutations and indels with the help of 
two algorithms, Mutect and STRELKA (Cibulskis et al., 2013b, Saunders et al., 
2012). This mutation calling included filtering against variants detected in the 
patients’ normal tissue (blood). The intersection of somatic variants from the two 
algorithms were considered high confidence variants and used for further downstream 
analysis. The somatic variants were then further annotated for functions (potential 
effect on gene / amino acid sequence). Annotations were performed using Annovar 
(Wang et al., 2010). The called and annotated mutations were then restricted to those 
affecting the protein coding regions of genome. Further, for some sub-analyses, 
somatic mutations were then classified into driver and passenger mutations (Hodis et 
al., 2012, Cancer Genome Atlas, 2015, Lawrence et al., 2014). We studied mutational 
signature patterns, using DeconstructSigs (Rosenthal et al., 2016), involved in these 
samples to study whether mutations are likely to be caused by any particular 
previously known mutational process (as reflected by a mutational signature) 
(Alexandrov et al., 2013). We also studied copy number profiles of the samples along 
with estimation of allelic tumor copy numbers and tumor purity. These latter analyses 
were performed using an in-house algorithm that was generated through the work on 




above, we assessed the clonality of mutations and relative timing of mutations, copy 
number changes and genome duplication events. 
 
Paper II 
DNA was extracted from samples taken from healthy individuals recruited form 
mammography screening and analysis was carried out using SeqCap Epi Enrichment 
system by Roche. We captured regions of interest for methylation events, with a 
custom probe design followed by solution-based bead capture of bisulfite DNA. The 
libraries obtained from capturing was then subjected to a paired end bisulfite 
sequencing. In collaboration with Roche, an in-house methylation calling workflow 
was designed and used to identify methylation levels on each single CpG within the 
regions of interest. In the workflow, the initial steps of preprocessing and quality 
control was carried out with help of tools in the package Trimmomatic (Bolger et al., 
2014). After this step, we aligned processed read to human genome (GRCh38), with 
Enterobacteria phage lambda (NC_001416.1) complete genome (added for bisulfite 
conversion efficiency control) using bisulfite mapping algorithm BSMAP (Xi and Li, 
2009). Methylation calling needed further processing of aligned reads with help of 
tools SAMtools (Li, 2011), BamTools (Barnett et al., 2011). This process involves 
gathering methylation information from both strands, as after bisulfite conversion the 
DNA strands are no longer complementary. Methylation analysis was carried out by 
calculating methylation percentage using methratio.py package in BSMAP and SNP 
calling using BisSNP (Liu et al., 2012). Differentially methylated regions were 
identified with help of z-score evaluation of average methylation across samples. Sets 
of identified regions (promoters) with differential methylation were functionally 
annotated with use of GATHER (Chang and Nevins, 2006) and KEGG (Kanehisa and 










We carried out single end small RNA sequencing of 50 selected patient samples from 
a study including a total of 223 patients. Sequenced reads were processed and aligned 
to human reference genome (hg19) as well as known miRNAs from humans and 
other hominids from miRbase 20 (Sasidharan et al., 2013), using the miRNA 
prediction algorithm mirdeep v2.0.0.5 (Friedlander et al., 2008). We predicted novel 
miRNAs from sequencing data after completion of quality control assessment. We 
quantified levels of selected miRNA in all samples from the study (n=223) with the 
help of quantitative PCR. We further validated the presence of miRNAs with help of 
cloning followed by capillary sequencing, to assess in vitro poly-adenylation and thus 
correct miR size. We also predicted target genes for newly identified miRNAs using 
the offline algorithm miRanda (Enright et al., 2003, John et al., 2004) and the online 
algorithms miRDB (Wong and Wang, 2015) as well as  TargetScanHuman Custom 
(Release 5.2) (Lewis et al., 2005). Pathways involved  and gene ontology for those 
genes were identified were assessed using GATHER (Chang and Nevins, 2006) and 
KEGG (Kanehisa and Goto, 2000). Different statistical analysis was carried out with 
help of the SPSS software v.19 and R, to study the potential clinical impact of the 






4. Summary of results 
Paper I 
In this study, we carried out whole exome sequencing of metastatic lesions with 
matched normal tissue (blood) from 60 patients with advanced melanoma. Among 
these 60, multiple lesions were available from 23. Mutation spectrum and copy 
number landscape was determined for all samples and the 23 patients from whom 
multiple samples were available were used to assess intra-patient, inter-metastatic 
heterogeneity.  
 We found the genetic differences between metastatic lesions within the same 
patient to be relatively small. All identified driver mutations were shared between 
lesions within patients with multiple lesion, but a mutation in p.Y163C of TP53, was 
identified as heterogenous driver mutation. Mutational signature analysis of the 
detected mutations indicated that most of the mutations arise from influence / damage 
caused by UV radiation. Whole genome duplication events were identified in 40 % of 
the patients by copy number analysis and genomic complexity was observed to be 
higher in these patients than in patients with diploid tumors. The genome duplication 
is often followed by copy number losses and duplication events. This in turn leads to 
more copy number variations and increasing genomic complexity. From analysing 
clonal status of private mutations, it was seen that there was no evidence to support 
polyclonal seeding with an exception in the case of one patient. Assessing the 
influence of therapy, two patients showed peculiar mutation patterns as compared to 
the others. One of the patients treated with dacarbazine exhibited mutations most 
likely occurring from inactivation of DNA repair pathways, thereby leaving the cells 
vulnerable to the DNA damaging nature of the drug. Another patient showed 
mutations recognised as a mutational signature linked to damage from ionising 
radiation. Importantly, this patient had received radiation therapy towards a previous 
metastatic lesion and we found the signature in a subsequent lesion outside of the 
radiation field. As such, these results provided proof of concept of secondary 
metastatic seeding in melanoma. Importantly, patients with BRAF mutations showed 







In this study we carried out methylation specific sequencing of 565 capture regions 
representing 356 target regions from of 283 tumor suppressor genes in blood samples 
from 34 healthy woman (post-menopausal). We obtained 4.95 million reads per 
samples, on average, and subsequent quality filtering left 88% of reads for further 
analysis. These reads mapped to genome at an average of 3.6 million reads per 
sample, yielding a mean primary target coverage of 189.6x across samples. We found 
CpGs with read depths around 15 x 103 and 0.1 x 106 islands per sample. Bisulfite 
conversion rate in an internal lambda DNA control was found to be on average of 
99.7 %. The reproducibility of the assay was tested and found to be very good, with a 
technical variability far below the biological variability found in the samples. Thus, 
overall, the technical quality of the data was found to be sufficient for proper 
methylation calling analyses. 
 We found variable levels of methylation across the panel of promoter regions for 
the 283 tumor suppressor genes included. We identified 149 genes and 206 regions 
within their promoter regions to be differentially methylated with a confidence level 
of more than 99%, within the sample set, based on a z-score matrix assessment of 
methylation ratios across 565 regions from all 34 samples. We found 115 regions 
with a positive z-score, indicating hyper-methylation in a minority of the samples 
compared to the majority. Out of these 115, 25 regions showed more than 10 percent 
points difference from highest to lowest methylated sample. There were 7 regions 
with more 30 percent points difference within promoter regions of genes: CIITA, 
RASSF1, CHN1, PDCD1LG2, GSTP1, XPA, and ZNF668. We also identified regions, 
in genes, having more than 2-fold relative difference, while lower than 20 percent 
points, in AIP, RABEP1, RASSF1. From extensive literature and database searches on 
the 7 identified genes, we found that CHN1, PDCD1LG2, XPA, ZNF668, RABEP1 
were not reported differentially somatically methylated in tumors. On the other hand, 
CIITA was reported as hypo-methylated in a very small fraction of tumors. RASSFI 




genes could be potential candidates for normal cell methylation assessment, for 
identification of involvement cancer risk.  
 In our study we also used the methylation data to assess potential co-methylation 
patterns across genes and individuals. By hierarchal clustering, we identified two 
potentially major clusters and other sub clusters of altering methylation. However, 
given the limited number of samples in the present study, these clusters must be 
validated in larger sample sets. Assessing difference in methylation and relative 
difference of between region with minimum and maximum methylation across 
patients, methylation was found to be highly variable across tumor suppressor genes. 
It was also observed that some genes showed hyper methylation across regions for 
each patient as well as across patients for each region. Genes identified as hyper 
methylated have been previously reported to be hypermethylated in different cancers. 
This solidifies the impact of studying tumor suppressor genes as candidates that could 
be used to assess cancer risk on large case-control studies. Most importantly, we 
present a feasible method by which future studies in this field could be conducted. 
 
Paper III 
We investigated small RNA sequencing data from biopsies taken before treatment, 
from 50 patients with locally advanced breast cancer. Our initial analysis predicted 10 
novel miRNAs within these samples. Eight out of these were found in single samples. 
Thus, based on the presence in two or more patient samples, we narrowed these 
findings down to two novel miRNAs. First, we validated the presence of these 
miRNAs by cloning them into a carrier plasmid and sequencing them. Further 
validating the presence of these two miRNAs, we applied a highly sensitive qPCR to 
the entire patient set from which the first 50 were drawn (n=223). The qPCR results 
showed presence of the two miRNAs (temporarily named as hsa-miR-nov3 and hsa-
miR-nov7) in 206 and 214 patients, respectively. We then analysed a separate set of 
13 breast cancer patients, where we had samples from both tumor tissue and normal 
tissue from a non-tumor quadrant of the same breast. In this paired sample set, both 




as compared to normal breast tissues, strongly suggesting overexpression of these 
miRNAs in locally advanced breast cancer. We used mRNA expression data 
available for 203 patients out of the 223 patients to narrow down predicted target 
genes for the identified miRNAs. Assuming the miRNAs to inhibit and/or degrade 
mRNAs, we took predicted target genes that were inversely correlated with the 
miRNAs and analysed gene ontology and pathways. It was seen from pathway 
analysis of target genes for these 2 miRNAs that they played roles in cell 
development, communication and homeostasis. Assessing the miRNAs’ impact on 
prognosis, we found hsa-miR-nov3 to have no association to patient survival. hsa-
miR-nov7, showed an association between high expression levels and poor survival, 






We believe that this is the first study that explored heterogeneity in multiple 
metastatic deposit in melanoma in a systematic fashion, thus assessing the genomic 
evolution in the late stages of the disease. While some previous studies have also 
dealt with genomic evolution in melanoma, these have dealt with alterations in the 
genome occurring during melanoma progression, along with locally advanced disease 
and thus provided little or no information about the late metastatic evolution (Shain et 
al., 2015, Ding et al., 2014, Sanborn et al., 2015, Harbst et al., 2014, Harbst et al., 
2016).  
 In general, we found heterogenous mutations in low numbers and the vast majority 
of mutations to be truncal, in accordance with regional metastatic disease (Harbst et 
al., 2016, Harbst et al., 2014, Sanborn et al., 2015). Scarcity of private mutations in 
metastases was similar to previous findings in breast cancer (Yates et al., 2017), that 
shows metastasis to be a late event that occur during evolutionary divergence. The 
fact that we observed branch mutations of UV-related mutational signature 
(Alexandrov et al., 2013), is consistent with our proposed hypothesis, that different 
metastasis may arise from different subclones in the primary tumor. We found a low 
number of private mutations across individual lesions with a correspondingly high 
intra-patient consistency. A similar observation was described in metastatic breast 
cancer (Yates et al., 2017). As this phenomenon was found across two tumor forms 
with the presence of different mutational signature patterns, this may indicate it to be 
an intrinsic propensity related to several cancer forms. Along with this finding we 
observed that heterogeneity correlates to BRAF mutation status, similar study done in 
primary melanoma (Shain et al., 2015), that imply presence of genetic mechanisms 
associated with this process. From our data, most metastases tend to have a 
monoclonal origin with exception on one patient that had indications of re-seeding, 
contradictory to findings made by Sanborn and colleagues that suggests re-seeding to 
be a common phenomenon (Sanborn et al., 2015). Notably, it appears that many of 




that were in close anatomical proximity to each other. Loco-regional relapses, in spite 
of having wide surgical excision margins (Leiter et al., 2004, Urist et al., 1985), are a 
characteristic of thick and large primary melanomas. We found signs of re-seeding 
between metastases in one patient (MM61). This patient showed an unusual clinical 
phenotype, having cutaneous metastatic deposits at more than 100 sites prior to death. 
These deposits were found at different anatomical locations like truncus, shoulders 
and head area and it was along with the 5 other lesions sampled. This suggests the 
development of cutaneous melanoma metastases to have an organ specific propensity 
in line with the studies from Nguyen and colleagues (Nguyen et al., 2009). Even 
though the patient showed distant metastases, tumor cells trafficking were similar to 
patterns of reseeding observed in disease that disseminated regionally (Sanborn et al., 
2015). We observed whole genome duplication (WGD) events prior to metastatic 
divergence and it was associated with high copy number diversity relative to near-
diploid tumors. This ongoing process of copy number alterations was similar to 
observations from other cancer forms (Yates et al., 2017, Jamal-Hanjani et al., 2017). 
 We found BRAF mutations with arm- or chromosome-spanning gains of 7q, that 
have previously been described in primary melanoma (Maldonado et al., 2003). Also, 
we found that low level gains of mutated BRAF allele occurred earlier than whole 
genome duplication. Thus, in general, the amplification of mutant BRAF alleles is a 
rather early event in BRAF-mutated tumors. While BRAF gains through focal 
amplification of smaller segments has been described as a mechanism for acquired 
resistance to BRAF-inhibitors occurred (Shi et al., 2012, Shi et al., 2014), our finding 
indicates BRAF amplification also to be progression driving in non BRAF-inhibitor 
treated cancers. It would be necessary to validate that selective advantage growth is 
boosted by the presence of low level gains of BRAF similar to low level gains of 
KRAS mutants in lung cancer (Kerr et al., 2016). 
 In one patient, we observed an alkylating chemotherapy mutational signature, in 
relation to DNA mismatch repair defects. The signature was previously reported in 
melanoma in relation with temozolomide treatment but not linked to any other 
genomic alteration (Alexandrov et al., 2013). In our study, we observed this signature 




receiving the same therapy had a similar mutational signature, this finding may 
indicate that a DNA mismatch repair impairment is required as a background for the 
therapy induced mutational signature to occur. 
 In another patient, MM85, we found a metastatic deposit with a radiation damage 
mutational signature. Previously, a prominent mutational signature was observed in 
secondary cancer from areas that had undergone carcinogenic ionising radiation 
(Leuraud et al., 2015). This signature was characterised by accumulation of small 
deletions in secondary cancers (Behjati et al., 2016). In our patient, we found truncal 
2-nt deletions and multiple private deletions that resembled the above-mentioned 
signature in two distant metastatic deposits after 5 and 6 months of radiotherapy for a 
regional lymph node metastasis. It is difficult to find direct evidence for secondary 
spread of tumor in melanoma and cancer forms and it remains a topic of controversy 
(Morton et al., 2006). However, our finding of a radiation signature in deposits far 
away from the previously irradiated region (that in turn was far away from the site of 
the primary tumor), strongly indicates secondary seeding of metastases in this patient. 
Unlike chemotherapy, where tumor cells and metastases are affected irrespective of 
their anatomical location, radiation therapy is more focused and applied at localised 
regions with limited radiation scattering outside the treatment field. We identified 
from radiation signature that in turn acts as a “cellular labelling”, that indicated 
secondary seeding from radiation treated lymph node to chest wall and liver. 
Emergence of clonal 2-nt deletions in two deposit within 6 months of radiation may 
even raise some concerns regarding whether radiotherapy treatment could have acted 
as an enhancer of metastatic propensity and tumor aggressiveness. However, although 
we observed the mutational signature to occur, the biological effects of these 
radiation-induced deletions are still unknown, and it may well be that none of them 
were real driver-mutations contributing to the disease progression.  
 In general, for melanoma progression, this study provides evidence for common 
patterns of genomic alterations. It seems from our study that in most cases, metastatic 
deposits have a monoclonal origin with a possible exception of patients harbouring 
multiple cutaneous deposits. The secondary spread from metastatic deposits may 




characterize this phenomenon in advanced melanoma. 
 
Paper II 
As described in chapter 2.4, previous findings have linked methylation of both MLH1 
and MGMT to cancer risk. Importantly, our team’s recent findings have also firmly 
established that early life methylation of BRCA1 confers an increased risk of ovarian 
cancer (Lonning et al., 2018, Lonning et al., 2019). We see it as likely that similar 
mechanisms may be at play for other tumor suppressor genes and other tumor forms. 
In other words that early life and/or inherited methylation may be a cause of a 
considerable fraction of human tumors. 
 In light of this hypothesis, it will be crucial to investigate additional tumor 
suppressor genes where differential methylation in the healthy population may be 
detected. We therefore set out to establish a wet-lab- and informatics pipeline for this 
type of investigation. In order to investigate such hypothesis, it is important to apply 
adequate tools. There are vast variety of epigenetic data based on single gene 
analyses by MSP, MLPA, pyrosequencing or global methylation-array analyses or 
other similar technologies. However, a broad approach, at a base pair resolution is 
required to pinpoint exactly what CpGs / regions of CpGs that are important for 
individual genes to screen for potential candidate genes as risk factors for cancer. The 
ideal case would be to perform whole genome methylation specific massive parallel 
sequencing, but this is currently limited by high costs.  
 We established a gene panel of 283 tumor suppressor genes, consisting of the main 
regions of interests with respect to transcriptional regulation, i.e. restricted to the 
promoters. Also, we established a massive parallel sequencing-based approach, 
enabling base pair resolution analyses methylation status in the gene promoters. 
Using the gene panel helped in massively reducing the cost/resources required for 
analyses and increasing the potential for high-throughput assessments. We 
successfully made DNA-libraries that could be run on any illumina instrument and to 
save time and availability, we ran it on MiSeq. In our runs, we obtained an average 




managed to achieve a sensitivity 0.5%, on average. From our previous studies, we 
found methylation of BRCA1 to confer a risk of ovarian cancer when >4% of alleles 
in WBC were methylated. As such, a sensitivity of 0.5% should be adequate, 
although in theory, there could be tumor suppressors that confer a significant cancer 
risk even when methylated in a lower fraction of alleles in an individual. 
 In our present proof-of-concept experiments, the limited number of samples from 
individuals precluded any form of formal assessment of potential risk factors related 
to genes that are methylated in a low percentage of the population. We know 
methylation is required in at least 11% of the population in order to detect at least one 
methylated individual among 34, with 95% CI. One of the best-characterized 
epimutations conferring cancer risk so far, for BRCA1-methylation, we previously 
observed methylation in approximately 4%, of healthy individuals (Lonning et al., 
2018, Gazzoli et al., 2002).  This states that our study was too limited to fully uncover 
all tumor suppressors that may be cancer risk factors when methylated. However, we 
put forward a proof-of-concept for a strategy to identify risk factors that should be 
extended to large cohorts. 
 Even within our limited cohort of 34, we were able to identify some genes that may 
be potential risk factors that could be explored in case-control studies in a larger 
cohort. We also identified the tumor suppressor promoters most hypermethylated in a 
minority of individuals, to be those of CIITA, RASSF1, CHN1, PDCD1LG2, GSTP1, 
XPA, ZNF668 and RABEP1. Interestingly, in these tumor suppressor genes, three of 
them were reported with germline mutations and have been found to be epigenetically 
deregulated somatically in cancer. Hypo methylation was reported in CIITA across 
several cancer form, in the COSMIC database (Forbes et al., 2017), while 
importantly, both RASSF1 and GSTP1 have been found somatically hyper-methylated 
in cancers (Forbes et al., 2017). Normal cell methylation of RASSF1 and GSTP1 is 
not well studied, but the presence of somatically epigenetic deregulation of these 
genes in cancers, may indicate a potential role also in terms of cancer risk and thus 
potential roles as targets in larger scale case-control studies designed for assessment 
of cancer risk.  




may harbor different methylation patterns. This poses a scenario where differences in 
detected methylation between individuals might arise from differences in their 
distribution of leukocyte sub-fractions. From our previous studies we know that CpG-
rich region of the BRCA1 promoter, seems equally methylated across all leukocyte 
fractions (Lonning et al., 2018), indicating that this problem may be negligible for 
tumor suppressors. On the other hand, there is no guarantee that the findings in 
BRCA1 could be extrapolated into all other tumor suppressor promoters. In our 
present study, we found certain regions in well-known cancer risk genes such as 
MSH2 and PALB2 to be relatively highly methylated in all individuals. However, the 
finding of e.g. MSH2 methylation on limited, defined regions, rather than entire 
promoters, makes their effect on transcription uncertain. 
 In a heterogenous population, it may be a challenge to assess and identify 
methylation differences as potential cancer risk factors, since characteristics of DNA 
methylation is more dynamic than mutations, that are stable alterations. In our study 
design, one of the strengths in this respect, is that the individuals included are drawn 
from a relatively homogenous group. This homogeneity relates to several key factors 
that are well known to affect epigenetics, such as gender, age and hormonal 
influence. Also, the analysed individuals (Norwegians) were homogenous in terms of 
ethnicity. 
 We found 2 major clusters of genes in individuals based on the tumor suppressor 
methylation patterns. Since the individuals we analysed were limited in number, these 
clusters should be interpreted with caution and the results need confirmation in larger 
sample series. Nevertheless, one group of genes clearly differing between the two 
clusters (A), consisted of genes important in pathways like Wnt signalling and TGF-
beta signalling that are important in developmental and regulation cellular processes. 
Another group of differing genes (B) were found to be involved in apoptotic 
pathways and leukocyte differentiation. This implicates that group A may reflect 
methylation patterns of relevance to cancer risk while group B could also be 
implicated in cancer risk but may well be a result of our tissue of choice for analysis 




 In conclusion, we here designed a proof of concept for a relatively fast and 
affordable strategy for detailed assessments of differential methylation of tumor 
suppressor promoters. This strategy is attractive in the warranted search for additional 
tumor suppressors that may be cancer risk factors when methylated in normal tissues. 
Here, we applied a MiSeq sequencer, but use of HiSeq or NovaSeq for high capacity 
analyses of many more individuals over short time would be feasible. This would also 
help to discover and identify regions and other specific features between individuals. 
We made some interesting findings indicating some potential genes that could be 
interesting to do larger case control studies are warranted. 
Paper III 
In this paper our aim was to identify novel miRNAs, potentially specifically 
expressed in breast cancer, in a cohort of locally advanced breast cancer samples. By 
use of massive parallel sequencing, we found 10 novel miRNAs out of which 2 were 
found present in more than one patient, and therefore considered as trustworthy 
findings (these were preliminary termed hsa-miR-nov7 and hsa-miR-nov3). In spite of 
these two miRs only being predicted in 2 and 6 out of 50 initially sequenced biopsies, 
both were found expressed in the vast majority of patients with varying levels of 
expression, when assessed by highly sensitive qPCR. Our initial findings were also 
validated in vitro.  
 In a separate set of breast cancer patients, we assessed expression of these 2 miRs 
in tumor tissue versus matched normal breast tissue, from a non-tumor bearing 
quadrant. From the relative expression from matched samples, we suspected that 
these miRs may play a role in breast cancer as they were more highly expressed in 
tumor samples as compared to normal breast tissue. However, the absolute expression 
levels as well as the ratio of overexpression in tumors versus normal tissue were still 
rather low, so the biological roles of these miRs with respect to breast cancer have to 
be interpreted with caution.  
 The potential involvement of these miRs in cancer development and progression 
was also studied with help of in silico prediction of targets followed by validation 




While correlations to biological and cellular processes were detected, no of these 
were clearly linked to cancer, to such a degree that the miRNAs specific function can 
be said to be cancer related.  
 We found hsa-miR-nov3 to be significantly higher expressed in ER-positive breast 
cancers as compared to ER negative ones. We also found high expression levels of 
hsa-miR-nov3 in the expression based breast cancer subtypes like luminal and 
normal-like tumors. Whether the hsa-miR-nov3 has any role in the development in 
these subtypes of breast cancer or whether the correlations are mere co-variates of 
other molecular features in these cancer remains to be assessed. 
 We then carried out a search for potential targets for these two miRs. Realising the 
variability in different prediction algorithms, we chose a conservative approach and 
used three different target prediction algorithms followed by filtering of the results by 
only using the intersection of predicted target from all these 3 algorithms. In a 
subsequent step, we further refined the list of targets using the intersection with a 
predefined list of tumor suppressors. We could not observe any statistically 
significant inverse correlation of these final set of genes to miRNAs. But there were 
some interesting connections. We propose ATRX as a target hsa-miR-nov3. This is a 
gene involved in in chromatin remodelling. It is part of the SWI/SNF family, and it 
has been associated with LOH in breast cancer (Roy et al., 2008). This was in line 
with our finding where it was reported that mutations in the SWI/SNF family genes to 
be enriched in relapsed breast cancer as compared to primary cancers (Yates et al., 
2017). Thus, this supports the hypothesis of a breast cancer promoting function for 
hsa-miR-nov3. Similarly, for hsa-miR-nov7, we propose APC, SFRP2, and CDH11 
as potential targets. Interestingly both APC and SFRP2 are involved in regulation of 
the Wnt-signalling pathway (von Marschall and Fisher, 2010, Rattner et al., 1997, 
Hankey et al., 2018) and are reported targets for targets for several miRNAs in breast 
cancer (Isobe et al., 2014, Tan et al., 2016, Liu et al., 2018). This may imply a role 
for hsa-miR-nov7 in Wnt signalling from our observations. Notably, hsa-miR-nov7, 
during our work with the present project, was identified by Lim and colleagues as 
miR-10393-3p (Lim et al., 2015). Their study reported this miRNA was associated 




involved in chromatin modifications. While this differs from our present finding and 
study setting, this may be like due to tissue specific effects of the miRNA. As such, 
we need further investigations to fully identify the functions of these two miRs. 
 We examined the possibility of association of miRNAs hsa-miR-nov7 and hsa-miR-
nov3 with clinical outcomes in 223 breast cancer patients based on finding that were 
overexpressed in the tumor tissue of breast cancer patients. These patients were 
enrolled to assess response to primary chemotherapy (monotherapy epirubicin or 
paclitaxel in the neoadjuvant setting) that enabled us to assess association of hsa-miR-
nov7 and hsa-miR-nov3 levels with primary therapy response and also with long term 
survival (10-years). We found weak trends only and no significant impact on 
treatment response or survival, regarding any predictive or prognostic role for the two 
investigated miRNAs. We found no effect in epirubicin arm, but we found trends 
towards poor overall survival and relapse-free survival linked to hsa-miR-nov7, in the 
paclitaxel arm of the assessed clinical trial.  No prominent association to clinical 
outcome was found for hsa-miR-nov3.  
 As number of samples included in the quadrant study was low, even though we 
observed overexpression in cancerous tissue versus normal breast, we cannot confirm 
the prognostic role of these miRNAs. This issue can only be sorted with further 
studies with a larger patient cohort. Alternatively, as the observed overexpression in 
tumor tissue compared to normal breast tissue may indicate signals from 
tumorigenesis and implies the miRNAs could play a role in tumorigenesis but not 
later tumor progression. 
 
General discussion 
The presented work, focus on molecular features of two of the most common cancer 
forms in Norway. Although both are well studied, there are still many important 
unanswered questions regarding the molecular features of both cancer forms. In the 
present work, paper I represent a large effort to reach new insight into the genomic 
evolution of metastatic melanoma. Here, we provide new biological information. 




studies that may be much larger and answer the biological question that was 
underlying the pilot: are there any additional genes where early life methylation of 
normal cells may cause cancer. This question remains open, but we have provided a 
possible strategy by which future studies can address this question. The work for 
paper III was originally designed with the intention to identify novel miRNAs. Even 
if we did so, the number of detected novel miRNAs was limited and the question of 
the biological importance of low level expressed miRNA remains open.  
 From a methodological perspective, the work in the present thesis represent three 
different approaches for application of massive parallel sequencing in translational 
cancer research. While the small RNA sequencing to identify novel miRNAs is a 
“global” approach, without any pre-selection of regions, both papers I and II rely on 
selection of specific regions before sequencing. Although these strategies of pre-
selection have their advantages as discussed in the sections above, it is clear that the 
way forward for translational cancer research will be full genome assessments, both 
for mutation calling, but also probably for methylation calling. As such, it is likely 
that the sequencing strategy used in paper III will be applied also in a longer time 






6. Future perspectives 
Paper I 
This study provided insight into common patterns involved in genomic alterations at 
time of melanoma progression. We performed our study on metastatic lesions of 
melanoma and we could track back “historical events” in the evolution of the disease. 
In order to validate our findings and possibly also dig deeper in the earlier events 
during disease progression, it would be very interesting to perform in depth analysis 
of primary tumors as well as regional metastatic deposits. It is very hard to design a 
prospective study for both primary and metastatic disease because one would have to 
recruit patients at the time of primary and then “wait” for the metastases. The most 
realistic option would be to use retrospective material by gaining access FFPE-block 
of the primaries after patients have been recruited to the study due to metastatic 
disease. For the sample set used in Paper I, such collection of FFPE-material from the 
primary tumors is currently ongoing.  
 It should also be noted that we applied WES in our present study. This led to a very 
low number of data points for some patients in some of the analyses (both analyses 
with respect to subclonality and with respect to mutational signatures of branches 
versus trunks in the phylogenetic trees of each patient’s disease). It is clear that, in the 
future, such analyses would benefit from full genome sequencing (WGS), a method 
that would also allow for analyses of other types of mutational signatures than SNV-
signatures, such as rearrangement signatures. As such full WGS would provide us 
with richer data set to assess the timing of events during the metastatic process in 
melanoma. 
 In addition, heterogeneity between metastases is most likely not limited to 
alterations on the genetic / genomic level. There may be important differences with 
respect to epigenetic features. As such, it would be of interest to characterise the 







In this study, we have effectively established a workflow to identify potential cancer 
risk factors in healthy individuals by the evaluation of patterns in promoter 
methylation of tumor suppressor genes. The main limitation to our study was the 
smaller selection of individuals (n = 34). Even though we provided proof-of-concept 
that our method could be used to identify hypermethylated tumor suppressors in 
normal tissues in a small minority of healthy population, it is clear that the real 
validity of the approach lies in finding a real risk factor in a much larger sample set. 
Our initial study was restricted to females following the findings in our previous 
paper identifying BRCA1 promoter methylation as a risk factor for ovarian cancer. In 
next phase, where we plan to include more samples, we would also include male 
individuals since we expect similar mechanism of tumor suppressor methylation as 
risk for other tumors irrespective of gender. We have provided an analysis strategy to 
identify novel potential candidates as these epimutations may confer elevated risk of 
cancer in individuals. Provided we can identify likely important risk factors by larger 
screening of healthy individuals, an obvious second step would be scale up further, 
and perform larger case-control studies to assess the level of risk (ORs) related to 
methylation in our candidate genes. Since the ORs related to methylation might be 
limited (lower than what we see for mutations in the same genes), it is clear that large 
cohorts are needed. Such cohorts are perhaps difficult to get access to in Norway, but 
for our findings related to BRCA1, we have now an established collaboration with the 
American Women Health Initiative (WHI) biobank, and it may be possible to use 
this, or similar, case-control studies of other genes as well in the future. 
 
Paper III 
The main aim of our study was to identify novel breast cancer miRNAs. We detected 
two novel miRNAs in 2 and 6 patients, respectively, by initial screen using NGS 
analysis, and then in all most all patients by quantitative PCR. This indicates that the 
sensitivity was much higher for the qPCR method than NGS and underlines the 




application of NGS.  
 In our screen, we found 8 novel miRNAs in one patient each. Due to the sensitivity 
issue discussed above, it may be that these miRNAs are specifically expressed in 
locally advanced breast cancers and/or that these are in fact expressed in many more 
patients, but that they were missed by our screening. If we had chosen to test these by 
ultra-high depth of sequencing or by qPCR assay, then the outcome could potentially 
have been different. However, even if detected in the patient samples, we are unsure 
of the biological impacts of these miRNAs on clinical features such as response to 
treatment and prognosis since the expression levels must be very low.  
 The next step, based on the findings for hsa-miR-nov7 and hsa-miR-nov3, would be 
to further assess why they are overexpressed in breast cancer; whether they have any 
impact on features such as cell cycle progression, invasiveness, metabolic changes 
etc, or whether the observed overexpression is merely a side effect of some other 
deregulated mechanism. 
 
Future of NGS-based molecular cancer research 
Many of the issues discussed above as future perspectives, are related to the 
generation of more data, higher sequencing depth etc. Today, many of the analyses 
we would like to do are limited due to prohibitively high costs related to sequencing, 
availability of proper informatics tools, storage space etc. It is important to note that 
new and exciting technologies and instruments are already on their way, that would 
enable many of the analyses we cannot do today. In the time passed since the wet-lab 
work for this thesis was completed and up until now, the team has acquired and 
installed the very first NovaSeq instrument in Norway. This has led to large drop in 
sequencing costs and enabled a massive increase in the throughput of analyses. With 
time, in the not so far future, it is likely that further drops in sequencing prices will 
make WGS almost as cheap as WES. In a longer time, perspective, it is clear that 
most of the issues related to restrictions in data amounts will be solved by affordable 
high depth WGS.  




developed. The nanopore technology is already established in many laboratories 
requiring long reads. For the field of cancer research, this technology is still 
hampered with a high error rate for single base calls, making it challenging to use for 
mutation calling. However, cancer researchers already use this type of sequencing for 
calling of structural rearrangements, since it gives high confidence in identifying 
break points. Also, it is an ideal technology for identification of splice variants on the 
mRNA level. With reduced error rates, it is reasonable to assume that this type of 
sequencing will become more used in cancer research in the future. Notably, it is also 
possible that this technology will be able to distinguish between methylated and 
unmethylated Cs in the DNA, and thereby merge genetic and epigenetic wet-lab 
analyses into one. 
 With the ongoing rapid technological development in DNA sequencing and the 
continuous generation of large data sets, handling the vast amounts of information 
will for sure be a major challenge in the future, but also a great source of knowledge 
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Patterns of genomic evolution in advanced
melanoma
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Genomic alterations occurring during melanoma progression and the resulting genomic
heterogeneity between metastatic deposits remain incompletely understood. Analyzing 86
metastatic melanoma deposits from 53 patients with whole-exome sequencing (WES), we
show a low branch to trunk mutation ratio and little intermetastatic heterogeneity, with driver
mutations almost completely shared between lesions. Branch mutations consistent with UV
damage indicate that metastases may arise from different subclones in the primary tumor.
Selective gain of mutated BRAF alleles occurs as an early event, contrasting whole-genome
duplication (WGD) occurring as a late truncal event in about 40% of cases. One patient
revealed elevated mutational diversity, probably related to previous chemotherapy and DNA
repair defects. In another patient having received radiotherapy toward a lymph node
metastasis, we detected a radiotherapy-related mutational signature in two subsequent
distant relapses, consistent with secondary metastatic seeding. Our findings add to the
understanding of genomic evolution in metastatic melanomas.
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The incidence of melanoma is rapidly increasing amonglight-skinned people1, where both epidemiological2 andgenomic evidence have established the link between mel-
anoma etiology and UV radiation3–5. Many melanomas reveal an
indolent course characterized by locoregional relapses followed by
a rapid emergence of metastatic disease, and there is evidence
suggesting that systemic dissemination may bypass intermediary
stages of lymph node involvement6,7.
Somatic mutations found in a cancer mirror its initiation and
evolution, and genomic sequencing may thus map the progression
of melanomas from earlier stages of development, enabling
inferences that are empowered by comparisons of multiple lesions.
While a few studies have used comparative lesion sequencing to
assess genomic events during the process from benign lesions to
primary melanomas8 and progression from primary to regional
disease9, most studies of metastatic melanoma have explored
genome evolution in response to targeted therapy10–12. A picture
is emerging where most UV-associated mutations arise in the
primary tumor prior to malignant transformation, followed by an
increased frequency of copy number alterations8. The genomic
events driving tumor progression toward advanced disease, how-
ever, remain incompletely understood.
Melanomas have low sensitivity to chemotherapy13. While
recent developments including immune checkpoint inhibitors
and BRAF/MEK targeting agents have improved the outcomes
significantly, many patients do not achieve durable remis-
sions14,15. Thus, improvements in therapy are needed. This may
be facilitated by an improved understanding of genomic events
associated with accelerated growth and dissemination.
Here we performed whole-exome sequencing (WES) of single
or multiple metastases from a cohort of patients with advanced
melanoma. Our findings add novel data to the understanding of
the chronological sequence of genomic alterations. This
includes early copy number gain of the mutated BRAF allele and
the finding that whole-genome duplication (WGD) in general
occurs as a late truncal event. While we found evidence
indicating polyclonal seeding in one patient, this seems to be a
rare event. Among four patients exposed to dacarbazine, we
observed a “mutational signature” in one, probably related to
several MSH6 mutations in her tumor. Moreover, the finding that
radiotherapy toward a lymph node metastasis may influence
mutation signatures in subsequent deposits in organs
distant from the treatment site supports the hypothesis that
cancers may progress also through secondary spread from
metastatic deposits.
Results
Single-base substitutions and indels. We analyzed 114 meta-
static lesions with matched normal tissue from 60 patients
diagnosed with advanced melanoma by WES. All patients were
from a prospective study assessing dacarbazine therapy for
metastatic melanoma16,17. Eighty-six lesions from 53 patients
consisting of at least 20% tumor cells (threshold for copy number
profiling) were selected for further analysis (identified mutations
in these samples are presented in Supplementary Table 1). Mul-
tiple lesions were available from 23 out of the 53 patients, and
single-metastatic lesions were available from the remaining 30
(Table 1, and Supplementary Tables 2 and 3).
The number of somatic variants identified in coding regions
per patient (average across samples for patients with multiple
biopsies) varied substantially, with between 17 and 4089
mutations identified (range: 0.34–81.8 mutations per megabase,
median: 9.6; Fig. 1a). With few exceptions, tumors with primary
origins at sun-exposed sites all displayed mutational patterns
characterized by C>T transitions at dipyrimidine sites, in contrast
to tumors derived from areas not exposed to UV radiation
(Fig. 1b), consistent with UV-induced DNA damage (Fig. 1c).
One acral melanoma had a UV-associated mutational signature,
as has also been observed by others18,19. Overall though, patients
with sun-exposed primary tumors had a higher mutational load
than patients with primary lesions at sites with little or no such
exposure (p < 0.001, Mann–Whitney U-test [MW]; Supplemen-
tary Figure 1a). No difference in mutation load between the
lymph node and subcutaneous or visceral organ metastases was
recorded (Supplementary Figure 1b).
Among nine patients diagnosed with metastatic melanoma
without known primary lesions, the types and numbers of mutations
resembled those observed in metastases from sun-exposed primary
lesions, strongly suggesting cutaneous origins (Fig. 1, Supplementary
Figure 1a) as previously reported by others20.
Driver mutations and genomic complexity. Using a con-
servative approach to identify driver mutations, we considered
mutations in a set of predefined genes based on recently pub-
lished studies3,21,22. Mutations in these genes were manually
assessed to determine their status as drivers or passengers
(Methods section). The complete list of mutations in these
genes is presented in Supplementary Table 4. Driver mutations in
BRAF and NRAS were detected among 28 (53%) and 17 (32%)
patients, respectively (Fig. 1d), with one patient carrying a non-
canonical driver mutation in BRAF (p.E586K) in combination
with a driver mutation in NRAS (p.Q61L). While protein-altering
mutations in NF1 were identified in five patients, only two of
these fulfilled our criteria for definition as driver mutation. Driver
mutations in GNAQ and GNA11 were identified in two uveal
melanomas, and a driver mutation in KIT was found in mucosal
melanoma.
Considering patients with multiple sampled lesions, all driver
mutations identified were shared between metastatic deposits,
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except for two patients, both revealing heterogeneous and
subclonal distribution of the p.Y163C TP53 mutation.
In accordance with previous reports22,23, we found the
number of mutations to vary according to driver mutation
status in BRAF, NRAS, and NF1 (p= 0.002, Kruskal–Wallis
rank-sum test [KW]; Supplementary Figure 1c). Based on copy
number profiling (Supplementary Figure 2a), we inferred
whole-genome duplication (WGD) events to have occurred in
about 40% of patients (Supplementary Figure 2b), with no
difference between tumors harboring BRAF (11/27) or NRAS
(7/17) mutations. The duplication events likely predated
evolutionary divergence of metastases, as they were identified
across all lesions obtained from these patients. Notably, the
genomic complexity (defined as the fraction of the genome in
an aberrant state, i.e., deviation from a balanced copy number
of two for diploid tumors and four for WGD) was substantially
higher in samples with WGD, with a mean of 69% for WGD
and 30% for diploid tumors (p < 0.001, MW test; Supplemen-
tary Figure 2c). A difference in genomic complexity of this
magnitude indicates a greater propensity for genomic altera-






















































































































Fig. 1 Overview of mutations. a–d Left: patients from whom multiple lesions were analyzed. Right: patients from whom single lesions were sampled.
Patients are ordered by the number of mutations identified per patient, and lesions are further ordered according to time of sampling. a Number of
mutations per megabase in each individual sample. Samples from different patients are indicated by alternating shades of blue. † One patient had a
borderline acral primary tumor situated at a toe. ‡ One patient had a perianal cutaneous primary tumor, likely not exposed to UV radiation. b Fraction of
mutation types per lesion. c Estimated contribution of mutational processes by fraction of mutations explained by each mutational signature26, according to
the classification of Alexandrov et al.32. Only signatures explaining >5% of mutations are shown, and only signatures 7, 1, 5, 11, and 17 were assessed.
d Mutations identified per lesion in established melanoma driver genes are color-coded: red boxes indicate driver mutations and gray boxes indicate
passenger mutations. Multiple mutations per gene are indicated with ”+”. Genome duplication events are shown per sample in gray (diploid) or black
(genome duplication) for each sample
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Heterogeneity across intraindividual lesions. We also observed
larger copy number diversity (defined as the mean number of
copy number alterations separating samples from individual
patients) in patients if WGD was present compared to patients
with diploid tumors, where the median copy number diversity of
patients with diploid and WGD cancers was 2.8 (range 1–26) and
23 (range 6–161), respectively (p= 0.004, Fig. 2a). This suggests
the copy number evolution to be an ongoing process occurring at
a higher rate in melanomas with WGD. Diversity in copy num-
bers was observed across the genome, with no chromosome being
overrepresented (p= 0.3, KW test; Supplementary Figure 3).
In order to investigate the mutational heterogeneity between
melanoma metastases, we identified trunk and branch mutations
for each of the 23 patients having multiple lesions examined.
Mutations were classified as trunk mutations when found in all
lesions examined from a particular patient, or when the absence
of a mutation could be explained by a copy number loss or lack of
sequencing depth in a sample without this mutation. Branch
mutations were accordingly defined as those mutations whose
absence could not be explained by the same features. Branch
mutations were further defined as private when exclusively
identified in a single sample. Thus, we defined mutational
diversity for each patient as the average number of branch
mutations across lesions.
Patients generally displayed a low degree of mutational
diversity (range: 0.5–893, median: 5) when compared to the
number of trunk mutations (range: 17–3966, median: 465; Fig. 2b,
c). Thus, with the exception of a single patient (MM02) whose
metastatic deposits contained 89% branch mutations (probably
related to chemotherapy exposure; see below), the branch
mutations for each individual patient accounted for only
0.08–14.9% of the mutation load. Notably, across patients, no
correlation between the number of trunk mutations and
mutational diversity was observed (rs= 0.01, p= 0.95, Spear-
man’s rank correlation).
While the number of mutations private to any lesion varied
substantially (range 0–1156), the number of private mutations
revealed a remarkable within-patient consistency, indicating an
intrinsic propensity for mutational accumulation (Supplementary
Figure. 4). Excluding patient MM02, who had an extremely high
number of private mutations in both lesions sampled, from
statistical comparison, we found the degree of intraindividual
variation across the sample set to be significantly lower as
compared to interindividual variation (p= 0.003, Levene’s test for
homogeneity between groups). Assessing within-patient differ-
ences in types of branch mutations, we found small variations in
mutation types related to private mutations across samples, as
well as branch mutation types according to clonal status
(Supplementary Figure. 5a and b), supporting mutational
accumulation to be related to tumor intrinsic phenotypes.
Mutational diversity was significantly lower in tumors harbor-
ing a BRAF versus an NRAS or NF1 mutation (p= 0.01, KW test;
Fig. 2d). While this mirrored the difference in mutational load in
general, the lack of correspondence between the number of trunk
mutations and mutational diversity between tumors suggests
these observations to be independent. No correlation between
mutational and copy number diversity across patients was
observed (rs=−0.07, p= 0.8, Spearman), and copy number
diversity was unrelated to BRAF, NRAS, or NF1 mutational status










































































































































Fig. 2 Mutational heterogeneity. a Copy number diversity according to whether genome duplication was identified in samples from each patient.
b Branch mutations (found in more than one, but not all samples) and private mutations (found exclusively in one sample) per lesion. For MM02, a
separate axis is used to capture the large number of private mutations. c All mutations (private, branch, and trunk mutations) presented together for each
lesion. d Mutational diversity (average number of branch mutations per sample) in patients according to driver mutation status of BRAF and NRAS. The Y-
axis is broken for clarity due to the high mutational diversity in MM02
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Categorizing patients into four groups based on the largest
anatomical distance between sampled lesions (same site; different
site, but same region; different regions; or different organ system),
we observed no difference in either mutational or copy number
diversity related to anatomic distance between the samples (p=
0.3 and p= 0.7, KW test; Supplementary Figure 6). Also, there
was no difference in diversity between synchronous metastases
and those collected with an intervening time period (p= 0.5 and
0.7, KW test, for mutational and copy number diversity,
respectively).
Shift in mutational processes. Comparing trunk to branch
mutations, there was a clear shift in the types of mutations
between the two groups, with branch mutations being drawn
from a much more widely distributed repertoire of mutation
types (Fig. 3). All of the patients with multiple sampled lesions
had primary lesions in sun-exposed locations (or unknown pri-
maries) and, consistent with a history of sun-exposure, muta-
tional signature analysis26 revealed 42–93% (median 84%) of
trunk mutations to belong to the UV signature (Supplementary
Figure. 7a). The limited number of branch mutations made any
signature derivation uncertain. However, we observed a mutation
pattern consistent with an UV signature in a total of six out of 14
patients (Fig. 3 and Supplementary Figure 7b), and in one patient
(MM01), UV-related mutations was the major mutation type in
the branches. In contrast, we observed no enrichment of UVA-
associated T>G transversions27,28.
Evaluation of polyclonal seeding. Studies of metastatic
cancers including melanoma have unveiled polyclonal seeding
and complex patterns of metastatic dissemination9,29. Applying
the pigeonhole principle30, the cellular prevalence of
mutations can be used to infer the order of mutational accu-
mulation and selective sweeps in populations of cancer cells.
When comparing the cellular prevalence of mutations in two
different samples of common ancestry, subclonal mutations
shared across lesions may indicate polyclonal seeding, while the
presence of lesion-private and clonal (defined as a mutation
occurring in all tumor cells in that lesion and not in others)
mutations would preclude such an interpretation and likely
indicate a monoclonal origin.
We compared the relative variant allele frequency (rVAF;
reflecting cellular prevalence) of private mutations in each lesion
to that of trunk mutations (Fig. 4a, Supplementary Figure. 8). The
rVAF distribution of trunk mutations was used to infer the likely
clonal status of private mutations in each sample. Although many
private mutations were clearly subclonal (e.g., MM17; Fig. 4a), 41
out of 53 samples revealed at least one clonal private mutation
(Fig. 4b), implying an absence of polyclonal seeding. Only two
patients (MM24 and MM31) lacked clonal private mutations
altogether. Except for two mutations in MM31 having low rVAFs
in both sampled lesions, these patients did not have shared
subclonal mutations. Thus, we concluded that there was no
strong evidence supporting polyclonal seeding in these patients
either. Cross-sample mutation clustering, applying PyClone31,





























































































































































Fig. 3 Comparison of trunk and branch mutations. Heatmaps show the relative frequency of mutations among branch mutations (top panel; gray) and
branch mutations (bottom panel; blue) for each patient. C>T transitions are categorized as occurring downstream of pyrimidines (Y) or purines (R). The
combined fractions of mutations represent the sum of mutations for each type relative to the total number of mutations for either trunk or branch
mutations. * Due to the high number of branch mutations in MM02 (n= 1786), the bar is truncated for this patient. ** In the summary of branch mutation
types, mutations in MM02 are omitted for clarity (branch mutations in MM02 displayed a particular mutational signature; see Supplementary Fig. 7 and 11
for details)
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one patient (MM61; Supplementary Figure 10), from whom five
lesions were sampled, three were without clonal private muta-
tions, and a number of shared mutations with low rVAFs were
detected in multiple samples, possibly indicating a population of
cells shared subclonally between lesions31. These findings may
indicate polyclonal origins of, or reseeding between, lesions in this
patient.
The common finding of private clonal mutations is consistent
with a monoclonal origin of most metastatic lesions and
indicates branching evolution. Furthermore, the observation
of a UV-related mutational signature in a fraction of branch
mutations (Supplementary Figure. 7b) could indicate that different
metastases may originate from different subclones in the primary
tumor.
Potential influence of therapy. Two patients revealed atypical
mutational patterns probably caused by prior therapy. One
patient (MM02) had received two cycles of dacarbazine after
mistakenly being diagnosed with metastatic disease. Eight months
later she was correctly diagnosed with a distant subcutaneous
metastasis to the abdominal region and a locoregional relapse,
both of which were sampled. Nearly all private mutations were
observed to occur clonally (within all cells) in the distant
metastasis, but in a minor subpopulation of cells (~15%) in the
locoregional relapse (Figure. 11a) and were further attributed to a
mutational process previously ascribed to temozolomide treat-
ment in glioblastoma and melanoma32,33. Emergence of this
signature has been found to depend on concomitant inactivation
of DNA mismatch repair and, potentially, DNA methyltransfer-
ase MGMT in glioblastoma33,34. Here we identified three private
MSH6 mutations in two lesions sampled from this patient, all of
which coincided with the (sub-)clonal populations of hypermu-
tated cells (Supplementary Figure. 11a). Further, reassessing
previously published data16, we identified transcriptional loss of
MGMT in one, while the second sample revealed an MGMT
expression level close to the median across the sample set (Sup-
plementary Figure. 11b). Notably, neither this signature nor
mutations affecting MSH6 was detected in tumors from any other
of the three patients with at least one sample collected ≥6 months
after dacarbazine therapy.
The second patient (MM85) received regional radiotherapy
following surgical removal of a submandibular lymph node
metastasis, with subsequent sampling of two metastatic lesions: a
liver deposit (5 months later) and a subcutaneous lesion on the
chest wall (6 months later; Supplementary Figure. 12a). Here, a
large fraction of both trunk and private mutations constituted a
unique mutational signature of small deletions, typically two
nucleotides in length (Supplementary Figure. 12b), akin to a
recently described pattern of mutations in radiation-induced
secondary malignancies35. To the best of our knowledge, such a
signature has not been described in melanomas. Strikingly, all
private deletions were clonal, contrasting other private mutations
in these samples (Supplementary Figure 12c). The finding of this
signature in both subsequent samples located well outside the
radiation field strongly favors the hypothesis of secondary spread,
indicating the cells from the radiated submandibular area, and
not the calvarian primary lesion (Supplementary Figure. 12a), to
be the most recent common ancestor. However, in another five
patients having tumor samples collected ≥6 months after
initiation of radiation therapy, we did not observe a similar
mutational signature. While we could not detect any mutations in
DNA repair genes in the tumor tissues of patient MM85, it
remains likely that this tumor may harbor particular defects
conducive to the development of signature mutations in response
to ionizing radiation.
Sequence of genetic alterations during melanoma development.
The relative timing of genomic events occurring throughout
cancer progression may be inferred by integrating information











































































































































Fig. 4 Cellular prevalence of mutations. a Relative variant allele frequency (rVAF); that is observed variant allele frequency corrected by tumor purity, local
total copy number and estimated number of mutated alleles, for mutations in six representative samples from three patients. In theory, relative VAF is
equivalent to cellular prevalence of the mutations. Mutations are colored according to presence in other lesions; gray, trunk mutations; red, private
mutations. Boxes with whiskers are based solely on the trunk mutation relative VAFs and span the interquartile range (IQR), with whiskers extending to 1.5
times the IQR of the trunk relative VAF from the upper and lower bounds of the boxes. The three lower panels show examples of pairwise comparisons. b
Private mutations were classified according to status as clonal or subclonal, where subclonal mutations are those whose relative VAF is below the whiskers
in a. Mutations below half the median relative VAF and above the subclonality threshold are defined as unknown
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finding of a higher genomic complexity (Supplementary Fig-
ure. 2c) and a higher copy number diversity (Fig. 2b) among
patients with WGD is consistent with ongoing genomic evolution
following WGD38. Indeed, the majority of copy number events in
patients with WGD was estimated to have occurred after genome
duplication (n= 21, median: 63%, range: 27–83%; Fig. 5a).
Contrasting copy number alterations, most SNVs and indels
appeared prior to WGD in most patients (median: 89%; range:
22–100%; Fig. 5b).
BRAF mutations are known to be early events in melanoma39
and have been associated with an increase in BRAF copy
number5,22,40,41. We observed low-level copy number
gains of at least one BRAF-containing allele in 21/27 tumors
with BRAF mutations, compared to four out of 26 in tumors wild
type for BRAF (p < 0.001, Fisher exact test). The copy
number gains all comprised broad regions of chromosome 7,
except for a single patient harboring a focal (although still low
level) gain of the BRAF gene. Strikingly, out of the 21 patients
with concurrent mutation and copy number increase of
BRAF, the mutated allele was the one gained in 20 patients
(Fig. 5c). We did not observe associations between copy number
elevations and driver mutations for any other oncogene,
including NRAS (Supplementary Figure. 13). Interestingly, when
assessing the allele-specific copy numbers of segments carrying
BRAF, the most parsimonious solution indicated that BRAF gains
are most likely to occur prior to WGD in eight out of nine
informative patients.
Based on the evidence presented, we may postulate a general
model for the order of events in the evolution of metastatic
melanoma (Fig. 6). This model is characterized by early
acquisition of driver mutations in key genes such as BRAF and
NRAS which, in the case of BRAF, is usually followed by a gain of
the mutated allele. Whole-genome duplication in general occurs
as a later event, taking place after most UV-induced mutations,
but prior to most copy number alterations. Following divergence
of metastases, mutational accumulation is low and shifts away
from UV-induced mutations to others, with a fairly consistent
mutational rate within each patient.
Discussion
While previous studies have described genomic alterations
occurring in melanoma progression8,42, including regionally
advanced disease9,43,44, limited knowledge exists in regard to
distant metastases. To the best of our knowledge, this is the first
study systematically exploring genomic heterogeneity in mela-
noma across multiple distant metastatic deposits.
We found most mutations to be truncal events. This is of
relevance to driver mutations in particular, as we found a very
low number of these to be heterogeneous in line with observa-
tions in regional metastatic disease9,43,44. The low number of
heterogeneous mutations indicate metastatic divergence to be a
late event, resembling recent findings in breast cancer45. Taking
the observation of a UV-related mutational signature among
some branch mutations into account, these findings are con-
sistent with the hypothesis that different metastases may arise
from separate late-developing subclones in the primary tumor,
although other explanations may not be excluded.
We observed a surprisingly high intrapatient consistency
regarding the number of private mutations across individual
lesions. Interestingly, a similar phenomenon was recently
described in metastatic breast cancer45. The finding of this phe-
nomenon across two tumor forms with quite different mutational
patterns32 indicates this to be an intrinsic propensity related to
several cancer forms. Moreover, the observation that hetero-
geneity correlates to BRAF mutation status, as was also made by
others in primary melanoma8, further supports the underlying
genetic mechanisms associated with this process.
Our data indicate most metastases to have a monoclonal origin,
even though we found indications of reseeding in one patient.
This somewhat contrasts the findings of Sanborn and colleagues9,
who described reseeding as a more common phenomenon.
Notably, many of the tumors from which they uncover shared
subclones were locoregional relapses located in close anatomical
proximity. Thick and large primary cutaneous melanomas are
known to be associated with a substantial risk of locoregional
relapse, despite wide margins in surgical excisions46,47, consistent

































































































































































































































































































































Prior to WGDAfter WGD
Fig. 5 Timing of genome duplication and gain of mutated BRAF. a, b Estimated fraction of copy number events (a) and mutations (b) in assessable regions
of the genome that occurred prior to and after genome duplication. c The relative allelic frequency (corrected to show allelic status of mutation) for
mutations in the genomic segment harboring the BRAF gene in samples with a BRAFmutation. Allelic states are shown as red (major allele) and blue (minor
allele) lines; mutations are shown as points, where the BRAF mutation is colored orange and all others are colored gray
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05063-1 ARTICLE
NATURE COMMUNICATIONS | (2018)9:2665 | DOI: 10.1038/s41467-018-05063-1 | www.nature.com/naturecommunications 7
processes may regulate the development of locoregional relapses
as well.
The patient (MM61) in whom we found indications of
reseeding between metastases had an unusual clinical phenotype
with numerous (>100 prior to death) cutaneous metastatic
deposits on the truncus, shoulders and head area in addition to
the 5 lesions sampled (Supplementary Figure. 10c-d). This sug-
gests this cancer to have an organ-specific propensity for the
development of cutaneous metastases48, potentially, including a
high migratory potential for metastatic cancer cells within the
skin. Thus, while this patient presented with distant metastatic
disease, the trafficking of tumor cells might be more akin to the
pattern of reseeding observed in regionally disseminated disease9.
An important topic relates to the sequence of genomic events
during cancer progression. We found WGD to occur prior to
metastatic divergence, and the high copy number diversity asso-
ciated with WGD relative to near-diploid tumors suggests an
ongoing process of copy number alterations, resembling findings
in other tumor forms45,49. While genomic complexity is a classic
prognostic marker in many tumor forms, how WGD relates to
melanoma prognosis remains to be elucidated in larger series.
We found selective low-level gains of the mutated BRAF allele as
a remarkably common early event in BRAF-mutated tumors, gen-
erally pre-dating WGD. BRAF mutations have previously been
described in primary melanoma to be associated with the frequently
observed arm- or chromosome-spanning gains of 7q40, which is
consistent with our current results. This likely contrasts BRAF gains
associated with acquired resistance to BRAF-inhibitors which, when
reported, has occurred through focal amplification of smaller seg-
ments10,50. While it seems reasonable to postulate low-level gain of
BRAF to provide a selective growth advantage analogous to the
fitness-gains associated with low-level gains of mutant KRAS in lung
cancer51, this issue warrants more research.
Emergence of the alkylating chemotherapy signature we
observed in one patient has been related to DNA mismatch
repair defects, with less evidence implicating inactivation of
MGMT in glioblastoma33,34,52. While the signature has been
described in melanomas subsequent to temozolomide treat-
ment32, so far it has not been related to any genomic altera-
tions. Our findings of this signature in a patient harboring
several MSH6 mutations, but not among dacarbazine-exposed
patients without mutations, may indicate DNA mismatch
repair defects to play a role in melanoma as well.
Ionizing radiation is a well-known carcinogen53, and sec-
ondary cancers arising in areas of previous radiation have been
described to reveal a distinct radiation-related mutational sig-
nature characterized by an accumulation of small deletions35.
We found multiple private and truncal 2-nt deletions resem-
bling this pattern of mutations in two distant metastatic
deposits 5 and 6 months after radiotherapy for a regional lymph
node metastasis. The issue of secondary metastatic spread
remains controversial in melanoma7, as well as in other tumor
forms, much due to the fact that it is difficult to find direct
evidence for this phenomenon. Chemotherapy exposure should
affect tumor cells, including micrometastases, independent of
anatomical location; in contrast, radiotherapy is applied to a
localized area, with limited radiation scattering outside the
treatment field. In this case, we found the radiation signature to
constitute a form of “cellular labeling”, strongly indicating
secondary seeding from the radiation-treated lymph node to
the chest wall and liver. While the biological effects of these
radiation-induced deletions are unknown, the rapid emergence
of two novel deposits <6 months after radiation both char-
acterized by clonal 2-nt deletions should raise concerns that
radiation therapy in some cases may enhance metastatic pro-
pensity and tumor aggressiveness.
In conclusion, this study provides evidence for common pat-
terns of genomic alterations in melanoma progression. In most
cases metastatic deposits seems to have a monoclonal origin with
the possible exception of patients harboring multiple cutaneous
deposits. The issue of potential secondary spread from metastatic
deposits may have significant clinical implications; thus, further
studies characterizing melanoma as well as other cancer metas-
tases should seek to identify radiation-induced mutation sig-
natures in all patients having previous exposure to radiotherapy.
Methods
Patients and sample collection. The patients analyzed in this study were part of a
single-arm prospective study assessing the response to dacarbazine therapy for
metastatic melanoma16,17. Out of a total study population of 85 patients,
114 samples from 60 patients and corresponding benign tissue material (blood)
were available for analysis by whole-exome sequencing. Samples from all biopsies
were examined by a pathologist to ensure representative tissue. Data from 53
individuals (86 samples) are presented; the remaining samples were excluded due
to low tumor cell content (<20%). Patient- and sample-level characteristics are
detailed in Supplementary Tables 2 and 3, respectively.
All tumor samples were snap-frozen in the operating theater. Peripheral blood
was collected at initial biopsy collection.
Ethical approval. The clinical study as well as the genomic analysis was approved
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Fig. 6 Model of progression for metastatic melanoma. Purple fields portray the timing of mutational processes, with increased thickness indicating higher
mutational activity. Lower opacity indicates variability in timing of processes in relation to each other; e.g., timing of UV radiation in relation to the timing of
genome duplication events
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numbers 020/00-109.99, 030/06-06/5520, and 2012/1740). All patients provided
written informed consent.
DNA sequencing. Approximately 1 mg of genomic DNA from tumor and mat-
ched normal tissue were used for library construction using the Agilent Sur-
eSelectXT Human All Exon V5 kit (covering 50 mega-bases of exonic sequence).
Libraries were paired-end sequenced using Illumina’s TruSeq SBS chemistry v3 on
a HiSeq2500, resulting in a median depth of coverage in the targeted regions
ranging from 140 to 422 for tumor samples (median across samples: 271), and
43–233 for normal samples (median across patients: 87).
Somatic variant calling pipeline. Reads of each sample were mapped (lane-wise)
with BWA mem54 to the human reference genome (build b37 with an added decoy
contig, obtained from the GATK resource bundle). Sample-wise sorting and
duplicate marking was performed on the initial alignments with Picard tools
(http://broadinstitute.github.io/picard). GATK tools55 were subsequently used for
two-step local realignment around indels, with matching samples (i.e., tumor and
its corresponding normal) being processed together. Each sample’s pair-end read
information was then checked for inconsistencies with Picard and base-quality
recalibration was performed by GATK. Somatic variant calling on the matching
paired samples was done by using the intersection of MuTect56 (somatic SNV
detection) and Strelka57 (somatic SNV and indel detection). Block substitutions
were defined as somatic mutations at consecutive positions where the variant allelic
frequency of each was within 5% of the average allelic frequency of the two var-
iants. The program FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/) was used for quality control of analysis input data. GATK tools were used
for computing coverage statistics based on the recalibrated alignment files. Func-
tional annotation of SNVs and InDels was performed with ANNOVAR (release
2015Mar22), using RefSeq as the gene transcript reference.
Most of the analysis (starting with the local realignment step) was limited to
exome regions (the “exome” was in this context defined by Agilent exome v.
5 sequencing probe targets).
Driver mutation definitions. Mutations in a set of genes previously identified as
drivers in melanoma3,21,22 were manually assessed for likely status as drivers. For
all considered genes, driver mutations were defined as drivers if they (1) were
canonical melanoma-associated mutations; (2) as likely drivers based on evidence
of gain or loss of function in the published literature, or if the positions were
recurrently mutated in other forms of cancer; or as (3) inactivating if they occurred
in tumor suppressors and disrupted the protein reading frame (i.e., nonsense,
frameshift, or splice site mutations). Otherwise, mutations were deemed to be
passengers (Supplementary Table 4). Patients were categorized according to driver
mutation status in BRAF, NRAS, and NF1, where mutations at the canonical
mutational hot-spots for BRAF (p.V600 or p.K601) and NRAS were prioritized in
the case of driver mutations in more than one of these genes.
Mutational signature analysis. DeconstructSigs26 was used to estimate the con-
tribution of mutational processes to the observed patterns of mutations. Con-
tributions from 5 mutational processes that have been described in melanoma were
assessed (signatures 1, 5, 7, 11, and 17)32,58. Observed mutational patterns were
corrected for the 3-base composition of exonic regions in the genome. Signatures
reported in the COSMIC database (v79) were used as reference for the mutational
pattern associated with each process58.
For signature analysis of branch mutations we used a lower threshold of n= 10
mutations. Given that this number of mutations is too low for precise estimates of
percentage contribution to individual signatures, we also performed manual
assessment of mutations, focusing on typically UV-related mutations (such as
YC>T transitions).
Copy number profiling. Copy number profiling was performed using an in-house
algorithm optimized for the present dataset. Our algorithm was established to take
advantage of two features in the data:
1. To optimize CNA and tumor purity estimates by use of the observed variant
allele frequency of somatic mutations (i.e., to fit CNA estimates on to VAF of
SNVs).
2. In the cases with multiple samples per patient, to take advantage of samples
with high tumor purity to optimize allele-specific copy numbers across
samples within the same patient.
In brief, copy number determination was carried out in three stages: First,
segmentation was performed based on shifts in observed allele frequencies of
heterozygous SNPs between genomic regions with differences in copy numbers.
Second, allele-specific copy numbers across the genome, as well as tumor cell
content, were estimated based on the magnitude of shifts in allele frequency of
heterozygous SNPs relative to regions with a loss of the minor allele, or based on
allele frequency of somatic mutations in the absence of copy number alterations.
Third, in patients with multiple samples, cross-sample corrections were made for
breakpoint identification and copy number determination based on a combination
of germ line and somatic variant allele frequencies. False discovery rates were
estimated by simulation, rather than SNP-based benchmarking tools59, since the
current dataset was restricted to WES.
The algorithm was based on the allelic frequency of germ-line variants in tumor
and normal samples. Based on the ratio of sequencing depth between tumor and
normal, tumor allelic copy numbers uncorrected for normal cell content, the
relative copy number (RCN), can be observed. In theory, the interval between
RCNs is directly proportional to the difference in number of alleles between
adjacent copy number segments. Therefore, the absolute tumor copy number
(TCNs) can be determined through inferring the interval of a RCN and the lowest
observed RCN value, which normally corresponds to a copy number of zero, or loss
of one allele. Based on this, we performed copy number profiling, as follows:
Segmentation. Identification of potential breakpoints: Potential break points were
identified based on shifts in allelic frequency of heterozygous SNPs in each tumor
relative to the corresponding normal sample across chromosomes. Here, a sliding
window approach was used, where the genome was split into bins of 4 Mb, with a
step size of 1Mb. If the number of SNPs in a given bin was <40, the bin was
merged with the nearest neighboring bin. For the i-th bin, which included ki SNPs,
we compared the standard deviation of major allele frequency between tumor and
normal sample. If there was no difference, the B allele frequency (BAF) of the bin
was regarded as 0.5 (bi= 0.5). Otherwise, bi was defined as the median value of
allele frequencies mi. A potential break point containing region was defined by a
difference in BAF exceeding 0.015 between adjacent bins. This cutoff at 0.015 was
determined by simulation of randomly generated break points:
At each BAF ranging from 0 to 1, with increments of 0.01, we generated
1000 simulation datasets, each including 40 segments. A randomly assigned
number of SNPs was assigned to each segment, ranging from 40 to 1200, and
coverage of each SNP followed the distribution of SNPs in the current exome
sequencing dataset (geometric distribution; p= 0.01). Allelic read counts were
modeled using the binomial distribution B(N, BAF), where N was the total
sequencing depth of the SNP, and BAF ranged from 0 to 1. For the simulation data
corresponding to each BAF we calculated the absolute differences of average BAF
from all SNPs between two adjacent segments. In order to determine the
significance of difference, we defined an empirical p-value for the likelihood that
two segments corresponding to the same theoretical BAF were randomly separated.
We estimated the empirical p-value based on the simulation data corresponding to
each BAF, and found that a difference of 0.015 corresponded to an empirical p-
value of 0.05.
p ¼ # Δ  cutoffð ÞBAF
# segmentsð Þ  1ð Þ # simulationð Þ ;
where # represented the counts and Δ represented the difference between adjacent
segments.
Determining the precise breakpoint and merging of segments: In order to deter-
mine a more precise breakpoint between bins, regions flanking the potential
breakpoint (±4Mb) were split into smaller windows, each including 3 SNPs. For
each SNP, we used the major allele frequency (m) in the following analysis. The
average m value of the first window was compared to the rest of the flanking region.
If the difference was more than 0.018, the midpoint of these two sub-regions was
regarded as the final breakpoint. The cutoff at 0.018 was determined by estimation
of simulation data using the same parameters as above. Based on the simulation
data, we found the maximum random error between adjacent segments with the
same theoretical BAF was no more than 0.018; although, the random error
increased when BAF was closer to 0.5 (Supplementary Figure 14). If a difference of
more than 0.018 was not identified by this initial assessment, the window was
extended to encompass the second window and compared to the rest of the flaking
region. This procedure was repeated until a break point was found, or until the end
of the flanking region was reached. If no break points exceeding 0.018 were found,
the potential break point was discarded. The genome was thus split into multiple
segments according to these final break points, and m values corresponding to each
segment were estimated (mi and mi
! representing the major allele frequency of
segment i and maximum allele frequency of all SNPs in segment i, respectively).
Estimating allelic tumor copy numbers and tumor purity. The relative copy
number (RCN) of each allele for each segment can be obtained based on the
following formula.




where i was the i-th segment. CNAH represents the relative allelic copy number of
the major allele, and CNAL represents the relative allelic copy number of the minor
allele. Ratio represents the ratio of sequencing depth between tumor and control.
For each segment, we estimated the allelic RCNs based on the CNAH and CNAL.
CNALs of all segments were integrated by multiplying it with the number of
SNPs in each segment. If the resulting distribution of weighted relative minor allele
copy numbers had at least two peaks, we considered the minimal peak value as CN
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= 0, and the second as CN= 1 or CN= 2. The distance between copy numbers,
DIS, can be calculated based on CN= 0 and CN= 1 or CN= 2.
DIS ¼ CN1 CN0
DIS ¼ ðCN2 CN0Þ=2:
According to the CN0 and DIS values, allelic TCN of each segment






Where i represented the i-th segment and round means that values are rounded to
the nearest nonnegative whole number. Major (CNH) and minor (CNL) allelic
copy numbers were thus calculated.
A tumor sample consists of a mixture of tumor cells and normal cells. For each
locus in a chromosome, the expected major allele frequency of SNPs can be
calculated as follows:
fmajor ¼
α ´CNHþ 1 αð Þ
α ´CNtotal þ 2 1 αð Þ
;
where α is the tumor cell fraction. Thus, the tumor purity for each imbalanced
segment was estimated through the following formula.
α ¼ 2 ´ fmajor  1
CNH 1þ fmajor 2 CNtotalð Þ
:
Weighting genomic segments as above, the density peak of purities calculated
across segments was used as the tumor purity for each sample. Without sufficient
imbalanced segments to obtain tumor purity, we used mutation allelic frequencies
in balanced segments (TCN= 2; i.e., mutations on one allele) to estimate tumor
purity. The allelic frequency of mutations is given by
fmut ¼
α ´CNmut
α ´CNtotal þ 2 1 αð Þ
:
Thus, the tumor purity would be the local peak of mutations density across
genome segments with balanced copy number 2. The tumor purity was then
inferred from the mutation allele frequency in these segments:
α ¼ 2 ´ fmut:
Inferring allelic tumor copy number and tumor purity of non-reference sam-
ple. For patients from whom multiple samples were analyzed, data from the dif-
ferent samples was used to adjust each other, adding strength to the estimates. In
these cases, the sample with the highest tumor purity was coined the “reference
sample” while the others were termed “non-reference” samples. Segments in non-
reference samples with copy number 0 or copy number 1 were inferred from the
corresponding segments in the reference sample. The difference in relative copy
numbers (DIS) was estimated based on these segments with copy number 0 and
copy number 1. Allele-specific copy numbers were re-evaluated based on the CN0
and DIS estimates, and tumor purity was calculated as shown above. For each non-
reference sample, if TCNs of 50% segments differed from the reference sample, we
would re-infer the TCN for this non-reference sample in case of genome doubling
or tripling.
Estimation of multi-sample tumor allelic copy numbers by clustering of
somatic mutations. The estimation of TCNs based on frequencies of mutations
can be used to tune the accuracy of copy number calls estimated from SNPs. This
approach can be strengthened by use of multiple samples from the same patient. In
the present study, such additional tuning was performed for patient MM01, due to
the combination of low tumor cell fraction and high ploidy. Thus, we submitted
mutations shared between different samples from this patient to K-mean clustering
based on variant allele frequencies of mutations in all combinations of the patient´s
samples. The number of clusters, k, was defined to select the optimal clustering.
Here, the number of clusters resulting in the minimum average sum of squared
errors E(C) for k in the range of 2–5 was selected, where E(C) was defined as:













where n was the number of samples, s was the combination of two sample, cents
was the centroids of cluster t in combination s, and o represented the mutation in
cluster t of combination s. The distance d was calculated as Euclidean distance.
The optimal combination of pairwise comparisons of samples based on
clustering was regarded as a standard to infer TCNs of each sample from the same
patient. For each previously identified segment of the samples, the median value of
mutation allele frequencies, corrected for copy number and tumor cell content,
mapping into each standard cluster was regarded as the value of the cluster. We
determined the optimal combination of two samples based on maximization of
inter-cluster distances and minimization of intra-cluster distances. First, the
distance between clusters from a combination of two samples was calculated. The
distance d between two clusters Ci and Cj was defined as the Euclidean distance












The combination with maximum clustering distance was retained. In cases with
more than one possible combination, the optimal combination of two samples was
derived from the minimum average intra-cluster distances between centroids; the












where Ctj j was the number of mutation cluster Ct. The combination with the
minimum intra-cluster distance was regarded as the optimal combination of two
samples.
Mutation frequencies of all standard clusters from all segments in the sample
were integrated to estimate their probability densities. For any tumor copy number
(TCN) state, F, local peak values of mutation frequency distributions were regarded
to correspond to specific copy number states, f.
F ¼ f1; f2; ¼ ; fnð Þ
f1<f2<¼<fn;
where fi was the i-th local peak in mutation frequency distribution. The minimum
mutation frequency (fi) in F was defined as corresponding to copy number of 1. We
calculated the interval of TCN as the difference between each fi and fi+1. Further,
based on f1 and interval of TCN, CNH, and CNL of each segment in the sample
were obtained.
Estimation of false discovery rates. To estimate the false positive CNA calls
corresponding to the applied cutoff (a difference in BAF of 0.018 between seg-
ments), we assumed scenarios where the total copy number in tumor cells ranged
from 1 to 8 following a uniform distribution. We simulated 1000 segments (similar
with previous simulation process) under different tumor purities ranging from 1 to
100%, with the different total copy numbers (1–8, respectively; Supplementary
Figure 15). Based on the segments with the same BAF, combining all tumor purity
and total copy numbers, we found the global average false positive rate (FPR) to be
9.88% and the global average false negative rate (FNR) to be 8.44%. The FPR and
FNR decreased with the increasing of tumor purity. At tumor purities below 20%,
FPR and FNR increased rapidly. Importantly, when the tumor purity was higher
than 20%, FPR and FNR was always <10% (Supplementary Figure 15).
Exclusion of samples from analysis. Simulations (see above) introducing dif-
ferent percentages of reads from normal DNA into samples of data from tumor
DNA, indicated that aberrant cell fractions higher than 20% would be sufficient for
accurately calling copy number alterations. Out of the 114 tumor samples that
underwent sequencing, 86 fulfilled this criterion and were used in subsequent
analyses.
Inference of whole-genome duplication. For each sample, to infer whether a
whole-genome duplication event had taken place, we enumerated the fraction of
the genome with a minor allele at copy number 2 and the estimated ploidy. A
manual assignment was then performed, based on the assumptions that (1) the
overall ploidy of a sample having undergone genome duplication would generally
be higher than those of diploid samples, and (2) that the minor allele should be at
copy number 2 in at least some fraction of the genome after a whole-genome
duplication event (Supplementary Figure 2b).
Mutational heterogeneity between samples. For the analysis of inter-lesional
mutational heterogeneity, we considered only mutations whose heterogeneity could
not be reasonably be explained by copy number alterations or lack of sequencing
depth. Thus, mutations were considered to be potentially heterogeneous if (1) in a
sample without a particular mutation, there was no evidence of copy number loss
relative to samples carrying the mutation; and (2) the sequencing depth at the
position was high enough to have a 95% chance of detecting the mutation given an
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allelic fraction of 1 allele out of 4 and the sample-specific tumor cell fraction,
assuming a binomial distribution of variant reads. This resulted in a sample-wise
depth threshold ranging from 56 for samples with a low aberrant cell fraction, to 18
for samples with a high aberrant cell fraction. In addition, a mutation that was not
called by the somatic variant calling pipeline was deemed to be present if the
number of reads supporting the mutation was over 1 and higher than what would
be expected with an error rate of 1/200, assuming a binomial distribution of
supporting reads, with a binomial test p-value of under 0.05. One patient (MM43)
exhibited parallel loss of chromosomes 11q and 14 in each of the sampled lesions.
Heterogeneous mutations on these chromosomes were considered to have been lost
due to copy number alterations.
Calculation of relative VAF and assessment of clonality. As a measure of the
cellular prevalence of each mutation, we calculated the relative variant allele fre-
quency (rVAF) of each mutation as the ratio of observed to expected VAF, given






2 ´ 1ρð Þþntot ´ ρ
  ;
where nmut refers to the number of mutated alleles, ntot refers to the total copy
number at the mutated locus, and ρ refers to the tumor cell content.
Relying on the accuracy of the determination of inter-lesional mutational
heterogeneity, we evaluated the clonality of mutations by comparing the rVAF of
trunk mutations to that of private mutations to infer likely clonal relationships,
using clustering of mutations across samples to validate our findings31. Evaluations
of mutation clonality were based on the interquartile range (IQR) of rVAF values of
trunk mutations only. Thus, mutations were categorized as being subclonal if their
rVAF were below the 25th percentile by 1.5 times the IQR, and otherwise as clonal
if their rVAFs were above 0.5 times the median rVAF. Mutations not specified as
subclonal, and with rVAFs below 0.5 times the median rVAF were considered to be
of unknown clonality.
Relative timing of whole-genome duplication. To determine the fraction of copy
number events that preceded or followed genome duplication, the shortest route to
obtain the observed copy number state for each segment was determined. Here, a
copy number change before duplication would lead to a change in observed copy
number of two copies from the “unaltered” state of two copies, and a copy number
change after genome duplication would lead to a change of one copy. Solving the
resulting equation for the minimum number of events, the sum of events occurring
prior to and following genome duplication was estimated for each allele in each
segment. For each patient, the average number of events across samples was used as
a measure of copy number changes prior to and following duplication. To estimate
the number of mutations that occurred prior to and following genome duplication,
mutations at each allelic state in informative regions of the genome (those with
major:minor allele states of 2:2, 2:1 or 2:0) were enumerated. The fraction, m1, of
mutations preceding duplication was estimated as m1 ¼ 3n2n1n2 for copy number 2:1,
or m1 ¼ n22n1 for copy number 2:2 and 2:0, where n1, and n2 were the number of
mutations with allele status 1 and 2, respectively.
Statistical analyses. All statistical analyses were performed in the statistical
programming language R (v3.4.1)60. Ranked tests were used for comparisons of
continuous variables across groups (Mann–Whitney U-tests or Kruskal–Wallis
rank-sum tests), or when assessing correlations between continuous variables
(Spearman’s rank correlation), except if otherwise specified. All significance tests
were two-sided, and statistical significance was considered for p < 0.05.
Data availability. Raw sequencing data are not publicly available due to national
regulations regarding privacy concerns of study participants. Data on somatic
mutations are presented in Supplementary Table 1.
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Supplementary Figure 1: Unique mutation per patient: a) number of mutations per patient 
(average of samples) in coding regions per megabase according to site of the primary lesion. 
The category “Not exposed” includes mucosal (n=2), acral (n=3), uveal (n=2), and one patient 
with a skin lesion that was situated perianally. b) The number of mutations per lesion 
according to the site of the lesion the patient’s primary tumor. Boxes with whiskers span the 
interquartile range (IQR), with whiskers extending to 1.5 times the IQR from the upper and 
lower bounds of the boxes.  c) The number of unique mutations per patient according to 






Supplementary Figure 2: Genomic complexity and genome duplication. a) Prevalence of 
copy number gains and losses across the genome. Gain or loss for any region was defined as 
≥3 copies in total, or ≤1 copy in total, respectively. For patients with genome duplication, the 




fraction of samples with gain or loss was recorded. b) Using the fraction of the genome 
where the minor allele was at copy number 2 in combination with ploidy, we categorized 
patients as having undergone a genome duplication event (blue) or not (red). c) Measuring 
genomic complexity as the fraction of the genome not at a balanced copy number of 2 
(diploid) or 4 (genome duplicated), we compared patients with diploid tumors to patients 
with tumors having undergone genome duplication. For patients with multiple samples, we 

























Supplementary Figure 3: Copy number diversity. a) Prevalence of heterogeneous copy 
number gains and losses across the genome. Gains and losses are defined as in figure S2. 
Grey fields represent the fraction of patients with gains or losses in all individual samples. 
Red and green fields represent the fraction of patients with heterogeneous copy number 
gains and losses, respectively. Only patients with multiple sampled lesions are included in 
this figure. b) The copy number diversity according to chromosome; each patient is 









Supplementary Figure 4 (previous page): Phylogenetic trees showing the relationships 
between samples collected from the same patients. The phylogenetic trees are derived from 
the presence or absence of mutations across samples as depicted in figure 2b and c in the 
main text. Sampled lesions are indicated by black dots, and the color of branches match the 
color code in figure 2b and c: grey = trunk; blue = branch; red = private mutations. The 
trunks of the phylogenetic trees have been truncated, with the total number of mutations 
indicated next to the base of each tree. Branch lengths are proportional to the numbers of 
mutations specific to each branch, with the number of mutations indicated by a scale bar. 
Patient MM02 is depicted separately due to the high number of branch mutations in the 















Supplementary Figure 5: Mutation type distribution of branch mutations for each sample. a) 
Private mutations per lesion in each patient, or (b) branch mutations per patient according 
to status as subclonal are compared as portrayed in diagrams below barplots. Blank columns 
represent samples without mutations in the relevant category. The numbers of mutations 
are shown above each column. Asterisks indicate significant differences according to fisher 








Supplementary Figure 6: mutational (a) and copy number (b) diversity according to the 
anatomical diversity of sampled lesions. Patients were categorized according to the 
anatomical distance between biopsy sites. For patients with more than two samples, the 
largest distance was used. Anatomical distance was categorized as same site, with samples 
taken from the same lesion at different time points; same region, defined as lesions in areas 
draining to the same lymph nodes; different regions; or different organs. Subcutaneous and 







Supplementary Figure 7: Estimated contributions of mutational processes to (a) trunk and 
(b) branch mutations for each patient in which the total number of branch mutations was 
over 10 (the number of trunk or branch mutations is shown under each bar). The residual 
sum of squares (RSS) is shown below, which is a measure of how closely the observed 
mutations match the estimated process contributions. Only contributions of 5 mutational 
processes were assessed, and mutational signatures corresponding to less than 10% of 
mutations were not considered; thus, for some patients, the mutational signature 




to be caused by alkylating agent exposure, only two of these samples had been exposed to 
such therapy, each predicted to have less than five mutations assigned to this source. We 



































Supplementary Figure 8: Relative variant allele frequency (VAF) of mutations according to 
heterogeneity and subclonality status. Relative VAF represents the variant allele frequency 
corrected by tumor purity and local copy number, and is thus analogous to cellular 
prevalence. Mutations are color-coded according to status as trunk (found in all lesions; 
gray), branch (found in some, but not all lesions; purple), and private (found uniquely in one 
lesion; red). Boxes span the interquartile range and whiskers extend to 1.5 times the 








Supplementary Figure 9: Cross sample clustering of mutations according to cellular 
prevalence using PyClone. Mutations and their relative variant allele frequencies (rVAF) are 




they were predicted to belong. The predicted cellular prevalence of each population of cells 
is indicated by lines, the weight of which correspond to the number of mutations belonging 











Supplementary Figure 10 (previous page): Mutations with a recurrent subclonal rVAF could 
indicate reseeding between lesions. a) Cross sample clustering of mutations according to 
cellular prevalence1 as in Supplementary Fig. 9. The number of mutations on which the 
inference of each cell population is based, are shown in a panel in the top right corner. b-d) 
Patient MM61 had an unusual disease course, characterized by an extensive and rapid 
spread of cutaneous metastases, first described 13 months following surgical excision of the 




for the current study, regional and distant skin metastases were present on the truncus, 
neck and upper extremity. Wide-ranging cutaneous progression occurred in the months 



































Supplementary Figure 11: MSH6 and MGMT deficiency in patient MM02. a) Cellular 
prevalence of mutations in each sample from MM02. The lower and left panels show the 
frequency distributions of private (blue) and trunk (red) mutations in each sample. These 
correspond to clonal populations and each major peak of mutations coincides with private 
MSH6 mutations, which are indicated with stapled lines. Private mutations in both samples 
conformed to the dacarbazine signature. b) Expression levels of MGMT (O-6-methylguanine-
DNA methyltransferase) mRNA relative to those of B2M (beta-2-microglobulin) were 
measured for each sample, and compared to the relative MGMT expression levels in the 
melanoma cell line Sk-Mel-28. Samples collected in excess of one month following 
dacarbazine exposure are shown in red and samples from MM02 in blue. All other samples 
are shaded gray. Both samples from MM02 displayed a mutational signature consistent with 
dacarbazine treatment. One sample from MM02 displayed a loss of MGMT expression, 
whereas the other was found to have hypermethylation of the MGMT promoter (results not 
shown). Expression levels and promoter methylation status of MGMT for this patient cohort 







Supplementary Figure 12: Mutational pattern of 2-nt deletions in patient MM85. a) The 
upper panel shows the timing of disease progression and radiation treatment (m = months). 
The lower panel shows the localization of each lesion and the field of radiation. Lesion 1 and 
lesion 2 were sampled for the current study. b) The frequency of deletions according to the 
length of deletions in all patients except MM85 (upper left), and deletions in MM85; trunk 
deletions, or deletions private to each lesion (top to bottom, right). c) Relative VAF of trunk 
mutations (gray), private mutations other than deletions (red circles), and private deletions 







Supplementary Figure 13: Frequency of gains of activating driver mutations. Patients are 
categorized according to whether there is evidence of an increase in copy number of one 
allele relative to a balanced state of each gene, and whether a driver mutation is identified in 










Supplementary Figure 14: Estimation of empirical p-values for random difference in f values 
between segments exceeding the chosen threshold (0.018). (a) Probability density plot of 
global random differences (x-axis). The gray arrow indicates the f value difference 
corresponding to the global empirical p value 0.05. The black arrow indicates the BAF 
difference of 0.018 corresponding to the global empirical p value 0.017. (b) Plot of local 
empirical p values for the cutoff at each specific f value. The x-axis shows f values ranging 
from 0.01 to 1, with with an increment of 0.01. For the black line, the y- axis is the local 
empirical p value corresponding to the difference 0.018 in each specific f value. For the red 






























































Supplementary Figure 15 The false positive rate (FPR) and false negative rate (FNR) of copy 
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Abstract
Background: The number of tumor suppressor genes for which germline mutations have been linked to cancer
risk is steadily increasing. However, while recent reports have linked constitutional normal tissue promoter
methylation of BRCA1 and MLH1 to ovarian and colon cancer risk, the role of epigenetic alterations as cancer risk
factors remains largely unknown, presenting an important area for future research. Currently, we lack fast and
sensitive methods for assessment of promoter methylation status across known tumor suppressor genes.
Results: In this paper, we present a novel NGS-based approach assessing promoter methylation status across a
large panel of defined tumor suppressor genes to base-pair resolution. The method omits the limitations related to
commonly used array-approaches. Our panel includes 565 target regions covering the promoters of 283 defined
tumor suppressors, selected by pre-specified criteria, and was applied for rapid targeted methylation-specific NGS.
The feasibility of the method was assessed by analyzing normal tissue DNA (white blood cells, WBC) samples from
34 healthy postmenopausal women and by performing preliminary assessment of the methylation landscape of
tumor suppressors in these individuals. The mean target coverage was 189.6x providing a sensitivity of 0.53%,
sufficient for promoter methylation assessment of low-level methylated genes like BRCA1. Within this limited test-
set, we detected 206 regions located in the promoters of 149 genes to be differentially methylated (hyper- or hypo-)
at > 99% confidence level. Seven target regions in gene promoters (CIITA, RASSF1, CHN1, PDCD1LG2, GSTP1, XPA,
and ZNF668) were found to be hyper-methylated in a minority of individuals, with a > 20 percent point difference
in mean methylation across the region between individuals. In an exploratory hierarchical clustering analysis, we
found that the individuals analyzed may be grouped into two main groups based on their WBC methylation profile
across the 283 tumor suppressor gene promoters.
Conclusions: Methylation-specific NGS of our tumor suppressor panel, with detailed assessment of differential
methylation in healthy individuals, presents a feasible method for identification of novel epigenetic risk factors for
cancer.
Keywords: Methylation, Epimutations, Cancer risk, Promoter, Massive parallel sequencing
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: stian.knappskog@uib.no
1K.G. Jebsen Center for Genome Directed Cancer Therapy, Department of
Clinical Science, University of Bergen, Bergen, Norway
2Department of Oncology, Haukeland University Hospital, Bergen, Norway
Full list of author information is available at the end of the article
Poduval et al. Clinical Epigenetics          (2020) 12:131 
https://doi.org/10.1186/s13148-020-00920-7
Introduction
The number of tumor suppressor genes for which germ-
line mutations are linked to elevated cancer risk is stead-
ily increasing [1–3]. Mutations across different genes
present a continuum of penetrance, ranging from mod-
erately to massively elevated risk of different cancer
forms. Further, while mutations in some genes (so far)
are restricted to increased risk of a single, or a few can-
cer forms, mutations in other genes may increase the
risk of multiple different types of cancer [4, 5].
Some of the best described “classical” high penetrance
genes include BRCA1/2, for which germline mutations
are associated with an elevated risk of ovarian and breast
cancer [6], MLH1/MSH2 linked to colorectal cancer [7],
CDKN2A and RB1, associated with melanoma and ret-
inoblastoma, respectively [8–10], as well as TP53, associ-
ated with the Li-Fraumeni syndrome with an elevated
risk for multiple cancer forms [11]. However, the list of
genes for which germline mutations are ascertained to
confer cancer risk is continuously increasing due to ap-
plication of massive parallel sequencing [12, 13]. Still, for
many families with multiple cases of a specific tumor
form (like breast, ovary, or melanomas), no pathogenic
germline gene variant has been identified.
Epigenetic gene inactivation may occur through differ-
ent mechanisms [14, 15]. So far, promoter methylation
is the best studied of all the epigenetic modifications,
and such methylation is well established as a mechanism
of inactivation of tumor suppressor genes. While many
germline mutations affecting tumor suppressor genes
are well studied as cancer risk factors, knowledge regard-
ing constitutional epigenetic inactivation [16] as a poten-
tial cancer risk factor remains limited. Somatic promotor
methylation in tumor suppressor genes is a common
event in cancer [17], but the role of aberrant epigenetic
events, or constitutional promoter methylation of tumor
suppressor genes in normal cells as potential cancer risk
factors, remains largely unexplored. While mosaic
methylation of the MLH1 gene in normal leukocytes has
been observed in colorectal cancer patients [18, 19] and
a haplotype leading to secondary constitutional methyla-
tion in the MGM2 promoter [20] has been found in a
cancer-prone family [21], in general, data on normal tis-
sue methylation patterns and cancer risk are scarce [22].
Recently, in a large study, we reported low-grade mo-
saic (< 10% of alleles) normal tissue BRCA1 promoter
methylation to confer a significantly increased risk of
high-grade serous ovarian cancer (HGSOC) [23]. In our
study, we found > 4% of healthy adult females in a Cau-
casian population to harbor mosaic BRCA1 promoter
methylation in their normal white blood cells (WBC).
Individuals carrying such methylation had a 2-3 fold in-
creased risk of HGSOC. Importantly, WBC BRCA1 pro-
moter methylation was strongly associated with
corresponding methylation in other normal tissues, and,
in HGSOC patients, also associated with methylation in
the tumor. Taken together, this indicated that methyl-
ated normal cells in the ovary may act as tumor
precursors.
Based on these results and the findings of others [19,
24–29], we hypothesized that additional tumor suppres-
sors could be hyper-methylated in normal cells, thereby
causing an elevated risk for certain cancer forms within
subgroups of healthy individuals in the general popula-
tion [30].
To explore such a hypothesis, there is a need for im-
proved methodologies. Although methylation status may
be analyzed by conventional arrays, such assessments are
limited to the selection of CpGs covered by the array
probes. These selected CpGs may not necessarily repre-
sent all the CpGs crucial for gene silencing [23]. An alter-
native is methylation-specific whole genome sequencing,
but this remains prohibitively costly. In the present study,
we aimed to establish, and provide proof-of-concept for, a
novel strategy assessing the full CpG spectrum across pro-
moter areas of tumor suppressor genes. The assay applies
methylation-specific massive parallel sequencing of the
promoter areas of a panel of 283 tumor suppressor genes.
We show the feasibility of the method by depicting pro-
moter methylation variation across the promoter panel in
a set of white blood cell (WBC) DNA obtained from 34
healthy individuals. Further, by performing an exploratory
hierarchical clustering, our findings indicate that the pro-
files of normal cell promoter methylation of tumor sup-
pressor genes fall into two main clusters defined by
differences in genes regulating key biological pathways.
Results
Methylation specific sequencing
We analyzed WBC DNA from 34 healthy individuals.
After bisulfite conversion of the DNA, we performed
methylation-specific sequencing of 565 capture regions
representing 356 target regions from 283 tumor suppres-
sor gene promoters (the full list of genes and regions is
presented as Supplementary Table S1). Sequencing was
performed on an Illumina MiSeq, running 8 samples per
run. Regarding average values per sample, we obtained
4.95 × 106 reads (range 3.36-7.85 × 106) (Fig. 1a; for de-
tails per sample see Table 1). Subsequent to quality fil-
tering, 88% of the reads, were retained. Thus, after
filtering, 4.30 × 106 reads were attempted mapped to the
genome, yielding 4.08 × 106 mapped single reads. Out of
these, 3.6 × 106 reads mapped with properly paired reads
for each sample (average values; Fig. 1a). These reads led
to a mean primary target coverage of 189.6x (114.8x-
269.5x) and a mean capture target coverage of 199.4x
(120.7x-283.4x). Every sample had almost equal
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percentage of reads mapped to capture targets and pri-
mary targets (Fig. 1b).
The overall number of informative CpGs identified for
each sample were on average 1.0 × 105 (range 0.9 × 105
to 1.6 × 105). Restricting the CpGs to those with a
methylation ratio > 0, and more than 10 reads in cover-
age, the number was reduced to 1.5 × 104 (range 1.1 ×
104-1.9 × 104; Fig. 1c).
We defined the sensitivity of our strategy as 1/x, where
x = sequencing depth at any given CpG. With the aver-
age primary target depth being 189.6x, the sensitivity
was 0.53%. In theory, the fragility of this sensitivity esti-
mate lies in that, for some samples, the results may de-
pend on a single read, rendering them more sensitive to
artifacts such as inadequate bisulfite conversion. How-
ever, assessing the bisulfite conversion rate (C to T) of
the internal Lambda DNA control (see the “Methods”
section), we found the conversion efficiency to be on
average 99.7% (range 99.6-99.8%) across the analyzed
samples (Fig. 1d). This indicates a rate of technical arti-
facts (falsely retained C’s instead of T’s) to be lower than
0.2-0.4%, thus approaching the error rate in the sequen-
cing per se (Q30 threshold).
Reproducibility was assessed in a separate standard
sample (pooled DNA from 5 healthy donors) that was
run in 6 parallels per run over 2 independent runs. In a
selection of 12 out of the 565 regions, we found the
mean coefficient of variation to be 7.1% (median 4.4%;
Supplementary Table S2). As such, the technical vari-
ability in this standard sample was considerably lower
than the detected biological variation (see below) in our
study set of 34. Variability was considerably lower when
assessing all CpGs in a region than when limiting ana-
lyses to randomized selections of CpGs within the re-
gions (e.g., for PRDM2, the coefficient of variation was
1.5% when considering all CpGs while it was on average
4.7% when assessing randomized selections of 5 CpGs
within the region).
Methylation landscape of tumor suppressors
For each sample, we calculated the mean methylation
for each of the 565 capture regions based on individual
CpG methylation ratios within each actual region (see
the “Methods” section for details). We observed large
Fig. 1 a Output reads from methylation specific targeted
sequencing. Bars indicate the output yield in terms of number of
reads (millions) for each of the analyzed individuals. Blue bars
indicate the total number of reads, while red bars indicate number
of reads mapping to the genome. b Percentage of mapped reads
on primary (blue) and capture target regions (red) for each sample. c
Number of CpGs called in the analyzed samples. Blue bars show
identified CpGs and red bars show CpGs with > 10 reads in all
samples and a non-zero methylation ratio. d Bisulfite conversion
efficiency (> 99.5% recommended; dotted line) for each sample
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inter-region variation in the methylation levels of the re-
gions within the 283 tumor suppressor gene promoters
analyzed (Fig. 2). Some regions were completely methyl-
ated (e.g., regions within the promoters of AIP, PRDM2,
ATR, DICER1, SFPQ), while others in general were non-
methylated in most individuals (e.g., regions within
ARID2, TRIM33, SETD2, IKZF1, and ARID1B; Supple-
mentary Figure 1).
In some regions, there was a large variability between
CpGs within the promoter region, indicating that some
CpGs may be constitutively methylated, while others
(perhaps more crucial for transcriptional regulation) had
a lower methylation level and may be more dynamically
methylated (Supplementary Figure 2).
Constitutional promoter hyper-methylation has been
classified either as secondary due to a rare genetic/SNP
variant [16], typically resulting in high methylation levels
[31, 32] or primary, in which case, methylation may
occur at a low mosaic level (VAF of < 10%) [23]. As for
both cases, we may not expect identifying several
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10046_S2 5043578 90.39 78.71 3588074 54.01 54.31 209.99 220.84
10071_S7 5167738 89.08 83.62 3849392 44.54 44.81 186.40 196.12
10077_S3 4622790 90.13 81.18 3382228 52.35 52.66 198.17 208.34
10078_S8 4148304 89.91 83.59 3117970 33.13 50.13 175.26 184.27
10081_S4 4408742 89.53 81.99 3236368 50.31 50.60 186.37 195.79
10082_S5 4146244 88.90 82.83 3053058 48.82 49.10 171.00 179.62
10086_S6 4665150 89.39 80.91 3373894 49.76 50.06 186.09 195.68
10088_S2 5683572 88.12 83.26 4169990 49.01 49.29 219.04 230.48
10097_S3 5372752 87.46 84.09 3951544 44.74 45.00 195.13 205.17
10107_S1 4659718 89.67 80.24 3352898 55.68 56.00 213.95 224.78
10110_S6 5369964 86.87 82.21 3835038 47.17 47.45 199.76 210.11
10113_S7 3862862 89.44 83.54 2886124 36.11 36.31 120.48 126.52
10117_S5 4243470 89.93 85.80 3274194 46.15 46.42 169.10 177.78
10126_S7 5490894 87.68 83.36 4013294 44.39 44.65 198.79 209.00
10131_S1 5338282 87.00 82.62 3836988 53.58 53.88 232.54 244.35
10146_S6 4326882 90.13 85.57 3337118 45.47 45.73 168.34 177.00
10149_S7 4129130 90.01 84.46 3139126 45.78 46.04 159.55 167.77
10155_S5 4450890 86.31 84.99 3264796 46.65 46.91 170.60 179.37
20011_S4 5923516 87.27 85.49 4419628 41.19 41.42 203.82 214.20
20019_S1 3972578 89.46 84.62 3007020 49.39 49.68 163.80 172.27
20022_S4 7091616 88.48 81.02 5083584 47.19 47.47 257.88 271.25
20023_S1 7854298 88.16 81.78 5662728 43.72 43.98 269.47 283.35
20024_S5 6284900 88.04 82.23 4549698 41.85 42.09 215.05 225.92
20062_S2 3554848 88.54 84.13 2648098 40.36 40.54 127.76 133.78
20068_S3 3355298 89.51 84.38 2534292 48.89 49.18 138.43 145.54
20078_S2 7541786 88.33 84.85 5651984 38.94 39.16 246.67 259.20
20088_S4 4083996 90.28 84.33 3109332 33.27 33.46 114.79 120.70
20092_S3 4686060 89.01 83.38 3477852 50.58 50.88 196.38 206.39
20098_S1 4501632 88.21 83.23 3305210 53.58 53.89 197.69 207.78
20106_S2 4430250 86.96 83.43 3214408 45.12 45.32 173.69 181.84
20117_S4 4802994 88.70 86.01 3664364 44.22 44.48 178.18 187.37
20119_S5 4525080 89.19 85.57 3453670 46.90 47.16 180.35 189.59
20122_S6 4741150 88.79 85.18 3585870 51.76 52.07 204.62 215.16
20160_S3 5848296 88.30 84.30 4353508 46.02 46.28 220.04 231.29
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affected individuals in a small dataset like the present;
thus, lack of differential methylation here may not ex-
clude a gene as a potential epigenetic pathogenic factor.
Still, to validate the feasibility of our method, we aimed
at exploring potential differential methylation between
individuals across our data set. To do so, we took three
approaches: first, we assessed differential methylation
across the dataset in general. Second, we specifically
assessed for individual hyper-methylation, assuming this
to be the most relevant alteration regarding inactivating
tumor suppressors. Third, we specifically assessed those
tumor suppressors where previous data have linked pro-
moter methylation to cancer risk.
Differential methylation
Subsequent to methylation calling, we identified pro-
moter regions differentially methylated across our sam-
ple set. Although low levels of methylation (allele
methylation frequency of < 5%) have been shown to
affect cancer risk [23], in the present sample set we fo-
cused on identifying those genes presenting the largest
inter individual methylation variation as a proof-of-
concept for our methodological approach. We defined
methylation variation in a region according to the differ-
ence in absolute but also relative methylation level. First,
we assessed the difference in absolute methylation as the
difference in percentage of alleles methylated between
individual (i.e., difference presented as percent points).
Second, we assessed the relative difference between indi-
viduals, i.e., the ratio between the highest and lowest
methylated individual with respect to percentage of
methylated alleles.
Based on a Z-score assessment of a methylation matrix
consisting of averaged methylation ratios for each of the
565 capture regions across all 34 samples (see the
“Methods” section for details), we identified 206 regions
(within the promoters of 149 genes) where a minority
(one-third or less) of the samples analyzed were signifi-
cantly differentially methylated as compared to the ma-
jority of samples at a ≥ 99% confidence level (i.e., outside
the 99% confidence interval; Supplementary Table S3).
Assessing the difference between the samples with the
highest and the lowest level of methylation within these
206 regions, about half of the regions (n = 101) displayed
less than 5 percent point difference. However, several of
the tumor suppressor regions displayed a large variation
in methylation, with 72 regions displaying > 10 percent
point difference and 22 regions displaying > 20 percent
points difference between the highest and the lowest
methylated samples (Table 2). The largest difference was
observed for GAS7, where the difference between the
highest and the lowest methylated sample was 66.6 per-
cent points.
Fig. 2 Heatmap showing average methylation ratio for all samples
and genes. Scale: Red indicates high methylation and blue indicate
low methylation
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Assessing the relative difference (ratio between the high-
est and lowest methylated sample), again GAS7 was the
top-ranking promoter, showing a relative difference of 3.5
fold between the highest and the lowest methylated sam-
ple. As expected, in addition to GAS7, we found a substan-
tial overlap between top-ranking regions based on
absolute differences and the top-ranking regions based on
relative differences (ratio) in methylation levels (Table 2).
Especially the AIP gene also had a region that was highly
differentially methylated both in terms of percentage dif-
ference (> 20%) and fold difference (> 3 fold). The only re-
gions with less than 20 percent point difference but a high
fold difference (> 2 fold), were regions in RABEP1, RASS
F1, AIP, and FOXO4 (Table 2, lower section).
Hyper-methylated tumor suppressors
Regarding tumor suppressor genes, we hypothesized that
in case constitutional methylation is associated with a
significantly elevated cancer risk, we may expect a minor
sub-fraction of healthy individuals to have hyper-
methylated promoters. We therefore performed add-
itional sub-analyses restricting 206 genes identified
above, to the genes/region with positive Z-scores with >
99% confidence level, i.e., genes/regions that were
Table 2 Differentially methylated genes. Gene regions with > 20 percent points difference in methylation ratio, between least
methylated sample to most methylated sample along with fold change differences are listed. Hyper-methylated target region of
those genes are shown in bold
Gene name Gene capture region Min. methylation ratio Max. methylation ratio Difference in methylation ratio Fold change
GAS7 chr17: 10199716 - 10200316 0.2670 0.9332 0.6662 3.4951
ELAC2 chr17: 13019069 - 13019845 0.4581 0.8332 0.3751 1.8188
GSTM1 chr1: 109686327 - 109687046 0.6438 1.0000 0.3562 1.5533
THBS1 chr15: 39579298 - 39579871 0.4671 0.7885 0.3214 1.6881
CIITA chr16: 10874982 - 10875928 0.2511 0.5577 0.3066 2.221
RASSF1 chr3: 50339388 - 50340021 0.1786 0.4720 0.2934 2.6428
CHN1 chr2: 174846842 - 174848034 0.2141 0.5074 0.2933 2.3699
MSH2 chr2: 47401613 - 47402319 0.5897 0.8734 0.2838 1.4811
PALB2 chr16: 23642511 - 23643136 0.6333 0.9134 0.2801 1.4423
RUNX3 chr1: 24964233 - 24965550 0.3920 0.6479 0.2559 1.6528
TP63 chr3: 189789769 - 189790448 0.6612 0.9059 0.2446 1.3701
PDCD1LG2 chr9: 5510022 - 5511326 0.3182 0.5511 0.2330 1.7319
AIP chr11: 67481632 - 67482276 0.6716 0.9002 0.2286 1.3404
GPC3 chrX: 133986729 - 133987434 0.5842 0.8036 0.2194 1.3756
AIP chr11: 67482202 - 67482880 0.1035 0.3214 0.2180 3.1053
GSTP1 chr11: 67581895 - 67582976 0.2673 0.4834 0.2162 1.8085
AIP chr11: 67481257 - 67481869 0.7857 1.0000 0.2143 1.2728
XPA chr9: 97698585 - 97699193 0.6991 0.9130 0.2139 1.306
APC chr5: 112736082 - 112736959 0.6361 0.8479 0.2118 1.333
CTCFL chr20: 57524096 - 57527440 0.6554 0.8663 0.2109 1.3218
CASP8 chr2: 201259179 - 201260169 0.3698 0.5799 0.2102 1.5681
ZNF668 chr16: 31064314 - 31065859 0.4513 0.6584 0.2070 1.4589
-- -- -- -- -- --
RABEP1 chr17: 5281240 - 5283045 0.0415 0.1033 0.0618 2.4902
AIP chr11: 67482382 - 67483805 0.0517 0.1229 0.0712 2.3783
RASSF1 chr3: 50338258 - 50339618 0.0976 0.2178 0.1202 2.2322
FOXO4 chrX: 71094692 - 71096928 0.1256 0.2592 0.1335 2.0629
ZRSR2 chrX: 15789350 - 15791219 0.0559 0.1021 0.0462 1.8252
RUNX1T1 chr8: 92102449 - 92105016 0.0558 0.1008 0.0450 1.8068
RHOH chr4: 40196452 - 40197679 0.1059 0.1914 0.0855 1.8067
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significantly hyper-methylated in a minority of individ-
uals as compared to the majority of individuals (see the
“Methods” section). Among the 206 differentially meth-
ylated regions, 115 revealed positive Z-scores. Out of
these 115, 25 displayed > 10 percent points difference
from the highest to the lowest methylated sample. The
corresponding number of regions revealing > 20 percent
points difference was 7. These 7 regions were within the
promoters of CIITA, RASSF1, CHN1, PDCD1LG2,
GSTP1, XPA, and ZNF668, with the three former genes
revealing a difference of more than 30 percent points
(Table 2). Re-assessing these data based on fold differ-
ence instead of percent points, we identified three re-
gions (in AIP, RABEP1, and RASSF1) with a lower than
20 percent point absolute difference but a relative ratio
> 2. Since another region of RASSF1 was already identi-
fied as having a difference > 20 percent points, this left
us with 9 different genes with substantial differences in
methylation levels.
Further, we reasoned that if methylation of any of
these genes may act as a cancer risk factor, then somatic
methylation of the same genes should be present in a
fraction of human cancers. We therefore mined the
COSMIC data base [33] for reported somatic methyla-
tion of the 9 genes. Six of these genes (CHN1,
PDCD1LG2, XPA, ZNF668, RABEP1, AIP) were not re-
ported to be aberrantly somatically methylated in tu-
mors, while one gene (CIITA) was reported to be hypo-
methylated in a very small fraction (0.19-1.53%) of vari-
ous solid tumors. In contrast, somatic hyper-methylation
of RASSF1 was reported in > 4% of endometrial cancers
and > 1% of breast cancers. Further, somatic hyper-
methylation of GSTP1 was reported in > 7% of prostate
cancers and > 1% of breast cancers. Thus, this finding
indicates that some genes found hyper-methylated in
tumor tissue are also differentially methylated in normal
tissue of healthy individuals. Although these data do not
provide any conclusive evidence per se, the findings war-
rant further investigations exploring constitutional
methylation as a potential cause of cancer risk.
Methylation in established cancer risk genes
Among some of the best-characterized cancer risk genes
in terms of mutations (BRCA1, TP53, and RB1), we
found the mean methylation level to be 0.7% in the
known regulatory region of the BRCA1 promoter, in line
with our previous findings [23]. For TP53, the mean
methylation level was 7.9%, while the corresponding
number for RB1 was 24.9%. For some additional genes
where methylation has been found as a cancer risk fac-
tor, MLH1 and MGMT, these revealed mean methyla-
tion levels of 6.4% and 18.6%, respectively. Among these
established cancer risk genes (BRCA1, TP53, RB1,
MLH1, and MGMT), we found no significant differences
between the individuals in the present data set.
Co-methylated tumor suppressors
The cause of differential DNA methylation, and, in par-
ticular, tumor suppressor promoter methylation, remains
poorly understood. Thus, in an exploratory analysis, we
assessed potential covariation between promoter methy-
lation on an individual basis. For this purpose, we per-
formed hierarchical clustering of the samples by
applying the Z-scores from average methylation ratio
across the 565 capture regions. Doing so, all samples
could be classified into two distinct major clusters, each
harboring distinguishable sub-clusters (Fig. 2). Interest-
ingly, the two major clusters (1 and 2) were character-
ized by different promoter methylation in two groups of
genes (A and B), where cluster 1 had high methylation
in genes in group A and low methylation in genes in
group B, while the opposite methylation pattern was
seen for samples in cluster 2 (Fig. 2).
We identified genes falling into these two groups
(A and B), and analyzed their involvement in func-
tional pathways by KEGG pathway analysis and GO
enrichment analysis via Gather. Many of the genes in-
volved in group A were important in development
and regulation of cellular processes like Wnt signaling
and TGF-beta signaling pathways. In contrast, genes
from group B showed involvement in apoptotic path-
ways and leukocyte differentiation (Supplementary
Table S4).
Notably, some individuals were characterized by hav-
ing a majority of genes either hyper- or hypo-methylated
as compared to the rest of individuals. Applying a 95%
confidence interval across samples with respect to the
overall methylation level of the regions analyzed, one
sample (S24) fell below the lower limit of the CI, while
three fell above the upper limit of the CI (Supplementary
Figure 3). However, these individuals were distributed
across the two main clusters with no preference for one
group over the other. Assessing the available general
clinical data for these individuals, no notable associa-
tions were observed between methylation and factors
such as age or BMI (data not shown).
Validations in external data sets
Although our data are unique since they are generated
by targeted massive parallel sequencing analyses, we
sought to validate our biological findings by mining
available data sets generated by application of methyla-
tion arrays.
A technical concern is that methylation could poten-
tially vary between subfractions of leukocytes and differ-
ential methylation between individuals could then
potentially be a result of individuals having different
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compositions of leukocyte subfractions in their blood.
Assessing the 7 most differentially methylated regions in
our data set, in the leukocyte subfractions published in
the Bioconductor Experiment Data Package FlowSorted.-
Blood.450K revealed no major difference in any of the 7
regions (Supplementary Table S5, with figures). In
GSTP1, 6 out of 19 CpGs revealed lower methylation in
CD14+ T cells and/or CD56+ NK cells than other sub-
fractions, but the impact of this on the average levels in
total WBC was negligible. Very similar observations
were made in another data set of cord blood (R package
FlowSorted. CordBlood Norway.450 K in Bioconductor
[34]; Supplementary Table S6, with figures). This con-
firmed potentially varying composition of leukocyte sub-
fractions not to be a likely cause of the observed
methylation differences.
Further, we sought to validate the biological differences
observed for the 7 most differentially methylated regions
in our sample set, by assessing their methylation in a sam-
ple of blood DNA from 845 individuals (GSE51032). In
this sample set, data was available for CHN1, PDCD1LG2,
GSTP1, and ZNF668. In addition, we here included the
two top-ranking genes with high differential methylation
calculated as ratio, but where percent point difference was
below 20 (see above; RABEP1 and AIP; Table 2). In gen-
eral, the methylation levels were called as slightly higher
in the GSE51032 set than by our own sequencing. How-
ever, the differences between individuals were confirmed
for all genes and the difference in percent points between
the highest and lowest methylated individual was similar
(Supplementary Table S7). The exception was ZNF668,
where our maximum observation was 66% methylation,
while in the GSE51032 set, some individuals were scored
as 100% methylated. This difference probably relates to a
substantially higher number of individuals analyzed in the
validation set increasing the chance of observing outliers.
Discussion
While to this end constitutional epimutations of tumor
suppressors have been linked to cancer risk for a few
genes only [23, 27, 31, 35–37], one may postulate that
constitutional epimutations affect other tumor suppres-
sors as well. This may have implications to our under-
standing of cancer risk. A substantial number of cancer-
prone families in which no underlying germline muta-
tion have been identified, and it is tempting to postulate
that some of these individuals may be at increased can-
cer risk due to constitutional epimutations in tumor
suppressor genes [30]. In addition, germline mutations
in several tumor suppressor genes have been associated
with other conditions such as skin and limb develop-
ment deficiencies, Cowden syndrome, and Fanconi
anemia [38–40]. Thus, exploring constitutional
promoter methylation across tumor suppressor genes
may be of importance to other medical conditions as
well.
To this end, the vast majority of epigenetic data re-
ported in respect to different health conditions are based
on global methylation-array analyses or single gene pro-
moter analyses by methods like MSP or MLPA. While
the array-based approaches do provide data for single
CpGs, a large number of (potentially important) CpGs
are lacking from the arrays, limiting the possibilities to
identify methylation pattern across all regions of interest
(e.g., as seen for BRCA1 [23]). As for MSP and MLPA,
such methods are fast and cheap but they are sensitive
only to a general methylation presence in the CpGs cov-
ered by the primers and probes, precluding assessment
at a single CpG resolution level.
Here, we established a massive parallel sequencing-
based approach, enabling base-pair resolution analyses
of methylation status in gene promoters. The method
provides several advantages as compared to previous
methods. First, as compared to conventional methods
like MSP and MLPA, our method allows for detailed
single-CpG resolution analyses of multiple promoter re-
gions in concert. Second, our method limits both work-
load and costs compared to application whole-genome
methylation sequencing for promoter methylation ana-
lysis. Third, the benefit of determining exact methylation
levels, instead of binary assessments, has been confirmed
in clinical studies [23], underlining the importance of
high sensitivity required to detect low-grade mosaic
methylation [30]. Fourth, as compared to available array-
based approaches, our NGS-assay allows for methylation
assessment of all CpGs in the region of interest, not only
those covered by array probes. As mentioned above, this
proved to be crucial in analyses of the cancer risk associ-
ated with mosaic BRCA1 methylation [23].
In principle, the sequencing of the DNA-libraries we
prepared could be run on any Illumina instrument. As
such, the method is flexible and scalable. Here, we used
the MiSeq instrument due to the rapid run time. In our
set-up, we chose to run 8 samples in one run, yielding
an average coverage of 189.6x, corresponding to a mean
sensitivity limit of 0.53%. Although indicating a very sen-
sitive method, this is an average value, and some regions
reveal lower coverage. If needed, however, coverage
could be increased in order to improve the sensitivity of
the method [23]. Notably, the reproducibility of the
assay may vary between the different covered regions.
However, we show that the reproducibility is very
good even in regions with low levels of methylation.
Importantly, the observed technical variation was con-
sistently negligible compared to the biological varia-
tions described. Further, we found that technical
variations were lower when assessing all CpGs across
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a given region than when assessing randomized selec-
tions of CpGs as “representative” for a region. This
emphasizes the value of applying assays where all
CpGs in a given region are covered, instead of relying
on scattered, selected CpGs.
While constitutional methylation is considered an
early life event affecting different germinal layers, methy-
lation status is also prone to environmental influences
and other factors and has been found to change during
lifetime [41], causing differential methylation of many
genes across different tissues [42]. One potentially im-
portant caveat when analyzing WBCs as surrogate
markers for constitutional methylation is the fact that
different leukocyte fractions may harbor different methy-
lation patterns [43]. While such differences, so far, have
been linked to global methylation patterns, it remains
unclear whether this may represent a problem with re-
spect to specific tumor suppressor methylation. Notably,
differential methylation across WBC subfractions was
found not be an issue regarding BRCA1 promoter
methylation [23], and in the present study, it was not
found to be an issue in the most differentially methyl-
ated promoter regions either.
The methylation level of the genes found to confer
cancer risk, so far, is highly variable. Regarding MLH1,
normal cell methylation affecting ~ 50% of the alleles
has been reported in a limited number of probands with
familial colorectal cancer (for original references, see
[30]). Recently, two families with a high breast and ovar-
ian cancer incidence were found to harbor secondary
constitutional BRCA1 methylation, also with a methyla-
tion level of ~ 50% [31]. In contrast, about 4% of females
in a Caucasian population was found to carry low-level
mosaic constitutional BRCA1 methylation (4-10% of al-
leles). Among these low-level methylated individuals, the
incidence of high-grade serous ovarian cancer was sig-
nificantly elevated with an odds ratio between 2 and 3
across two large cohorts [23]. As for the method pre-
sented here, this has the sensitivity required for explor-
ing both scenarios.
While the limited number of samples analyzed pre-
cludes formal assessments of methylation frequency
and/or potential correlations to health outcome, import-
antly, our findings confirm differential constitutional
promoter methylation across a panel of tumor suppres-
sor genes in healthy individuals. Interestingly, among
those promoter regions found to be hyper-methylated in
the normal tissue of some of the analyzed individuals,
we found promoters in genes previously reported to be
hyper-methylated in tumors (such as RASSF1 and
GSTP1). The presence of epigenetic deregulation of a
distinct tumor suppressor at the somatic (tumor) level
provides no evidence for constitutional methylation of
the same gene. However, the examples related to MLH1
and BRCA1 suggest that potential relationships may
occur for other genes as well. Thus, it is tempting to
speculate that, at least some of the genes detected here
(e.g., RASSF1 and GSTP1) could be constitutionally
methylated and, in such cases, methylated tumor cells
may have originated from the constitutionally methyl-
ated normal cells [30]. Notably, although not directly
comparable to our data, due to a restricted selection of
CpGs covered, mining of a large external data set re-
vealed similar interindividual differences largely confirm-
ing our findings.
Interestingly the methylation patterns revealed across
our gene panel indicated that the individuals analyzed
could be classified into two different methylation clus-
ters. These findings should be interpreted with caution
due to the limited number of individuals analyzed. How-
ever, the fact that the clusters were separated by differ-
ential methylation across important biological pathways
involving Wnt- and TGF-beta signaling pathways as well
as genes involved in apoptotic pathways and leukocyte
differentiation indicate potential underlying biological
differences to be explored in future studies.
Conclusions
We provide a relatively fast and affordable strategy for
detailed assessments of differential methylation of tumor
suppressors. This strategy is attractive in the warranted
search for additional tumor suppressors that may be
cancer risk factors when methylated in normal tissues.
Methods
Samples
The samples analyzed in the present study were from 34
individuals, selected from a set of 114 healthy postmeno-
pausal women previously described [44]. Subsequent to
providing informed consent, each individual donated
anonymized blood samples in accordance with Norwe-
gian regulations. All women were recruited during rou-
tine mammographic screening at Haukeland University
Hospital, Bergen, Norway. Individuals with diabetes or
other types of endocrine diseases as well as individuals
using hormone replacement therapy were excluded. All
samples were drawn > 2 years after the last menstrual
period. Within the selection of 34 individuals analyzed
in the present study, the mean age was 64 years (range
56-71 years) and the mean BMI was 24.8 (range 19.4-
39.6) at the time of sample collection.
DNA isolation
Genomic DNA was extracted from EDTA-whole blood,
using QIAamp DNA Mini kit (Qiagen). The procedure
was performed according to the manufacturer’s instruc-
tions with the exception that 400 μl of whole blood was
used as input.
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Selection of tumor suppressor promoter regions
Regions of interest were defined as 356 regions from the
promoters of 283 tumor suppressor genes. The selection
of genes was based on the cancer gene panel previously
described as “CGPv2/3” [45, 46], Roche’s “Comprehen-
sive Cancer Design” as well as a manual literature re-
view, in order to cover all well-established tumor
suppressor genes, independent of cancer type. As such,
the selection was independent of previous knowledge
about methylation status. For each transcription start
site (TSS), we designed probes covering a region span-
ning from −1500 to +500 relative to TSS. Positions of
TSS were determined by NCBI and Ensembl-curated
transcripts, literature search, and use of the FANTOM5
RNA expression resource (fantom.gsc.riken.jp/5/).
Probes for hybridization to the included regions were
manufactured by Roche and designed to bind the target
DNA of all possible methylation configurations (fully
methylated, partially methylated, and completely
unmethylated). Importantly, both strands were targeted,
in order to enable correction for potential overlap be-
tween CpGs and SNPs. By probe design, the 356 target
regions were split into 565 capture regions. Full lists of
included tumor suppressor genes and target regions are
given in Supplementary Table S1.
Library preparation and methylation sequencing
Processing of the sample libraries was performed using
the solution-based bead capture method for enrichment
of bisulfite-converted DNA, SeqCap Epi Enrichment Sys-
tem (Roche) according to the user guide (version 1.2).
For each sample, 1 μg DNA isolated from blood was
mixed with bisulfite-conversion control (Lambda DNA,
negative for methylation). DNA was fragmented to the
range of 180-220 bp using Covaris M220 followed by
end repair, A-tailing, ligation of index/adapters, and dual
size selection. Using the Zymo Research EZ DNA
Methylation-Lightning kit, the DNA was bisulfite-
converted according to manufactures protocol, and the
resulting sample was amplified prior to nanodrop quan-
tification. Based on these measurements, 1 μg bisulfite-
converted DNA was put into the hybridization with
custom-made probes for 68 h prior to capture by
streptavidin-coated beads, extensive washing, and a final
library amplification step.
The protocol was combined with the use of a custom-
made probe design enabling analysis of only regions of
interest (consisting of 356 promoter regions from 283
tumor suppressor genes, described above and in Supple-
mentary Table S1). In addition, the probe set included
probes targeting (Lambda DNA for conversion control).
The targeted regions were enriched by a bead capturing
method that captures both strands of DNA. Purified li-
braries were pooled, spiked with 10% PhiX, and
sequenced on an Illumina MiSeq sequencer, using v2
chemistry and 2 × 100 (200 cycles) paired-end reads.
RTA v1.18.54 and MCS v2.5.0.5 software was used to
generate data. Eight samples were multiplexed per run,
and resulting data were de-multiplexed based on
sample-specific indexes attached to the sequencing
adaptors. De-multiplexing was run automatically by the
MiSeq Reporter software before further processing.
Methylation calling
Raw sequencing data was analyzed using an in-house
workflow designed in collaboration with Roche, com-
prised of publicly available tools, implemented using
shell script (Fig. 3; for a detailed description see Supple-
mentary information). In brief, the first analytic steps in-
volved quality checking of fastq files by FASTQC.
Paired-end reads were filtered based on quality and
clipped using Trimmomatic [47]. Trimmed sequences
were aligned to the human genome (GRCh38) from
NCBI as well as Enterobacteria phage lambda (NC_
001416.1) complete genome, added for bisulfite conver-
sion efficiency control using the bisulfite mapping algo-
rithm BSMAP [48]. The aligned read statistics and
format conversions were carried out using SAMtools
[49]. After bisulfite conversion, the DNA strands are no
longer complementary. To achieve methylation informa-
tion from both strands, aligned reads were split into the
top and bottom strand [50]. Subsequently, the sequences
were sorted, and duplicates were removed and merged
back using Picard tools. In the next step, the analysis
was further restricted to those read pairs where both
mates in the pair could be mapped in the correct orien-
tation and at given distance consistent with the library
insert size (properly paired reads) using BamTools [51].
To avoid bias, overlapping reads were clipped using
BamUtils. Various statistics for reads, alignment, and
coverage were calculated using SamTools.
For each sample, methylation analysis was carried out
using methratio.py package in BSMAP by calculating
methylation percentage. An additional step involves SNP
calling for the targeted regions with BisSNP [52] from
aligned reads.
DNA conversion rate was calculated based on all ori-
ginal Cs in the Lambda DNA sequence. For all Cs in the
untreated sequence the following formula was used on
sequencing data post bisulfite treatment:
Conversion %ð Þ ¼ T= C þ Tð Þ  100
Assay reproducibility
To assess reproducibility of the assay, we performed 2
independent experiments with 6 parallels of a standard
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sample in each experiment. The standard sample con-
sisted of pooled DNA of equal amounts from WBC of 5
healthy donors. Reproducibility was assessed across 12
regions, selected based on three separate criteria: First,
we selected 4 regions found to have high biological vari-
ance in our original sample set of 34 healthy women
(GAS7, ELAC2, AIP, ZRSR2). Further, we selected 6 re-
gions in genes known to be high penetrance genes when
either mutated or hypermethylated (BRCA1, TP53 (2 re-
gions), RB1, MLH1, MGMT). Finally, we selected 2
regions at random (PRDM2, TMEFF2). Based on the 12
replicate analyses, we calculated mean methylation,
standard deviation and coefficient of variation for all the
regions (Supplementary Table S2a). Further, within the
2 randomly selected genes (PRDM2, TMEFF2), we per-
formed a randomized selection of 5 CpGs per region,
using the mean methylation in these 5 as “representa-
tive” for the region. Then, we calculated mean methyla-
tion, standard deviation and coefficient of variation
across the 12 replicate analyses of these 5 CpGs. This
Fig. 3 Workflow of the methylation analysis. Flow chart of the steps taken within the informatics analysis pipeline from raw FastQ files to
processed data used for biological interpretations. Main steps are indicated by blue background; smaller steps are indicated by gray background
(figure adapted from original design by Roche)
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randomization was repeated 5 times, yielding a general
overview of the variability when applying limited num-
bers of CpGs as “representative” for a region (Supple-
mentary Table S2b).
Differential methylation assessment
Among all CpGs in the 565 capture regions as well as
250 flanking bps at each end, the analysis was restricted
only to include CpGs with minimum of 10 reads in
coverage in all of the 34 samples. For each sample, we
then calculated the mean methylation per region, based
on individual CpG methylation ratios within the region.
Based on these data, we generated a methylation matrix
for all the common regions across all the samples (n =
34 in the present study), and calculated Z-scores for that
matrix. Then we assessed the Z-scores and identified all
the regions where a minority of individuals were differ-
entially methylated as compared to the majority. Differ-
ential methylation was here defined as Z-scores that
were outside of the 99% confidence interval. We used an
arbitrary definition of minority, set to one-third, or less,
of the total number of samples, i.e., minimum 1 individ-
ual and maximum 12 individuals (this definition may
need adjustment according to the size of subsequent
studies). Regions that had confidence level more than
99% were then categorized into negatively and positively
methylated regions based on the Z-score value and
whether the minority of individuals had higher or lower
methylation levels than the majority.
To find the differentially methylated regions, we calcu-
lated the mean methylation for these regions across
CpGs within individual samples and measured the differ-
ence in methylation between individuals with the lowest
and highest methylation mean. Although relatively small
differences in methylation levels have been shown to
modulate cancer risk [23], we here sought to identify the
regions with larger differences, applying arbitrary thresh-
olds of 5, 10, and 20 percent point difference in methyla-
tion. Further, we performed additional analyses assessing
ratios (fold difference) between individuals, taking into
account that biological important differences may have
high ratios, not necessarily reaching a certain threshold
set by percent point difference (e.g., a difference between
1% and 10% may be important, even if the percent point
difference is only 9).
Hierarchical clustering
We created a matrix of methylation ratios for all genes
across patients. We then calculated a variance for each
gene across patients to identify differential methylation.
Heatmap was produced with heatplot function from
made 4 package [53], with mean linkage cluster analysis
and a correlation metric distance. For the purpose of
clustering, missing values for regions in individual
patients were filled in using the impute R package [54,
55]. (Impute-knn function from impute R package, finds
k-nearest neighbors using a Euclidean metric and uses
their mean to substitute the missing value). Missing
values affected one region of GSTM1 in 16 samples, an-
other region of GSTM1 in 7 samples, and a region of
AIP in 3 samples.
Pathway analysis
We identified groups of genes from cluster analysis and
explored their functional roles by pathway analyses with
GATHER. GATHER is an online platform that predicts
functional molecular patterns and biological context by
incorporation of several biological databases [56]. In
GATHER, we analyzed KEGG pathways and gene ontol-
ogy enrichment analyses [57].
External data sets
We performed data mining and extracted detailed
methylation status for all available CpGs for a given re-
gion (defined by our NGS-panel) from the Bioconductor
Experiment Data Package FlowSorted.Blood.450K
(https://bioconductor.org/packages/release/data/experi-
ment). This data set was generated by methylation array
analyses across 6 independent samples from adult indi-
viduals and contains information on 10 different cat-
egories of leukocytes. The categories include the major
groups of granulocytes and lymphocytes.
We obtained similar data for umbilical cord blood from
newborns [34]. These data were available as the R package
FlowSorted.CordBloodNorway.450K in Bioconductor. This
data set was also based on methylation array and holds in-
formation about 7 categories of leukocytes, including the
major groups of granulocytes and lymphocytes, across 11
independent cord blood samples from newborns.
For validation of methylation differences in blood
DNA from healthy individuals, we mined data from
GSE51032, available through Gene Expression Omnibus
(GEO). This data set was generated by methylation array
and consists of 845 samples from the EPIC-Italy cohort
(out of which 188 were males and 657 were females).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-020-00920-7.
Additional file 1: Supplementary Figure 1. Fraction of methylated
alleles in promoter region of selected tumour suppressor genes. (A)
Regions with high methylation levels across samples from all 34 healthy
individuals. (B) Regions with low methylation levels across the same
samples. Note the different scale on the Y-axis for panel A and B. Data for
AIP were lacking for samples 32, 33, 34 due to low coverage (see details
in Materials and methods). Supplementary Figure 2. Plot examplifying
consistent high and low methylated CpGs in the same promoter, across
patients. Fraction of methylated alleles across CpGs in the promoter re-
gion of RB1 in the two samples S7 and S24 are displayed. These two
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samples were selected because they were the one with highest and low-
est overall methylation across the 283 investigated tumour suppressor
genes, respectively (ref. Supplementary figure 3), and as such should rep-
resent the extremes. Still within the RB1 promoter, they reveal a very simi-
lar pattern of some CpGs being highly methylated, while others are
hardly methylated at all. Supplementary Figure 3. Distribution of over-
all average methylation across 283 tumour suppressor gene promoters in
34 healthy individuals. (A) Bars indicate the average fraction of methyl-
ated alleles for all CpGs covered per patient. Dotted red lines indicate the
upper and lower border of the 95% confidence interval for the average
values per patient (CI for individual observations). Sample S24 falls below
the lower border of the CI, indicating general hypo-methylation. Samples
S4, S8 and S7 fall above the upper border of the CI, indicating general
hyper-methylation. (B) Q-Q plot based on the same data as displayed in
(A). S24 is encircled in green, while S4, S8 and S7 are encircled in red.
Additional file 2: Supplementary information – workflow
Additional file 3: Supplementary Table S1. Pan-cancer panel of 283
tumor suppressor genes for which promoters are included in methylation
analyses. The panel was generated based on CGPv2/3-panels [1], Roche’s
Comprehensive Cancer Design along with manual literature search.
Additional file 4: Supplementary Table S2a. Reproducibility test.
Supplementary Table S2b. Reproducibility test restricted to
randomised CpGs.
Additional file 5: Supplementary Table S3. Genes with >99
confidence level difference in methylation ratio between a minority (one
third or less) of samples versus the majority.
Additional file 6: Supplementary Table S4. groupAB_GE
Additional file 7: Supplementary Table S5. WBC fractions
Additional file 8: Supplementary Table S6. Coord blood
Additional file 9: Supplementary Table S7. EPIC
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Supplementary figure 1. Fraction of methylated alleles in promoter region of selected tumour 
suppressor genes. (A) Regions with high methylation levels across samples from all 34 healthy 
individuals. (B) Regions with low methylation levels across the same samples. Note the different scale 
on the Y-axis for panel A and B. Data for AIP were lacking for samples 32, 33, 34 due to low coverage 








Supplementary figure 2. Plot examplifying consistent high and low methylated CpGs in the same 
promoter, across patients. Fraction of methylated alleles across CpGs in the promoter region of RB1 
in the two samples S7 and S24 are displayed. These two samples were selected because they were 
the one with highest and lowest overall methylation across the 283 investigated tumour suppressor 
genes, respectively (ref. Supplementary figure 3), and as such should represent the extremes. Still 
within the RB1 promoter, they reveal a very similar pattern of some CpGs being highly methylated, 


































Supplementary figure 3. Distribution of overall average methylation across 283 tumour suppressor 
gene promoters in 34 healthy individuals. (A) Bars indicate the average fraction of methylated alleles 
for all CpGs covered per patient. Dotted red lines indicate the upper and lower border of the 95% 
confidence interval for the average values per patient (CI for individual observations). Sample S24 
falls below the lower border of the CI, indicating general hypomethylation. Samples S4, S8 and S7 fall 
above the upper border of the CI, indicating general hypermethylation. (B) Q-Q plot based on the 
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Abstract
miRNAs are an important class of small non-coding RNAs, which play a versatile role in
gene regulation at the post-transcriptional level. Expression of miRNAs is often deregulated
in human cancers. We analyzed small RNA massive parallel sequencing data from 50
locally advanced breast cancers aiming to identify novel breast cancer related miRNAs. We
successfully predicted 10 novel miRNAs, out of which 2 (hsa-miR-nov3 and hsa-miR-nov7)
were recurrent. Applying high sensitivity qPCR, we detected these two microRNAs in 206
and 214 out of 223 patients in the study from which the initial cohort of 50 samples were
drawn. We found hsa-miR-nov3 and hsa-miR-nov7 both to be overexpressed in tumor ver-
sus normal breast tissue in a separate set of 13 patients (p = 0.009 and p = 0.016, respec-
tively) from whom both tumor tissue and normal tissue were available. We observed hsa-
miR-nov3 to be expressed at higher levels in ER-positive compared to ER-negative tumors
(p = 0.037). Further stratifications revealed particularly low levels in the her2-like and basal-
like cancers compared to other subtypes (p = 0.009 and 0.040, respectively). We predicted
target genes for the 2 microRNAs and identified inversely correlated genes in mRNA
expression array data available from 203 out of the 223 patients. Applying the KEGG and
GO annotations to target genes revealed pathways essential to cell development, communi-
cation and homeostasis. Although a weak association between high expression levels of
hsa-miR-nov7 and poor survival was observed, this did not reach statistical significance.
hsa-miR-nov3 expression levels had no impact on patient survival.
Introduction
miRNAs are an important class of small non-coding RNAs, playing a versatile role in the gene
regulation at the post–transcriptional level [1–5]. These molecules have proven to be involved
in vital cellular functions, such as development, differentiation and metabolism [6–8]. In
recent years there has been increased focus on the role of miRNAs in cancer [9], and the
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implementation of next generation sequencing (NGS) has led to the identification of multiple
novel miRNAs as well as linked individual miRNA expression and combined signatures to
tumor characteristics [10]. Currently there are 2656 distinct human miRNAs identified in the
miRbase v22 [11], including more than 700 found to be deregulated in cancers [12].
Breast cancer is the most common malignancy in women. While outcome has improved
significantly over the last three decades, resistance to therapy still presents a major challenge
causing breast cancer related deaths [13]. As for chemoresistance in general, the underlying
biological mechanisms remain poorly understood [14].
Merging evidence has indicated miRNA deregulation to play a role in breast cancer biology
and outcome. Dysregulation of miRNAs may affect signal transduction pathways by targeting
oncogenes and tumor suppressor genes [15], important to cancer development, progression,
metastasis and potentially therapy response [16, 17]. Thus, while miR-10b, miR-125b, and
miR-145 are generally downregulated, other miRNAs, like miR-21 and miR-155, are generally
upregulated in breast cancer as compared to normal breast tissue [18]. Further, several miR-
NAs have revealed strong associations to clinical parameters [19, 20]: For example, differential
expression of miR-210, miR-21, miR-106b�, miR-197, miR-let-7i, and miR-210, have been
identified as a signature with prognostic value and also linked to invasiveness [21]. Moreover,
miR-21 has been found linked to breast cancer metastasis and poor survival [22], while mir-
29a overexpression has been shown to reduce the growth rate of breast cancer cells [23]. Given
that many of the observed miRNA alterations are strongly cancer specific, this has inspired
investigations into the potential use of miRNA as diagnostic biomarkers. Since miRNA are rel-
atively stable molecules, they may be particularly attractive biomarkers to screen for in liquid
biopsies (for original references, see [24])
miRNAs are also known to be differentially regulated across different subclasses of breast
cancer. E.g. while members of the mir-181 family are up regulated in breast cancer in general,
miR-181c in particular is activated by the expression of HER2 gene [25]. Also, miR-140 has
been found suppressed by estrogen stimulation in ERα-positive breast cancer cells, most likely
due to ER response elements in the flanking element of the miR-140 promoter [26].
In the present study, we analyzed global miRNA expression in 50 locally advanced breast
cancers using NGS, aiming to identify novel, potentially breast cancer specific miRNAs. We
identified and validated two novel miRNAs (one not previously described and one not previ-
ously reported in breast cancer), and subsequently evaluated their expression in an extended
patient series (n = 223), by high sensitivity qPCR. Both were found over-expressed in breast
cancer as compared to normal breast tissue. Considering different breast cancer subtypes, hsa-
miR-nov3 was expressed at particular high levels in ER-positive tumors contrasting lower levels
in basal-like and Her2-like tumors. No similar patterns were observed for hsa-miR-nov7.
Materials and methods
Patients
In the present work we have analyzed biopsy material from two breast cancer studies.
1) In the first study, incisional biopsies were collected before chemotherapy from 223
patients with locally advanced breast cancer in a prospective study designed to identify the
response to epirubicin (n = 109) and paclitaxel (n = 114) monotherapy. Primary response to
therapy as well as long-term follow up (>10 years or death) was recorded for all patients. This
cohort has been described in detail previously [27].
2) In the second study, tumor breast tissue and normal breast tissue from tumor bearing
and non-tumor bearing quadrants were collected from 46 anonymous breast cancer patients
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undergoing mastectomy, with the purpose of determining tissue estrogens. This cohort is
described in detail in [28].
Using NGS, we analyzed miRNA expression in 50 patients from study 1). Next, candidate
miRNAs were quantified using qPCR in all 223 patients from study 1), as well as 13 randomly
selected patients from study 2), where RNA was available from tumor tissue and matching
normal breast tissue (7 ER-positive and 6 ER-negative tumors). In addition, mRNA expression
array data was available for 203 out of the 223 patients in study 1).
All patients provided written informed consent, and the studies conducted in accordance
to national laws, regulation and ethical permissions (Norwegian health region West; REK
Vest).
Tissue sampling and RNA extraction
Tissue samples were snap-frozen in liquid nitrogen in the operating theatre and stored in liq-
uid nitrogen until further processing. Total RNA was extracted from the biopsies using miRva-
naTM kit (ThermoFisher), according to the manufacturer’s instructions. RNA integrity and
concentration were determined using Bioanalyzer 2000 and Nanodrop ND2000 spectropho-
tometer, respectively.
miRNA-sequencing
Sample preparation and single-end sequencing were performed at the core facility of the Nor-
wegian Genomics Consortium in Oslo, on Illumina HiSeq 2500, 1x50bp. De-multiplexing was
performed using the Illumina CASAVA software. FastQC was run on all samples with the
main purpose to assess sequence quality. The raw data are available through the Gene Expres-
sion Omnibus (accession: GSE145151).
Novel miRNA prediction
The raw sequencing files (fastq) were processed using the novel miRNA prediction algorithm
mirdeep v2.0.0.5 [10]. Potential novel miRNAs were identified using the human reference
genome (hg19) and already identified miRNAs from humans and other hominids from miR-
base 20 [29]. In the mirdeep2 algorithm, filtering parameters randfold P-value less than 0.05
and scores greater than or equal to 10 were applied. Precursor structures obtained after filter-
ing were manually identified based on the presence of 1–2 mismatches in the stem region, a
loop sequence of 4–8 nt, and the presence of mature sequence in the stem region (See S1 File.)
[30].
Validation of predicted novel miRNAs
Validation of the predicted novel miRNAs was performed by qPCR-based amplification of the
miRNAs, with subsequent cloning and capillary sequencing of the products, to pinpoint the
exact size and sequence of the miRNAs (see sections below for details).
cDNA synthesis and qPCR
cDNA from miRNAs was prepared using Exiqon’s Universal cDNA synthesis kit II, with 20 ng
of total RNA as input. qPCR was performed using Exiqon’s miRCURY LNA™ Universal RT
microRNA PCR system, with custom Pick-&-Mix ready to use PCR plates with an inter-plate
calibrator, on a LightCycler 480 instrument (Roche). Relative expression levels for each sample
were calculated by dividing the expression of the gene of interest on the average expression of
two reference miRNAs: miR-16-5p and miR-30b-5p.
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miRNA cloning and capillary sequencing
End products from custom miRNA specific qPCR were cloned into pCR 2.1 TOPO-TA vector
(Life Technologies) by TOPO-TA cloning according to the manufacturer’s instructions. The
generated plasmids were amplified by transformation and cultivation of E. coli TOP10 cells
(Life Technologies). The plasmids were then isolated using the Qiagen miniprep kit according
to the manufacturer’s instructions.
Sequencing was performed using the BigDye v.1.3 system (Applied Biosystems) and the
primers following thermocycling conditions as previously described [31]. Capillary electro-
phoresis and data collection were performed on an automated capillary sequencer (ABI3700).
Target prediction and pathway analysis
Target prediction was performed using the offline algorithm miRanda [32, 33] and the online
algorithms miRDB [34] and TargetScanHuman Custom (Release 5.2) [35].
miRanda predicts gene targets based on position specific sequence complementarity
between miRNA and mRNA using weighted dynamic programming, an extension of the
Smith-Waterman algorithm [36]. Also, the miRanda algorithm uses the free energy estimation
between duplex of miRNA: mRNA (Vienna algorithm [37]) as an additional filter.
The miRDB is an online database of animal miRNA targets, which uses SVM (Support Vec-
tor Machine) machine-learning algorithm trained with miRNA-target binding data from
already known and validated miRNA-mRNA interactions [34, 38].
TargetScanHuman Custom predicts biological miRNA targets by searching for match for
the seed region of the given miRNA that is present in the conserved 8-mer and 7-mer sites
[35]. It also identifies sites with conserved 3’ pairing from the mismatches in the seed region
[39, 40].
An in-house pan-cancer panel of 283 tumor suppressor genes was used to filter target genes
of interest. The panel was generated based on the tumor suppressors within the CGPv2/3-pan-
els [41], Roche’s Comprehensive Cancer Design as well as a manual literature search (S1
Table).
Further, we used GATHER, a functional gene enrichment tool, which integrates various
available biological databases to find functional molecular patterns, in order to find biological
context from the target gene list [42]. With the help of GATHER, we did KEGG pathway [43],
and GO (gene ontology) enrichment analyses for the common genes predicted by all three pre-
diction algorithms. Further, validations were performed using DAVID [44] and topGO [45].
mRNA expression
In the interest of validating miRNA targets, we analyzed inverse correlations between miRNA
expression and mRNA levels. mRNA expression levels were extracted from microarray analy-
ses performed on a Human HT-12-v4 BeadChip (Illumina) after labeling (Ambion; Aros
Applied Biotechnology). Illumina BeadArray Reader (Illumina) and the Bead Scan Software
(Illumina) were used to scan BeadChips. Expression signals from the beads were normalized
and further processed as previously described [46]. We re-annotated the data set using illumi-
naHumanv4.db from AnnotationDbi package, built under Bioconductor 3.3 in R [47], to select
only probes with “Perfect” annotation[48]. The probes represented 21043 identified and
unique genes (13340 represented by single probe and 7703 represented by multiple probes). In
the cases of multiple probes targeting the same gene, we calculated fold difference for these
probes. This was done to avoid losing potentially relevant biological information if expression
of one probe was significantly higher that expression of another. However, for no genes did we
find a fold difference >2 fold. Therefore, the mean expression for each such gene, was
PLOS ONE Novel miRNAs in breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0225357 April 16, 2020 4 / 23
calculated based on the values form each probe, weighted according to the number of beads
per probe.
Statistics
Expression levels of miRNAs in tumor versus normal tissue were compared by Wilcoxon rank
tests for paired samples. Inverse correlations between miRNA expression and mRNA expres-
sion were assessed by Spearman tests. The potential impact of the novel miRNAs on long-term
outcome (relapse-free survival and disease-specific survival) in breast cancer patients was cal-
culated by Log-rank tests and illustrated by Kaplan-Meier curves, using the SPSS software
v.19. All p-values are reported as two-sided.
Results
Novel miRNA prediction
In order to identify novel miRNAs, 50 patients with locally advanced breast cancer (from
study 1, see materials and methods) were subject to global miRNA-sequencing using massive
parallel sequencing. On average, the dataset resulted in 3 million reads per sample. Using the
miRNA identifier module in miRDeep2, we detected 10 novel miRNAs (Table 1). Eight out of
these 10 miRNAs were detected in a single sample only, while two were expressed in two or
more patients and therefore regarded as the most reliable predictions. These two miRNAs,
here temporarily named hsa-miR-nov3 and hsa-miR-nov7, were found in tumor samples from
2 and from 6 patients, respectively. For both of these novel miRNAs, we identified precursor
structures with not more than one or two mismatches in the stem region, as well as the pres-
ence of mature miRNA sequences (Fig 1; S1 Fig). Therefore, we selected these two miRNAs for
further analyses. Cross-checking the miRCarta database [49], no hits were found for either of
the two, but notably, while this work was conducted, hsa-miR-nov7 was identified by another
team in lymphomas, and reported as miR-10393-3p [50].
In-vitro validation of novel micro RNAs
Next, we aimed to validate our in-silico predictions and confirm that the sequences from
which we identified hsa-miR-nov3 and hsa-miR-nov7 represented bona-fide novel miRNAs
expressed in the patients. Utilizing total RNA from the patients found to express the two pre-
dicted novel miRNAs, we performed global poly-adenylation and cDNA synthesis followed by
miRNA-specific qPCR amplification. For both miRNAs we observed positive qPCR reactions.
Further, end products of the qPCRs were then ligated into carrier-plasmids and sequenced.
Table 1. Novel miRNA sequences as predicted by mirdeep v2.0.0.5 from massive parallel sequencing of total miRNA in 50 locally advanced breast cancers.
miRNA Co-ordinate Mature sequence Strand Number of samples
hsa-miR-nov2 chr2:36662749..36662809 AAAAACTGCGATTACTTTTGCA - 1
hsa-miR-nov3 chr3:186505088..186505149 AAAGCAGGATTCAGACTACAATAT + 2
hsa-miR-nov3_2 chr3:132393169..132393224 CAAAAACTGCAATTACTTTTGC + 1
hsa-miR-nov4 chr4:155140075..155140134 AAAAGTAATCGCTGTTTTTG + 1
hsa-miR-nov7 chr7:138728845..138728903 AATTACAGATTGTCTCAGAGA - 6
hsa-miR-nov8 chr8:116546693..116546762 TTAGAGCTTCAACCTCCAGTGTGA - 1
hsa-miR-nov10 chr10:31840034..31840078 CGCGGGTGCTTACTGACCCT + 1
hsa-miR-nov10_2 chr10:72163928..72163994 GCGGCGGCGGCGGCGGCG + 1
hsa-miR-nov17 chr17:36760852..36760906 CCCAGCCCCACGCGTCCCCATG - 1
hsa-miR-nov20 chr20:26189318..26189366 TGGCCGAGCGCGGCTCGTCGCC - 1
https://doi.org/10.1371/journal.pone.0225357.t001
PLOS ONE Novel miRNAs in breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0225357 April 16, 2020 5 / 23
We confirmed the resulting plasmids to contain the predicted miRNA sequences. Further, in
both cases, the sequences were flanked by a poly A tail, confirming that the original molecules
used as input in the poly-adenylation were present as short 22nt RNAs (Fig 2). Thus, we con-
firmed the presence of miRNAs with the exact sequence as predicted from the NGS-based
data.
Overexpression of hsa-miR-nov7 and hsa-miR-nov3 in breast cancer
Given that the sensitivity for the novel miRNAs was better in the qPCR than in the miRNA
massive parallel sequencing (MPS) analysis, we aimed to assess whether the miRNAs were
expressed in a limited number of breast cancer patients only (as indicated by their detection in
2 and 6 out of 50 patients in the MPS analysis), or if they were detectable in a higher fraction of
patients, when applying a more sensitive detection method. We therefore performed qPCR to
quantify the expression levels of hsa-miR-nov7 and hsa-miR-nov3 in tumor tissue across the
entire cohort of patients from study 1 (n = 223). With this method, we detected hsa-miR-nov7
and hsa-miR-nov3 in 206 and 214 samples out of total 223 samples respectively, albeit at vari-
able levels (Fig 3).
Interestingly, while no difference in the expression levels of hsa-miR-nov7 was observed
between breast cancer subgroups, we found a significant difference in the expression levels of
has-miR-nov3 related to estrogen receptor status. Thus, the expression levels of has-miR-nov3
were higher in ER-positive as compared to ER-negative tumors (p = 0.037; Fig 4A). Further,
Fig 1. Predicted novel miRNAs. Depiction of novel miRNAs (A) hsa-miR-nov3 and (B) hsa-miR-nov7, identified by
miRDeep2, showing (i) predicted mature and star sequences, exp, probabilistic model expected from Drosha/Dicer
processing and obs, observed sequences from sequencing data (ii) density plot for read counts for mature and star
sequences as well as (iii) miRNA secondary structure.
https://doi.org/10.1371/journal.pone.0225357.g001
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assessing the expression levels of the two miRNAs in mRNA-based subclasses of breast cancer
according to the Perou classification [51], comparing all five classes, we observed a significant dif-
ference between the subtypes with respect to miR-nov3 expression (p = 0.041; Kruskal-Wallis test;
Fig 4C). We found hsa-miR-nov3 levels to be lower in HER2 like (p = 0.009; Mann-Whitney test)
and basal-like (p = 0.04; Mann-Whitney) tumors as compared to tumors of the other classes.
Following the finding that the two miRNAs were detectable in more than 90 percent of
patients, in order to assess whether the expression of these miRNAs were tumor specific we
compared the levels of hsa-miR-nov7 and hsa-miR-nov3 expression in breast cancer tissue ver-
sus normal breast tissue. For this purpose, we randomly selected 13 patients from a study
where samples of breast tumor tissue and matching normal tissue from a non-tumor bearing
quadrant of the same breast were available (study 2, see materials and methods) [28]. We
detected expression of the novel miRNAs in both tumor- and normal tissue samples for all 13
patients. Notably, we found hsa-miR-nov3 expression to be elevated in tumor compared to
normal tissue in 10 out of the 13 patients (p = 0.009; Wilcoxon test; Fig 5A). Similar findings
Fig 2. miRNA sequences. Chromatogram of capillary-sequenced qPCR products after hsa-miR-nov3 (A) and hsa-miR-nov7 (B) amplification.
Highlighted background indicates the 22nt miRNA-sequence region (reverse complementary), followed by the Adenine homopolymer
indicating in vitro adenylation at the expected site, confirming the exact size and sequence of the predicted miRNAs.
https://doi.org/10.1371/journal.pone.0225357.g002
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were observed for hsa-miR-nov7 with elevated expression in 10 out of 13 tumors (Wilcoxon:
p = 0.016; Fig 5B). The level of overexpression (i.e. the ratio of expression levels in tumor ver-
sus normal tissue) for the two miRNAs did not correlate to each other (p>0.2; Spearman).
Notably, overexpression of hsa-miR-nov7 in tumor versus normal tissue was observed pre-
dominantly in ER-positive tumors (overexpression in 7 out of 7 ER-positive tumors, contrast-
ing 3 out of 6 ER-negative tumors; p = 0.070; Fischer exact test).
hsa-miR-nov7 and hsa-miR-nov3 target prediction
Based on our finding of both novel miRNAs to be overexpressed in breast cancer, we next
aimed to elucidate the functional roles for hsa-miR-nov7 and hsa-miR-nov3 by identifying
Fig 3. Expression of novel miRNAs in breast cancer tissue. Bars indicate the relative expression of hsa-miR-nov3 (A)
and hsa-miR-nov7 (B) in 223 breast cancer patients.
https://doi.org/10.1371/journal.pone.0225357.g003
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potential targets. We performed in silico target predictions using three different algorithms–
miRanda, miRDB and TargetScan Human Custom. miRanda, which predicts possible targets
from human transcripts in general, predicted 9200 and 12315 target genes for hsa-miR-nov7
and hsa-miR-nov3, respectively. miRDB, which contains curated and possible miRNA targets,
predicted 570 and 530 target genes each for hsa-miR-nov7 and hsa-miR-nov3, respectively,
while TargetScanHuman custom predicted 633 target genes for hsa-miR-nov7, and 282 target
genes for hsa-miR-nov3. For increased stringency in our predictions, we restricted the poten-
tial targets to the ones called by all three algorithms (Fig 6). This left a total of 97 and 180
potential targets for hsa-miR-nov3 and hsa-mir-nov7, respectively.
The two lists of 97 and 180 predicted gene targets were then used for KEGG pathway analy-
sis and GO enrichment analysis using GATHER. The top 10 KEGG pathways and GO terms
for each microRNAs are listed in Table 2. The KEGG and GO annotations for hsa-miR-nov3
showed pathways that are important in cell development, communication and cytoskeletal
organization. Similar analysis for hsa-miR-nov7 unveiled pathways playing a vital role in cell
functions such as communication and homeostasis. These findings were largely validated by
performing the same analyses applying alternative tools (DAVID and topGO; S2 Table).
Fig 4. Expression of novel miRNAs in breast cancer tissue. Expression levels stratified by ER-status (A, B) and by expression subtypes (C,
D).
https://doi.org/10.1371/journal.pone.0225357.g004
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Thus, both these miRNAs implied cell functions that are vital to cancer development and
progression.
In order to further substantiate these in-silico predictions, we performed a complete Spear-
man correlation analysis between the expression levels of hsa-miR-nov7 and hsa-miR-nov3 and
mRNA expression array data available for 203 out of the 233 patients in study 1. Assuming the
miRNAs, in general, to execute their function by suppressing gene expression (mRNA degra-
dation), we restricted the analysis to genes which were negatively correlated to expression of
the miRNAs. The top ranking negatively correlated genes are listed in Table 3. Notably, the
only genes with Rho-values < -0.2 were RMND5A for hsa-miR-nov3 and GLUD1 and SASH1
for hsa-miR-nov7. Given that the two novel miRNAs were overexpressed in breast cancer tis-
sue, we went on to restrict the correlation analysis to an in-house list of 283-tumor suppressor
Fig 5. Expression of novel miRNAs in breast cancer tissue. Bars indicate the ratio of expression in tumour tissue vs.
matched normal breast tissue in 13 breast cancer patients, for hsa-miR-nov3 (A) and hsa-miR-nov7 (B).
https://doi.org/10.1371/journal.pone.0225357.g005
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Fig 6. Target genes predicted. Venn-diagrams illustrating the number of target genes predicted by TargetScan,
mirDB and Miranda for the two novel miRNAs hsa-mir-nov3 (A) and hsa-mir-nov7 (B).
https://doi.org/10.1371/journal.pone.0225357.g006
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Table 2. Top 10 (arbitrary cut-off) GO and KEGG annotation.
A) GO annotation—hsa-miR-nov3
# Annotation ln(Bayes factor)a neg ln(p value)b FE: neg ln
(p value)c
FE: neg ln(FDR)d
1 GO:0009653 [3]: morphogenesis 94.88 7.98 100.5 92.91
2 GO:0007275 [2]: development 87.32 7.58 92.89 85.99
3 GO:0007154 [3]: cell
communication
85.41 7.46 90.99 84.5
4 GO:0009887 [4]: organogenesis 74.65 6.99 80.24 74.26
5 GO:0048513 [3]: organ
development
74.65 6.99 80.24 74.26
6 GO:0007165 [4]: signal
transduction
74.2 6.97 79.77 73.97
7 GO:0007242 [5]: intracellular
signaling cascade
66.52 6.59 72.18 66.53
8 GO:0007010 [6]: cytoskeleton
organization and biogenesis
55.54 6.04 61.15 55.63
9 GO:0009790 [3]: embryonic
development
48.63 5.7 54.28 48.88
10 GO:0006928 [4]: cell motility 47.82 5.65 53.49 48.2
B) KEGG annotation—hsa-miR-nov3
# Annotation Total Genes With Ann ln(Bayes factor)a neg ln(p value)b FE: neg ln
(p value)c
FE: neg ln(FDR)d
1 path:hsa04810: Regulation of actin
cytoskeleton
35 9.03 4.07 13.96 9.57
2 path:hsa04010: MAPK signaling
pathway
36 6.93 3.75 11.8 8.1
3 path:hsa04510: Focal adhesion 32 4.15 3.26 8.94 5.94
4 path:hsa04110: Cell cycle 18 4.1 3.25 9.08 5.95
5 path:hsa04060: Cytokine-cytokine
receptor interaction
33 3.23 3.07 7.97 5.24
6 path:hsa04620: Toll-like receptor
signaling pathway
17 2.97 3.01 7.92 5.24
7 path:hsa04210: Apoptosis 16 2.13 2.82 7.06 4.55
8 path:hsa04512: ECM-receptor
interaction
14 1.17 2.55 6.09 3.72
9 path:hsa04630: Jak-STAT
signaling pathway




5 0.7 2.41 5.9 3.59
C) GO annotation—hsa-miR-nov7





60.17 6.3 65.79 58.14
2 GO:0007275 [2]:
development
54.83 6 60.38 53.43
3 GO:0007165 [4]:
signal transduction
50.84 5.81 56.44 49.89
4 GO:0009653 [3]:
morphogenesis
48.96 5.72 54.56 48.3
(Continued)
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41.31 5.3 46.94 40.9
6 GO:0009987 [2]:
cellular process
40.56 5.26 46.33 40.48
7 GO:0009887 [4]:
organogenesis
40.37 5.25 45.94 40.24
8 GO:0048513 [3]:
organ development








39.18 5.18 44.62 39.27
D) KEGG annotation—hsa-miR-nov7














33 3.15 3.04 7.94 4.57
4 path:hsa04210:
Apoptosis













3 1.12 2.54 6.48 3.7
8 path:hsa04510:
Focal adhesion









13 -0.28 0 4.61 2.39
a Measure of the strength of annotation
b p-value for the Bayes factor estimate
c p-value for Fishcer’s exact test
d FDR for Fishcer’s exact test
https://doi.org/10.1371/journal.pone.0225357.t002
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Table 3. Spearman correlation table for hsa-miR-nov3 and hsa-miR-nov7 and their top 25 target genes (arbitrary cut-off for inclusion in the table; ranked by inverse
correlation).
A) hsa-miR-nov3
Gene Symbol Estimate P.value Expression (mean)
RMND5A -0.2018 0.0038 14.0750
YES1 -0.1649 0.0184 17.0218
PALM2-AKAP2 -0.1455 0.0378 13.0997
SLC7A1 -0.1224 0.0811 16.8650
RAPGEF5 -0.1208 0.0853 14.9652
CTDSPL2 -0.1196 0.0885 15.4945
SLC4A5 -0.1077 0.1251 15.0101
HIPK1 -0.1046 0.1366 13.3737
ABHD12 -0.0998 0.1555 16.2313
FMNL2 -0.0982 0.1624 16.0939
POU4F1 -0.0933 0.1844 13.4684
RPS6KA3 -0.0905 0.1981 14.6430
LARP1 -0.0890 0.2054 15.0210
WIPI2 -0.0702 0.3184 14.7316
MTCH1 -0.0575 0.4139 18.6604
DIAPH1 -0.0528 0.4530 16.7109
MARCKS -0.0481 0.4946 18.6286
LUZP1 -0.0453 0.5200 17.1097
DNAJC8 -0.0449 0.5238 18.2152
CLOCK -0.0436 0.5354 15.7894
SLAMF6 -0.0415 0.5557 15.4277
CDAN1 -0.0405 0.5655 16.6394
PCDH11X -0.0359 0.6104 13.4661
RYBP -0.0346 0.6234 16.9184
FGF1 -0.0344 0.6249 13.9423
B) hsa-miR-nov7
Gene Symbol Estimate P.value Expression (Mean)
GLUD1 -0.2274 0.0011 18.0399
SASH1 -0.2095 0.0026 16.9164
MARK1 -0.1883 0.0070 15.0356
ARID5B -0.1877 0.0072 17.7569
ELOVL5 -0.1854 0.0079 17.5656
PUM1 -0.1707 0.0147 17.8295
PNRC2 -0.1599 0.0224 15.4674
UNC13B -0.1583 0.0238 15.5633
FLRT2 -0.1581 0.0239 15.7323
ZFHX4 -0.1482 0.0344 14.7383
CHIC1 -0.1479 0.0348 13.5807
MAN1A1 -0.1457 0.0375 15.4956
CPEB2 -0.1387 0.0478 14.6995
PDE4D -0.1377 0.0495 13.9823
TMED7 -0.1366 0.0514 17.1083
NDFIP1 -0.1280 0.0680 16.1458
CSMD1 -0.1269 0.0704 13.8158
MITF -0.1187 0.0908 14.0482
(Continued)
PLOS ONE Novel miRNAs in breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0225357 April 16, 2020 14 / 23
genes previously described. Among these tumor suppressors, we found 115 to be negatively
correlated to hsa-miR-nov7 and 119 to hsa-miR-nov3 (S3 Table). Assessing the intersection
between these negatively correlated tumor suppressor genes and the predicted targets, we
obtained a list of one gene for hsa-miR-nov3 (ATRX) and three genes for hsa-miR-nov7 (APC,
SFRP2 and CDH11), but the correlations were non-significant in all 4 cases (Table 4, Fig 7).
In order to get a broader overview of potential biological function, we selected the 100 gene
transcripts with the strongest positive and the top 100 gene transcripts with the strongest nega-
tive correlation to the two miRNAs (independent of previous target-predictions) and per-
formed gene ontology analyses. We detected no cancer related pathways or cellular functions
to be significantly associated with hsa-miR-nov7 (S4 Table). However, for hsa-miR-nov3,
KEGG analysis of the negatively correlated genes revealed associations to Hepatorcellular car-
cinoma as well as several pathways related to drug metabolism (S5 Table). Notably, when seek-
ing to validate these findings by application of alternative tools (DAVID and topGO) the latter
was not validated. (S6 and S7 Tables).
Expression of hsa-miR-nov7 and hsa-miR-nov3 and clinical outcome in
breast cancer
Since both hsa-miR-nov7 and hsa-miR-nov3 were overexpressed in the tumor tissue of breast
cancer patients, we assessed whether any of the two novel miRNAs were associated to clinical
outcomes in study 1 (223 breast cancer patients). Given that these patients were enrolled in a
prospective study specifically designed to assess response to primary chemotherapy adminis-
tered as epirubicin or paclitaxel monotherapy in a neoadjuvant setting [27, 52], we assessed
the association of hsa-miR-nov7 and hsa-miR-nov3 levels with primary therapy response and
with long term survival (10-years).
We found no association between any of the two novel miRNAs and primary response to
either epirubicin or paclitaxel (S8 Table). Regarding survival, we observed a weak association
between high levels of hsa-miR-nov7 and poor survival in the paclitaxel treated arm of the
study, with the strongest associations observed for relapse free survival, however, none of these
associations reached statistical significance (Fig 8). No effect was observed in the epirubicin
treated arm. Further, for hsa-miR-nov3, no significant correlation to outcome was recorded.
Table 3. (Continued)
ITSN1 -0.1185 0.0915 14.8011
CTDSPL2 -0.1178 0.0932 15.4945
ATAD2B -0.1178 0.0932 14.9892
SFRP2 -0.1129 0.1080 18.4511
DPP10 -0.1119 0.1110 13.4306
BMPR2 -0.1107 0.1149 17.1664
EIF5A2 -0.1100 0.1174 14.5450
https://doi.org/10.1371/journal.pone.0225357.t003
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Given the skewed expression levels between breast cancer subtypes for hsa-miR-nov3, we
performed survival analyses stratified for ER-status and subtypes. These analyses revealed no
significant associations to survival (Log rank test p-values ranging from 0.09 to 0.98).
Discussion
We investigated whether we could detect novel, previously undescribed miRNAs and, if so,
address their potential association to other defined biological parameters and to outcome in a
cohort of locally advanced breast cancer. We successfully predicted 10 new miRNAs, out of
which 2 were deemed reliable because of their detected presence in more than one patient.
Although these two novel miRNAs (preliminary termed hsa-miR-nov7 and hsa-miR-nov3)
were only predicted from 8 samples among the 50 initially sequenced biopsies, we found them
to be expressed in all patients by highly sensitive qPCR at varying levels. In addition to our in
vitro validations, the qPCR detection validated the initial NGS based analysis, detecting these
two miRNAs.
Since expression of the two miRNAs was confirmed in breast tumor tissue from the major-
ity of patients analyzed, we went on to assess the relative expression levels in tumor versus
matched normal breast tissue, collected from a non-tumor bearing quadrant. Our finding that
both novel miRNAs had higher expression levels in tumor than in normal tissue indicates a
potential functional role in breast cancer. However, although being overexpressed, the biologi-
cal role of these two miRNAs in cancer should be interpreted with caution. The expression
Fig 7. Correlations to tumor suppressor genes. Scatter plots showing correlation of target tumor suppressors with A)
hsa-miR-nov3 and B) hsa-miR-nov7.
https://doi.org/10.1371/journal.pone.0225357.g007
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levels are very low, and it is therefore uncertain whether they will have a major impact on cel-
lular functions. Notably, given our approach and identification of the two miRNAs with low
expression level, this indicates that there may currently be a limited potential for new discover-
ies of miRNAs high expression levels and strong functional roles in breast cancer. However,
when assessing the potential functional roles of these microRNAs by in silico prediction of tar-
gets followed by validation using correlation to mRNA-array data, the KEGG and GO annota-
tions for these targets revealed cellular functions of potential importance in development and
progression of cancer. As such, our present findings may warrant further investigations into
the functions of the two miRNAs. Notably, regarding hsa-miR-nov3, it was of particular inter-
est that this miRNA was significantly higher expressed in ER-positive as compared to ER-nega-
tive breast cancers. Accordingly, we found relatively high expression levels of hsa-miR-nov3 in
tumors of the luminal and normal-like subtypes, contrasting low expression levels in basal-like
and her2-like tumors [53, 54]. This finding may indicate a potential role for hsa-miR-nov3
restricted to ER-positive tumors.
Regarding potential specific targets, we narrowed these down by first assessing the intersect
of three different target prediction algorithms, and then the intersect of this result with a
Fig 8. miRNAs and breast cancer survival. Kaplan-Meier curves showing (i) disease-specific and (ii) relapse-free
survival of locally advanced breast cancer patients treated with epirubicin or paclitaxel monotherapy in the
neoadjuvant setting (study 1), with respect to expression levels of (A) hsa-miR-nov3 and (B) hsa-miR-nov7 on all
samples.
https://doi.org/10.1371/journal.pone.0225357.g008
PLOS ONE Novel miRNAs in breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0225357 April 16, 2020 17 / 23
predefined list of tumor suppressors. Although none of the remaining genes after this filtering
had a statistically significant inverse correlation with the miRNAs, we identified some poten-
tially interesting connections: For hsa-miR-nov3, we propose ATRX as a target. This is a gene
in the SWI/SNF family, involved in chromatin remodelling, and it has previously been found
subject to loss of heterozygosity (LOH) in breast cancer [55]. Importantly, we recently reported
mutations in the SWI/SNF family genes to be enriched in relapsed breast cancer as compared
to primary cancers [56]. Thus, this supports the hypothesis of a breast cancer promoting func-
tion for hsa-miR-nov3. For hsa-miR-nov7, we propose APC, SFRP2, and CDH11 as potential
targets. Interestingly, the two former are involved in regulation of the Wnt-signalling pathway
[57–59] and both have previously been reported as targets for several miRNAs in breast cancer
[60–62]. Taken together, this may imply a role for hsa-miR-nov7 in Wnt signaling. Notably,
during our work with the present project, hsa-miR-nov7, was identified by Lim and colleagues
and coined miR-10393-3p [50]. They found this miRNA to target genes involved in chromatin
modifications associated with pathogenesis of Diffuse large B-cell lymphoma (DLBCL). While
this differs from our present finding, it may likely be explained by tissue specific effects of the
miRNA.
Regarding any predictive or prognostic role for the two investigated miRNAs, we found no
significant impact on survival. While we recorded a non-significant trend towards an associa-
tion between miRnov7 expression and overall survival in the paclitaxel arm, further studies on
larger patient cohorts are warranted to clarify this issue. Alternatively, the miRNAs could play
a role in tumorigenesis but not later tumor progression. As such, the observed overexpression
in tumor tissue compared to normal breast tissue may be a remaining signal from
tumorigenesis.
Whether cancer related overexpression of the two miRNAs described here is merely conse-
quences of other molecular mechanisms in cancer cells or whether the two miRNAs may be
involved in tumorigenesis, but not subsequent cancer progression, remains unknown.
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Figure 1: Predicted novel miRNAs. Table on the upper left shows miRDeep2 scores and read 
counts. RNA secondary structure for miRNA on the top right. Color code for depiction as 
follows mature sequence in red, loop sequence in yellow and purple for star sequences. 
Density plot in the middle shows distribution of reads in precursor reads predicted. Dotted 
lines illustrate alignment and mm, number of mismatches. Exp, is potential precursor model 
predicted by algorithm with taking accounts of stability based on free energy, position and 
read frequencies according to Dicer/Drosha processing of miRNA. Obs, is postion and reads 
found from deep sequencing data. (A) hsa-miR-nov3 and (B) hsa-miR-nov7. 
 
Supporting Table S1. In-house pan-cancer panel of 283 tumor suppressor genes, 
generated based on CGPv2/3-panels[1], Roche’s Comprehensive Cancer Design 
along with manual literature search, to filter target genes of interest. 
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Supporting Table S2. Spearman correlation table for hsa-miR-nov3 (A) and hsa-miR-nov7 




Gene Estimate  P value Mean Expression 
ARHGAP26 -0.0065 0.9262 14.4132 
ARID2 -0.0573 0.4160 15.5138 
ARID4A -0.0134 0.8493 14.6255 
ATRX -0.0483 0.4923 13.9469 
BCL7A -0.0926 0.1876 14.1301 
BLID -0.0529 0.4521 13.9765 
BMP3 -0.0124 0.8600 13.3724 
BMP7 -0.0004 0.9954 14.3881 
BRIP1 -0.0486 0.4899 13.8642 
CARS -0.0213 0.7627 15.8107 
CDH11 -0.0518 0.4618 17.7525 
CDKN1A -0.0217 0.7581 15.6141 
CDKN1C -0.0144 0.8379 16.0217 
CDKN2A -0.0842 0.2309 14.3086 
CDKN2B -0.0310 0.6595 15.0449 
CDX2 -0.0527 0.4537 13.5056 
CHD5 -0.0314 0.6555 13.7651 
CHD6 -0.0826 0.2401 15.8235 
CHFR -0.0805 0.2522 17.0289 
CHN1 -0.0013 0.9850 14.8979 
CIITA -0.0062 0.9298 14.5010 
CLTCL1 -0.1132 0.1071 14.1098 
CNBP -0.0703 0.3177 16.3166 
CTNNB1 -0.1208 0.0853 15.9912 
DAPK1 -0.1016 0.1480 15.6762 
DDB2 -0.0454 0.5191 15.2302 
DDIT3 -0.0077 0.9129 16.0630 
DDX53 -0.0291 0.6794 13.5698 
DKK1 -0.0004 0.9954 14.3922 
ELAC2 -0.1488 0.0336 16.1477 
EMP3 -0.0232 0.7418 17.4996 
EP300 -0.0645 0.3596 16.1435 
EPHA6 -0.0616 0.3815 13.3497 
ERCC1 -0.0019 0.9788 15.8715 
ERCC3 -0.1056 0.1326 15.5411 
ERCC4 -0.0049 0.9449 13.9151 
EXT2 -0.0937 0.1824 15.4237 
FANCF -0.0183 0.7952 13.9110 
FANCI -0.0072 0.9187 15.5721 
FANCL -0.0878 0.2119 14.9136 
FAT1 -0.0280 0.6909 17.3311 
FBXO11 -0.0567 0.4205 16.6127 
FHIT -0.0265 0.7071 14.5957 
FHL1 -0.0015 0.9831 16.5500 
FLCN -0.0163 0.8168 14.3452 
FOXL2 -0.0424 0.5466 13.3440 
GATA2 -0.0145 0.8364 14.8464 
GATA3 -0.0301 0.6686 16.8666 
GATA4 -0.0356 0.6128 13.4347 
GATA5 -0.1094 0.1193 13.5412 
GSTM1 -0.0315 0.6543 15.4934 
HAND2 -0.0792 0.2600 13.8374 
HIC1 -0.0022 0.9746 15.0303 
HOXA10 -0.0662 0.3468 14.3840 
HOXA11 -0.0274 0.6970 13.1974 
HOXA9 -0.0077 0.9126 13.3157 
IGFBP3 -0.0380 0.5898 17.3472 
KDM6A -0.0797 0.2569 16.1162 
KDSR -0.0348 0.6209 16.9388 
KMT2C -0.0108 0.8783 14.4106 
LMNA -0.0361 0.6079 17.5236 
MLH1 -0.0409 0.5617 16.5589 
MLLT11 -0.0638 0.3646 16.2646 
MSH2 -0.0441 0.5311 14.7562 
MSH6 -0.0715 0.3095 17.5512 
MUTYH -0.0348 0.6212 15.0585 
NF1 -0.0844 0.2298 14.0124 
NTRK3 -0.0140 0.8428 13.8522 
NUMA1 -0.0489 0.4877 16.7333 
PAX5 -0.0796 0.2576 13.2127 
PGR -0.0248 0.7245 14.3941 
PHF6 -0.0058 0.9346 13.4835 
PMS1 -0.0219 0.7559 15.2495 
PRDM1 -0.0004 0.9959 14.3366 
PRDM2 -0.0488 0.4879 14.1393 
PREX2 -0.0313 0.6568 13.2312 
PRKAR1A -0.0308 0.6624 16.5292 
PRKDC -0.0809 0.2502 15.4145 
PTPRD -0.0449 0.5235 14.4119 
RAB40AL -0.0991 0.1583 13.2453 
RABEP1 -0.0687 0.3290 17.3346 
RANBP17 -0.0771 0.2728 13.2919 
RAP1GDS1 -0.0263 0.7083 15.7314 
RASSF1 -0.0445 0.5278 15.2786 
RBBP8 -0.0025 0.9714 14.6984 
RBP1 -0.1739 0.0128 16.9774 
RNASEL -0.0623 0.3763 16.1561 
RPTOR -0.0351 0.6183 14.5302 
RUNX1 -0.0227 0.7477 15.3497 
RUNX1T1 -0.0367 0.6023 14.0611 
SDHAF2 -0.0895 0.2033 17.3818 
SDHB -0.1287 0.0665 17.9386 
SETD2 -0.0426 0.5454 17.2496 
SFRP2 -0.0279 0.6922 18.4511 
SMAD2 -0.0062 0.9302 14.1585 
SMAD3 -0.0963 0.1708 16.4175 
SMAD4 -0.0969 0.1679 17.3092 
SMARCA4 -0.0297 0.6736 17.6729 
SOCS1 -0.0933 0.1843 15.7624 
SOCS3 -0.0454 0.5192 14.8089 
SPEN -0.0853 0.2251 17.2409 
SRGAP3 -0.0210 0.7651 14.4660 
STK11 -0.0854 0.2244 15.3924 
TCEA1 -0.0642 0.3619 15.5099 
TET1 -0.0380 0.5899 14.1420 
TFAP2A -0.0262 0.7096 15.2176 
THBS1 -0.0850 0.2270 17.5950 
THRAP3 -0.1031 0.1421 15.7921 
TIMP3 -0.0010 0.9886 17.6612 
TLX3 -0.0153 0.8277 13.4299 
TMEFF2 -0.0201 0.7758 13.5501 
TMEM127 -0.0346 0.6228 15.6207 
TP73 -0.0772 0.2723 13.1015 
TRIM33 -0.0358 0.6112 15.7066 
TSC1 -0.0164 0.8158 15.6086 
TSC2 -0.0982 0.1622 15.2237 
YWHAE -0.0193 0.7836 15.5636 
ZNF331 -0.0028 0.9683 14.5922 




Gene Estimate  P value Mean Expression 
ATRX -0.0013 0.9850 13.9469 
BLID -0.1188 0.0906 13.9765 
BLM -0.0764 0.2777 14.6813 
BMP7 -0.0179 0.7990 14.3881 
BRCA1 -0.0176 0.8027 14.9580 
BRCA2 -0.0017 0.9810 13.4017 
BRIP1 -0.1504 0.0318 13.8642 
BTG1 -0.0686 0.3295 18.6391 
BUB1B -0.0014 0.9841 14.8483 
CASC5 -0.0248 0.7244 13.9560 
CCNB1IP1 -0.0924 0.1886 14.7104 
CD2 -0.0996 0.1563 16.4594 
CDH1 -0.0434 0.5375 18.1575 
CDH11 -0.0247 0.7257 17.7525 
CDK12 -0.1043 0.1375 16.3371 
CDKN1A -0.0502 0.4759 15.6141 
CDKN1C -0.0564 0.4230 16.0217 
CDKN2A -0.1455 0.0379 14.3086 
CHD5 -0.0255 0.7168 13.7651 
CHD6 -0.0342 0.6275 15.8235 
CHEK1 -0.0315 0.6542 15.1712 
CHEK2 -0.1116 0.1120 14.5868 
CHFR -0.0462 0.5116 17.0289 
CHN1 -0.1318 0.0602 14.8979 
CIITA -0.1004 0.1530 14.5010 
CLTCL1 -0.0321 0.6484 14.1098 
CNBP -0.1700 0.0151 16.3166 
COX6C -0.0124 0.8605 19.2678 
CTNNB1 -0.0667 0.3435 15.9912 
DAPK1 -0.1735 0.0131 15.6762 
DDIT3 -0.0390 0.5795 16.0630 
DKK1 -0.0305 0.6653 14.3922 
ELAC2 -0.0832 0.2367 16.1477 
EMP3 -0.0929 0.1864 17.4996 
EPHA5 -0.0245 0.7284 13.2599 
EPHA6 -0.0975 0.1653 13.3497 
ERCC2 -0.0053 0.9396 15.5522 
ERCC3 -0.0620 0.3782 15.5411 
EXT2 -0.0684 0.3307 15.4237 
FAM46C -0.0795 0.2583 16.9997 
FANCA -0.0477 0.4977 13.7107 
FANCC -0.0026 0.9707 14.0886 
FANCE -0.0240 0.7338 15.8101 
FANCI -0.0836 0.2344 15.5721 
FANCL -0.1365 0.0515 14.9136 
FAS -0.0390 0.5793 14.8132 
FAT1 -0.0256 0.7162 17.3311 
FBXW7 -0.0699 0.3205 14.7353 
FHIT -0.1178 0.0932 14.5957 
FOXL2 -0.1411 0.0441 13.3440 
FOXO1 -0.0258 0.7146 16.4032 
GATA5 -0.1373 0.0502 13.5412 
GMPS -0.0775 0.2704 17.0642 
GSTP1 -0.0014 0.9842 18.4426 
HERPUD1 -0.0438 0.5337 17.6315 
IGFBP3 -0.0180 0.7983 17.3472 
IKZF1 -0.0348 0.6209 14.8119 
IL21R -0.1125 0.1092 14.0628 
LMNA -0.0583 0.4075 17.5236 
MAL -0.0373 0.5964 14.6452 
MLF1 -0.0316 0.6541 14.8246 
MLH1 -0.0214 0.7617 16.5589 
MLLT11 -0.0240 0.7332 16.2646 
MSH2 -0.1006 0.1521 14.7562 
MSH6 -0.0823 0.2420 17.5512 
MTUS2 -0.0431 0.5402 13.2167 
MUTYH -0.0187 0.7906 15.0585 
NF2 -0.0952 0.1756 13.5838 
PALB2 -0.0779 0.2681 15.3981 
PAX5 -0.0889 0.2063 13.2127 
PHF6 -0.0703 0.3176 13.4835 
PLAG1 -0.0161 0.8191 13.6951 
PML -0.0076 0.9144 13.8870 
PMS1 -0.0374 0.5955 15.2495 
PRDM1 -0.0945 0.1790 14.3366 
PREX2 -0.0556 0.4293 13.2312 
PRKAR1A -0.0942 0.1804 16.5292 
PRKDC -0.0798 0.2563 15.4145 
PRLR -0.0225 0.7497 14.7949 
PTPRD -0.0128 0.8563 14.4119 
RAB40AL -0.1972 0.0047 13.2453 
RAD51B -0.0780 0.2675 13.9763 
RAD51C -0.1491 0.0333 15.4363 
RAD51D -0.0693 0.3245 14.4466 
RANBP17 -0.0678 0.3356 13.2919 
RASSF5 -0.0508 0.4708 14.5639 
RBBP8 -0.0517 0.4629 14.6984 
RBP1 -0.1176 0.0940 16.9774 
RMI2 -0.0087 0.9022 16.1039 
RPTOR -0.0373 0.5968 14.5302 
RUNX3 -0.0945 0.1786 15.1754 
SDHAF2 -0.2143 0.0021 17.3818 
SDHB -0.1346 0.0550 17.9386 
SLX4 -0.0092 0.8961 15.8230 
SMAD2 -0.0204 0.7720 14.1585 
SMARCA4 -0.0266 0.7057 17.6729 
SOCS1 -0.0468 0.5064 15.7624 
SPECC1 -0.0448 0.5249 14.1781 
SRGAP3 -0.0357 0.6122 14.4660 
STK11 -0.0150 0.8319 15.3924 
SYK -0.0274 0.6969 16.3501 
TCEA1 -0.0029 0.9671 15.5099 
TET1 -0.0135 0.8485 14.1420 
TFAP2A -0.0213 0.7627 15.2176 
THRAP3 -0.0139 0.8436 15.7921 
TMEFF2 -0.0639 0.3639 13.5501 
TMEM127 -0.0150 0.8318 15.6207 
TNFAIP3 -0.0886 0.2078 16.0023 
TOP2A -0.0328 0.6418 16.9282 
TP73 -0.0708 0.3145 13.1015 
TUBB3 -0.0276 0.6949 16.2461 
VDR -0.0587 0.4045 14.2406 
XPA -0.0031 0.9653 15.5822 
ZNF668 -0.0059 0.9328 16.0503 






This algorithm exploits Dicer’s miRNA precursor processing along with integrating massively 
parallel sequencing data into a simple probabilistic model. First it searches for potential 
precursor secondary structure and reads corresponding to them. It makes sure that precursor 
sequence has reads aligning to mature, star and loop of precursor, by-products of Dicer 
processing. Algorithm searches for both structural and miRNA signatures and scores 
precursor sequences based on of energetically stable it is, conservation on phylogenetic 
distance, number of reads mapping to it as wells number of reads aligning to all three Dicer 
products. The algorithm rejects reads that align to multiple positions (>5) in the genome. It 
also does not consider reads that map in to already annotated non - coding RNA regions in 
the genome.  Rest of the reads are assessed both structural stability and closeness to miRNA 
signatures. The precursor sequence is assigned mature position based on where majority of 
the reads align followed potential star sequence with a base pairing with an overhang that is 
phylogenetically conserved typically of lengths 2 – 3 nts. Stem loop sequence with at least 14 
nts between mature and star sequence that can form an unbifurcated hairpin structure is 
defined. Finally miRDeep2 give probability score for each predicted sequence, ruling out the 
possibility of background hairpin formation.  
[1, 2]. 
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In Paper III, during printing at the publisher figures 1B and 8B were left out. These are now 
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